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Abstract
Imaging biomarkers for Alzheimer’s disease are important for improved diagnosis and moni-
toring, as well as drug discovery. Automated image-based classification of individual patients
could provide valuable support for clinicians. This work investigates machine learning methods
aimed at the early identification of Alzheimer’s disease, and prediction of progression in mild
cognitive impairment. Data are obtained from the Alzheimer’s Disease Neuroimaging Initia-
tive (ADNI) and the Australian Imaging, Biomarker and Lifestyle Flagship Study of Ageing
(AIBL).
Multi-region analyses of cross-sectional and longitudinal FDG-PET images from ADNI are
performed. Information extracted from FDG-PET images acquired at a single timepoint is
used to achieve classification results comparable with those obtained using data from research-
quality MRI, or cerebrospinal fluid biomarkers. The incorporation of longitudinal information
results in improved classification performance.
Changes in multiple biomarkers may provide complementary information for the diagnosis and
prognosis of Alzheimer’s disease. A multi-modality classification framework based on random
forest-derived similarities is applied to imaging and biological data from ADNI. Random forests
provide consistent similarities for multiple modalities, facilitating the combination of different
types of features. Classification based on the combination of MRI volumes, FDG-PET in-
tensities, cerebrospinal fluid biomarkers, and genetics out-performs classification based on any
individual modality.
Multi-region analysis of MRI acquired at a single timepoint is used to show volumetric differ-
ences in cognitively normal individuals differing in amyloid-based risk status for the develop-
ment of Alzheimer’s disease. Reduced volumes in temporo-parietal and orbito-frontal regions in
high-risk individuals from both ADNI and AIBL could be indicative of early signs of neurode-
generation. This suggests that volumetric MRI can reveal structural brain changes preceding
the onset of clinical symptoms.
Taken together, these results suggest that image-based classification can support diagnosis
in Alzheimer’s disease and preceding stages. Future work may lead to more finely meshed
prognostic data that may be useful clinically and for research.
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Chapter 1
Introduction
1.1 Alzheimer’s disease
Alzheimer’s disease (AD), named after the German physician Alois Alzheimer, is a condition
defined by progressive dementia and the abundant presence in the brain of characteristic neu-
ropathological structures. The earliest symptom is generally memory loss, followed by further
functional and cognitive decline, such that patients become gradually less able to perform even
basic tasks (de Leon, 1999). AD is the most common cause of dementia in the elderly, with
a worldwide prevalence that is expected to rise, as the population ages, from the 26.6 million
reported in 2006 to over 100 million by 2050 (Brookmeyer et al., 2007).
There is currently no disease-modifying therapy for AD; however, symptomatic treatments can
help patients to maintain mental function and manage the behavioural symptoms. Ongoing
clinical trials are focused on the development of new treatments, including those aimed at
lowering the risk of developing the disease or delaying its onset and progression (Klafki et al.,
2006). As illustrated in Figure 1.1, changes associated with AD are thought to start occurring
many years before the onset of clinical symptoms. Any disease-modifying or causal therapy
would therefore likely be of greatest benefit to asymptomatic individuals at high risk of develop-
ing AD, so-called pre-symptomatic patients. Amnestic mild cognitive impairment (MCI) is of
interest because this can be a transitional stage between the cognitive decline associated with
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normal ageing and established AD. Memory is impaired in MCI, although general cognitive
function is preserved, and patients are at increased risk of developing AD. The yearly rate of
conversion from MCI to AD is around 12%, in contrast to the 1-2% yearly rate of conversion
reported in an age-matched general population (Petersen, 2004).
Figure 1.1: An illustrative timeline of AD progression. Produced by Jyrki Lo¨tjo¨nen, VTT
Technical Research Centre of Finland.
A diagnosis of AD is made according to consensus criteria such as the NINCDS-ADRDA1
Alzheimer’s Criteria (McKhann et al., 1984), which provide guidelines for the classification of
patients as having definite, probable, or possible AD. A diagnosis of definite AD requires that
neuropathological findings be confirmed by a direct analysis of brain tissue samples, which may
be obtained either at autopsy or from a brain biopsy. Since their proposal in 1984, studies
have shown these criteria to have a diagnostic accuracy of up to 90% when validated against
neuropathological gold standards (Ranginwala et al., 2008; Rasmusson et al., 1996). There
are, however, several significant challenges to be addressed. These include pre-symptomatic
diagnosis, differential diagnosis, and the assessment and prediction of progression. Research
has shown biochemical and neuroimaging biomarkers to have diagnostic and prognostic value
for AD, and recently published revisions to the consensus criteria aim to incorporate these
advances (Albert et al., 2011; McKhann et al., 2011; Sperling et al., 2011).
A delay of one year in both disease onset and progression would reduce the number of AD
cases in 2050 by an estimated 10% (Brookmeyer et al., 2007). The early identification of pre-
symptomatic patients is therefore important to allow the recruitment of appropriate participants
for clinical trials. If a successful disease-modifying therapy for AD were to be developed, early
identification would become even more important to allow targeting of patients for whom the
1National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer’s Disease
and Related Disorders Association (now known as the Alzheimer’s Association)
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treatment may be most effective. The aim of the research presented in this thesis is to use
machine learning methods with data from an array of diagnostic techniques to identify patients
at highest risk of future cognitive decline.
1.2 Neuroanatomy
The human brain, illustrated in Figure 1.2, is composed mainly of two cerebral hemispheres,
each of which is divided into four lobes: frontal, temporal, parietal and occipital. Each hemi-
sphere includes a cortex of grey matter containing the neuronal cell bodies. The cortical surface
is folded into ridges (gyri) and grooves (sulci). Other cortical regions relevant to the study of
AD include the cingulate gyrus and insula. The insula is folded deep within the lateral sulcus
between the frontal and temporal lobes. On the lateral surface of the brain, it is covered by
the operculum, which is formed from portions of the frontal, temporal and parietal lobes.
(a) Lateral view (b) Medial view
Figure 1.2: Sagittal views of the right hemisphere of the brain, showing its gross anatomy. S:
superior, I: inferior, A: anterior, P: posterior.
The cortex surrounds a core of white matter, consisting mainly of myelinated axons connecting
the cell bodies. The largest white matter structure in the brain is the corpus callosum, a bundle
of axons connecting the left and right cerebral hemispheres. Embedded within the cerebral
white matter are deep grey matter structures, including the basal ganglia and thalamus. At
the base of the brain, underneath the cerebral hemispheres, are the cerebellum and brainstem.
The brainstem is continuous with the spinal cord.
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The brain is separated from the skull by three layers of tissue known as meninges: the dura,
the arachnoid and the pia. To protect and support the brain, cerebrospinal fluid (CSF) fills the
subarachnoid space, as well as a continuous system of four cavities known as ventricles. These
are illustrated in Figure 1.3. CSF also fills the central canal of the spinal cord.
(a) Overview (b) Detailed view
Figure 1.3: Sagittal views of the ventricular system (Gray, 1918).
Pathological changes associated with the development of AD begin in the medial temporal
lobes. Several important sub-structures within this region are illustrated in Figure 1.4.
(a) Overview (b) Detailed view
Figure 1.4: Axial views of the brain, showing the sub-structures of the medial temporal lobe.
A: anterior, P: posterior, L: left, R: right.
1.3 Neuropathology
Changes occur within the brain even during the healthy ageing process. For example, the
cerebral hemispheres lose volume and the ventricles become enlarged. Both such changes may
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be attributed to neuronal loss (Graham and Lantos, 1997). These changes become progressively
exaggerated during the development of AD, with both cerebral atrophy and neuronal loss often
more pronounced in the medial temporal lobes (Dawbarn and Allen, 2007). However, a more
characteristic feature of the disease is the abundant presence in the brain of neuropathological
structures including extracellular amyloid plaques and intracellular neurofibrillary tangles. For
a diagnosis of definite AD to be returned, the presence and distribution of these structures
must be directly examined in brain tissue samples.
Amyloid plaques are dense, insoluble deposits of protein and cellular material that form around
neurons. Their main protein constituent is beta-amyloid (Aβ), which is produced when the
larger amyloid precursor protein is successively cleaved by β- and γ-secretase enzymes (Dawbarn
and Allen, 2007). The dominant form of Aβ found in amyloid plaques is Aβ1−42. This is
produced when cleavage by γ-secretase occurs after residue 42 of the Aβ molecule, rather than
the usual residue 40 (Selkoe, 2004). Once produced, Aβ proteins accumulate outside the cell,
forming small, soluble oligomers. These then aggregate further and combine with other proteins
and cellular material, eventually forming insoluble plaques (National Institute on Aging, 2008).
Neurofibrillary tangles are insoluble, twisted fibres found inside neurons, whose main protein
constituent is the microtubule-associated protein tau. With the development of AD, the bal-
ance between phosphorylation and dephosphorylation of tau is lost, and it becomes hyperphos-
phorylated (Dawbarn and Allen, 2007). Tau and other microtubule-associated proteins then
aggregate inside the cell, forming tangles. These disrupt the stability of the microtubules that
are a vital part of the neuronal communication system, ultimately leading to cell death (Na-
tional Institute on Aging, 2008). The amyloid cascade hypothesis suggests that the formation
of Aβ is directly responsible for triggering hyperphosphorylation of tau (Selkoe, 1991).
AD can be divided into two types which share the same pathological features: late-onset AD
(LOAD) which tends to manifest after age 60, and the less common familial AD (FAD) which
typically has an earlier onset (Dawbarn and Allen, 2007). The work presented in this thesis
relates to cases of sporadic LOAD. Age is the most significant risk factor associated with
the development of LOAD (Rocca et al., 1991), although genetic, environmental, and other
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factors are also relevant. The ApoE gene is the only one so far shown to be associated with
the development of LOAD (Dawbarn and Allen, 2007). There are three major alleles of the
ApoE gene: 2, 3 and 4. The most common allele is 3, which is present in 70-80% of most
populations (Zannis et al., 1981). The 4 allele is associated with an increased risk of developing
LOAD, while the 2 allele has a neuroprotective effect (Corder et al., 1993).
1.4 Neuroimaging
Neuroimaging techniques provide a way for clinicians to examine the structural and functional
changes in the brain associated with the development of AD in vivo. Commonly used modal-
ities include magnetic resonance imaging (MRI), X-ray computed tomography (CT), positron
emission tomography (PET), single-photon emission computed tomography (SPECT), and dif-
fusion tensor imaging (DTI). The work presented in this thesis will focus on PET and MRI,
both of which are described in the following subsections.
1.4.1 Positron emission tomography
The basic procedure for a PET scan involves injecting the patient with a tracer, labelled with
a positron-emitting radionuclide, and then scanning them. A positron emitted inside the body
can travel only a short distance through tissue, losing kinetic energy by Coulomb scattering from
atomic electrons as it does so, until it is almost at rest. When this low energy positron interacts
with an atomic electron, the particles can annihilate to produce two gamma ray photons that are
detectable outside the body. To conserve energy and momentum, the photons must be emitted
in opposite directions and each with an energy of 511 keV. Since the elements of the PET
detector form closed rings around the patient, the two photons are detected simultaneously
in opposite detector elements. This process, known as coincidence detection, allows spatial
localisation of the tracer in the body and the production of an image showing its distribution.
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Radiotracers
Positron-emitting nuclei are unstable, and they stabilise by the decay of a proton into a neutron,
positron and electron neutrino. The time taken for half the radioactive nuclei in a sample to
decay is known as its half-life. Two nuclei commonly used in PET imaging are 11C and 18F,
which have half-lives of 20 and 110 minutes, respectively (Rudin, 2005). Tracer molecules for
PET imaging are selected to target a particular physiological process, and then radiolabelled
with a suitable positron-emitting nuclide. Isotopic labelling, such as the replacement of 12C by
11C, is preferable because the resulting tracer has identical behaviour to the unlabelled molecule.
However, labelling with 18F is attractive because its longer half-life means that synthesis of the
tracer does not have to occur on-site. 18F is used as a pseudo-isotopic substitute for hydrogen
in a variety of PET tracers because this exchange generally has only a small effect on the
behaviour of the molecule in vivo.
Image acquisition
A PET scanner consists of a series of coaxial rings around the patient, each containing a
number of detector elements. In the most commonly used detection systems, these elements
are made up of an array of scintillating crystals which are optically coupled to location-sensitive
photomultiplier tubes (Rudin, 2005). When a gamma ray photon interacts with the scintillating
crystal, electrons in the lattice are excited from the valence band up into the conduction band.
These electrons return to the valence band at impurities in the crystal and, in doing so, dissipate
energy in the form of light. This is converted into a weak electronic pulse which is then amplified
into a measurable signal in the photomultiplier tubes.
To describe how data are acquired, a single ring of the detector is considered in isolation. Each
element in the ring is connected in a coincidence circuit with every other element, and an event
is registered if photons are detected simultaneously in two elements. The detection of two
photons must occur within a short coincidence window to be considered simultaneous. This is
between 10 and 12 nanoseconds in modern clinical PET scanners (Rudin, 2005). Registration
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of an event determines a path across the detector, known as the line of response, along which
the two photons were emitted, as shown in Figure 1.5 (a). Parallel lines of response are grouped
together to form projections for every possible orientation of the ring, as illustrated in Figure
1.5 (b). The number of events recorded along each line of response in a single projection
forms one row of a data matrix called a sinogram. The complete sinogram therefore contains
information recorded from all projections in a single ring, as shown in Figure 1.5 (c).
(a) Line of response (b) Ring orientations (c) Sinogram
Figure 1.5: Stages of PET image acquisition, showing (a) an annihilation event and the cor-
responding line of response, (b) the grouping of parallel lines of response to form projections,
and (c) the construction of a sinogram.
Photon attenuation in tissue
At energies around 511 keV, the dominant interaction of photons with tissue is by Compton
scattering from outer-shell electrons. This results in both a loss of energy and deflection from
the original path. Data must be corrected for errors occuring due to this attenuation, as
well as other effects, before an image can be reconstructed. The probability that a photon
undergoes no interactions as it travels through tissue along a line l is known as its survival
probability. The survival probabilities of the pair of photons produced as shown in Figure
1.5 (a) are independent. The combined probability that neither photon interacts may therefore
be expressed as
PC = exp
(
−
∫ b
a
µ(x)dx
)
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for tissue with the linear attenuation coefficient µ(x) (Ollinger and Fessler, 1997). The atten-
uation factor (1 − PC) is thus independent of the position of the annihilation event along the
line l . It can be calculated for every line of response, and the resulting values used to correct
the PET image for attenuation. The attenuation map may be obtained either from a transmis-
sion scan acquired using an external radiation source prior to injection of the radiotracer, or
from the CT image for combined PET/CT scanners. Not all attenuated photons are deflected
out of the field of view, and an incorrect line of response may be registered if such scattered
photons are detected. However, since energy loss is correlated with the angle of scatter, the
registration of scattered photons may be suppressed by only considering those with sufficiently
high energy (Rudin, 2005).
Image reconstruction
The aim of PET image reconstruction is to obtain a quantitative map of the spatial distribution
of radiotracer in the body. A commonly used method is filtered back projection (FBP), which
is described here by consideration of a single slice through an object, illustrated in Figure
1.6 (a). The projection at each angle is first extracted from the sinogram as an intensity profile,
shown in Figure 1.6 (b). Since the angle at which each projection was acquired is known, the
intensities can be back-projected to reconstruct the image, as shown in Figure 1.6 (c). The
resulting star artefact can be suppressed by the application of a ramp filter (Jain, 1989).
(a) Original object (b) Intensity profile (c) Reconstructed image
Figure 1.6: Image reconstruction by simple back projection, showing (a) a slice through an
object, (b) the intensity profile extracted from a single projection, and (c) the image obtained
following reconstruction.
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Iterative approaches may alternatively be used, such as the maximum likelihood expectation
maximisation (MLEM) algorithm. This aims to find the image most likely to result in the
observed projections, given some modelling of the data, noise and detection procedure. The
algorithm begins with an estimate of the image, often that obtained using FBP, which it then
modifies based on a comparison of the observed projections with those obtained from the image
estimate (Qi and Leahy, 2006). In theory, this procedure is repeated until convergence, but in
practice it can be very slow and a maximum number of iterations is often specified.
Image analysis
PET images may be acquired in static, dynamic, or gated modes. In static mode, images of sev-
eral planes through the body provide visual information showing the radiotracer distribution.
Although visual analysis can be a useful diagnostic tool, it lacks objectivity. Semi-quantitative
objective measures may be obtained from static images. For example, the standardised uptake
value (SUV) is the ratio of radioactivity in a region to a subject-specific scale factor which is
determined from the injected dose and body weight of the patient (Rudin, 2005). In some cases,
there is a region in which the radiotracer accumulates to the same extent in both patients and
healthy individuals. The SUV ratio (SUVR) between the region of interest and this reference
region provides an alternative measure of regional radiotracer accumulation. In dynamic mode,
a time-series of PET images is acquired, from which curves showing the regional tracer kinetics
can be extracted. The temporal behaviour of the tracer can then be modelled, and pharma-
cokinetic parameters derived. In gated mode, the image acquisition is synchronised with a
physiological function, such as the cardiac cycle.
1.4.2 Magnetic resonance imaging
MRI exploits the phenomenon of nuclear magnetic resonance (NMR) to produce high quality
structural images of the internal organs and other tissues. When undergoing a structural MRI
scan, the patient is placed in a powerful static magnetic field, with which the spins of hydrogen
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atoms in their body align. This alignment can be perturbed by the application of a radio
frequency (RF) electromagnetic pulse, resulting in the resonance emission of a measurable RF
signal. The strength of the static magnetic field determines the achievable image quality, and
current clinical systems generally employ field strengths of 1.5 T or 3 T. Spatial localisation
within the body is achieved by the application of magnetic field gradients, such that the static
field varies in strength across the body. The frequency of the resonance signal detected there-
fore becomes dependent on the location from which it was emitted. Different tissues can be
distinguished by the characteristic properties of their emitted RF signals.
Nuclear magnetic resonance
Although nuclei behave according to the laws of quantum mechanics, the principles of NMR
can be described with sufficient accuracy using a classical vector model in which nuclear spin is
viewed as a physical gyroscopic rotation. In the presence of a static magnetic field B0, the spins
of hydrogen atoms in the body align either parallel or anti-parallel to the field, as illustrated
in Figure 1.7. By convention, the coordinate system is defined such that B0 is oriented along
the z-axis. A net longitudinal magnetisation Mz results from the small excess of spins which
align in the lower energy parallel configuration. The spins precess about the static field at a
frequency which is dependent on its strength. This is known as the Larmor frequency ωL = γB0,
where the gyromagnetic ratio γ is characteristic of the nuclei under consideration. The Larmor
frequency for hydrogen atoms in the presence of a 1 T static field is 42.6 MHz (Becker, 2000).
Figure 1.7: Hydrogen atoms in the presence of a static magnetic field B0, which induces a net
longitudinal magnetisation Mz.
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Since the spins do not precess in phase about the z-axis, there is no net magnetisation in
the transverse plane. The application of a RF pulse oscillating at the Larmor frequency can
establish phase coherence amongst the randomly precessing spins. The application of such
a pulse perpendicular to the z-axis results in the rotation of the net magnetisation into the
transverse plane. When the RF signal is then switched off, the spins precess in phase about
the static magnetic field, thus inducing a measurable voltage in a receiver coil. The amplitude
of this signal is maximal immediately following the RF pulse, but then decays with time as the
precession loses phase coherence, and the system returns to equilibrium.
Fourier transforms
In the presence of a static magnetic field B0 oriented along the z-axis, the spins of hydrogen
atoms in the body precess in the xy-plane, as illustrated in Figure 1.8 (a). This precession can
be described by oscillating components in both the x- and y-directions, as shown in Figure
1.8 (b). A mathematical technique known as a Fourier transform can be used to convert these
temporal signals into a frequency distribution. The temporal signals illustrated in Figure 1.8 (b)
correspond to a single peak at the Larmor frequency, as illustrated in Figure 1.8 (c).
(a) Precession (b) Temporal signals (c) Frequency distribution
Figure 1.8: The application of Fourier transforms to MRI illustrated by consideration of (a)
the precession of spins in the presence of a static magnetic field. A Fourier transform converts
(b) the associated temporal signals into (c) the corresponding frequency distribution.
The RF signal detected following resonance emission from nuclei within the body is a temporal
signal consisting of many frequency components. A Fourier transform can convert this temporal
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signal f(t) into a multi-spectral frequency distribution f(ω), according to the expression
f(ω) =
∫ ∞
−∞
f(t)e−iωtdt =
∫ ∞
−∞
f(t)[cos(ωt)− i sin(ωt)]dt.
More detailed information about Fourier transforms and their properties may be found in
Jennison (1961).
Spatial localisation
Spatial localisation is achieved by using magnetic field gradients to modify the static field so
that it varies in strength across the body. Since the Larmor frequency is proportional to the
applied magnetic field, the location of the source signal can then be inferred from the frequency
of the resonance signal detected. Figure 1.9 depicts an example MRI pulse sequence illustrating
the additional gradients required for spatial localisation in 3-D (Hornak, 2010).
Figure 1.9: An example MRI pulse sequence, showing the RF pulse, slice-selection gradient GS,
phase encode gradient Gφ, frequency encode gradient Gf , and the detected RF signal.
The application of a slice-selection gradient GS along the z-axis results in a Larmor frequency
which varies linearly with z. A RF pulse with a narrow band of frequencies therefore excites
resonance within a single transverse section of the body. To achieve spatial localisation within
this transverse section, additional gradients are applied along the x- and y-axes. A phase
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encode gradient Gφ is first applied along one axis, such that the precession frequencies of the
nuclei within the transverse section become dependent on their position. When this gradient
is switched off, the precession frequencies of the nuclei are once again identical; however, they
precess out of phase. A frequency encode gradient Gf is applied along the remaining axis during
the signal detection. The locations of nuclei within a transverse section of the body can then
be unequivocally identified from the frequency distribution of the detected RF signal.
Tissue contrast
The decay of the RF signal as the nuclear spins return to equilibrium is associated with time
constants describing its longitudinal and transverse components. Recovery of the longitudinal
magnetisation as the spins realign with the static magnetic field is known as spin-lattice, or T1,
relaxation. Decay of the transverse magnetisation as the spins dephase is known as spin-spin, or
T2, relaxation. Magnetic field inhomogeneities cause the signal to decay faster in the transverse
plane than can be explained by T2 relaxation alone. This effect is known as T2
∗ relaxation. The
environment of the nuclei under consideration influences these time constants, and therefore
the decay properties of the RF signal. MRI contrast is dependent on the differing T1 and T2
relaxation properties of various biological tissues.
1.5 Biomarkers for Alzheimer’s disease
Since the publication of the NINCDS-ADRDA Alzheimer’s Criteria in 1984, significant progress
has been made in identifying the structural and molecular changes in the brain that are as-
sociated with AD. Much of the recent research has been based on data from the Alzheimer’s
Disease Neuroimaging Initiative (ADNI; http://adni.loni.ucla.edu), which aims to com-
pare neuroimaging, biological, and clinical assessment of the cognitive and behavioural changes
associated with normal ageing, MCI and AD. Participants undergo regular cognitive and func-
tional assessments, and some also opted to undergo lumbar punctures for the collection of CSF
biomarkers such as Aβ and tau. All ADNI participants had structural MRI scans, and approx-
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imately 50% also underwent PET imaging with the tracer [18F]-fluorodeoxyglucose (FDG).
Some participants additionally underwent PET imaging with the tracer [11C]-Pittsburgh com-
pound B (PiB). FDG-PET images depict brain function in terms of the rate of cerebral glucose
metabolism, and PiB-PET images show the distribution of amyloid deposition in the brain.
Figure 1.10 shows a hypothetical model of the temporal profiles of various biomarkers through-
out the development of AD. Amyloid accumulation occurs earliest in the disease process, pre-
ceding both cognitive and functional decline by years, and changing only gradually after symp-
toms develop. Compared to measures of amyloid deposition, CSF tau levels, MRI volumes, and
FDG-PET intensities are more dynamic biomarkers of AD progression. At present, a clinical
diagnosis of AD is made based on assessments of cognition and behaviour, which start to decline
fairly late in the disease process. Other biomarkers may therefore be better suited for the early
detection and prediction of AD, and for monitoring progression. These are briefly reviewed in
the following subsections.
Figure 1.10: Hypothetical temporal model of biomarker dynamics during AD progression.
Biomarker measures vary from normal to maximally abnormal as a function of the disease
stage. eMCI: early MCI, LMCI: late MCI. Adapted from (Aisen et al., 2010).
1.5.1 Cerebrospinal fluid
Recent consensus reports have identified CSF levels of Aβ and tau as among the most promising
potential AD biomarkers (Frank et al., 2003; The Ronald and Nancy Reagan Research Institute
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of the Alzheimer’s Association and the National Institute on Aging Working Group, 1998).
CSF levels of Aβ are approximately 100 times greater than those found in blood plasma, and
this biomarker is best measured in the CSF (Scheuner et al., 1996). The same is true of
tau, which is thought to be released from damaged neurons as they undergo neurofibrillary
degeneration (Kahle et al., 2000). CSF is extracted by lumbar puncture, in which a needle is
inserted between the lumbar vertebrae into the subarachnoid space of the spinal canal
Various studies have shown AD patients to have reduced CSF Aβ and elevated CSF tau com-
pared with cognitively normal individuals (Ishiguro et al., 1999; Motter et al., 1995; Vander-
meeren et al., 1993). When considered in combination, these two biomarkers can effectively
distinguish AD patients from healthy individuals (Sunderland et al., 2003), as well as from
patients with other types of dementia (Clark et al., 2003). AD patients with at least one ApoE
4 allele have lower CSF Aβ and higher CSF tau than those without (Tapiola et al., 2000).
This finding aligns with the observation that more extensive AD pathology is generally found
in AD carriers of the ApoE 4 allele than in non-carriers (Roses and Saunders, 1997).
MCI patients tend to have CSF Aβ and tau levels that lie between those expected of AD
patients and healthy individuals. Preliminary data suggest that MCI patients with AD-like
biomarker levels have a greater likelihood of converting to AD than those with biomarker
levels more typical of cognitively normal individuals (Hansson et al., 2006). The first study
of baseline CSF biomarker data from ADNI largely confirmed previous findings (Shaw et al.,
2009). CSF Aβ was found to be the most sensitive single CSF biomarker, and the overall best
group discrimination was achieved by combining CSF Aβ and tau, along with the number of
ApoE 4 alleles. The majority of MCI patients who converted to AD over the course of one
year had baseline CSF Aβ and tau levels that were more typical of AD patients than of healthy
controls.
1.5.2 Magnetic resonance imaging
The structural changes in the brain associated with AD can be non-invasively assessed using
MRI. As shown in Figure 1.11, AD patients typically have evidence of cortical atrophy, and
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enlarged ventricles in comparison with healthy individuals.
(a) Healthy individuals
(b) AD patients
Figure 1.11: Transverse sections from MR images of (a) healthy individuals, and (b) AD pa-
tients. These images demonstrate that AD patients typically show evidence of cortical atrophy,
and enlarged ventricles in comparison with healthy individuals.
Temporal lobe atrophy is closely associated with AD, and histological studies show that the hip-
pocampus, amygdala and entorhinal cortex are particularly vulnerable to AD pathology (Braak
and Braak, 1998). Correlation has been found between the rate of temporal lobe atrophy and
both current cognitive performance and future decline, even among healthy individuals (Hua
et al., 2008). Increased rates of hippocampal atrophy compared with cognitively normal in-
dividuals have been measured using MRI in both AD and MCI patients (Schuff et al., 2009;
van de Pol et al., 2007). Longitudinal studies have additionally shown that the rate of hip-
pocampal atrophy accelerates over time in both AD and MCI patients (Jack Jr. et al., 2008c;
Ridha et al., 2006). However, hippocampal atrophy alone is not sufficient to predict conversion
from MCI to AD, and other structures may prove more sensitive (Dickerson et al., 2001).
A recent analysis of the ADNI MRI data found that an increased rate of hippocampal volume
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loss was associated with presence of the ApoE 4 allele in AD patients, and with reduced
levels of CSF Aβ in MCI patients (Schuff et al., 2009). Another analysis showed that the
rate of temporal lobe atrophy in AD is correlated with reduced CSF Aβ and elevated CSF
tau, and that it is significantly faster in MCI subjects that later convert to AD than in non-
converters (Leow et al., 2009).
1.5.3 Fluorodeoxyglucose positron emission tomography
FDG is a 18F labelled glucose analogue, whose distribution in the brain gives an indication of
the cerebral metabolic rate of glucose (CMRgl). As shown in Figure 1.12, AD patients typically
have reduced glucose metabolism in temporo-parietal regions of the brain in comparison with
healthy individuals.
(a) Healthy individuals
(b) AD patients
Figure 1.12: Transverse sections from FDG-PET images of (a) healthy individuals, and (b)
AD patients. These images demonstrate that AD patients typically have reduced glucose
metabolism in temporo-parietal regions of the brain in comparison with healthy individuals.
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Numerous FDG-PET studies have shown that both MCI and AD are associated with significant
reductions in the CMRgl in brain regions preferentially affected by the disease (de Leon et al.,
2001, 1983; Herholz et al., 2002; Langbaum et al., 2009; Mosconi et al., 2008, 2007; Mosconi,
2005; Nestor et al., 2003). AD patients display reductions of greater magnitude and spatial
extent than MCI patients. Reductions in the CMRgl in AD patients can predict both their
cognitive decline and histopathological diagnosis (Hoffman et al., 2000; Minoshima et al., 2001;
Silverman et al., 2001), while those in MCI patients can predict their conversion to AD (An-
chisi et al., 2005; Mosconi et al., 2004). Longitudinal studies have shown these changes to be
progressive (Alexander et al., 2002; Mosconi et al., 2005). Based on comparisons of AD and
MCI patients, it has been suggested that posterior regions are preferentially affected in the
earlier stages of AD, with anterior regions such as the frontal cortex becoming involved only in
the later stages of the disease (Alexander et al., 2002; Langbaum et al., 2009).
Cognitively normal individuals with one or two ApoE 4 alleles already have reduced CMRgl in
some of the regions affected by AD (Langbaum et al., 2009; Reiman et al., 2005). This finding
suggests that FDG-PET can provide an early indicator for the disease. A single study of a
small group of MCI patients (Drzezga et al., 2005) has demonstrated complete separation of
those that rapidly converted to AD and those remaining stable, using a combination of reduced
CMRgl in AD-typical regions and ApoE 4 status.
1.5.4 Pittsburgh compound B positron emission tomography
PiB is a 11C labelled thioflavin-T derivative that binds to amyloid plaques in vivo. It can
thus be used to assess one of the characteristic neuropathological features of AD. As shown in
Figure 1.13, AD patients typically have increased PiB retention in areas known to accumulate
significant amyloid deposits in comparison with healthy individuals. A number of PiB-PET
studies have reported cortical PiB retention in AD patients, and mostly non-specific retention
in the white matter in healthy individuals (Forsberg et al., 2008; Jack Jr. et al., 2009; Klunk
et al., 2004; Villemagne et al., 2008). Cortical PiB retention is also observed in MCI patients,
but to a lesser extent than in AD. An inverse correlation has been found between cortical PiB
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retention and levels of CSF Aβ (Fagan et al., 2006). Patients are often classified as PiB positive
or negative, where a global cortical to cerebellar ratio is defined to separate the two groups.
Independent studies have consistently found that approximately 30% of cognitively normal
elderly individuals would be classified as PiB positive according to such criteria (Jack Jr. et al.,
2008b; Mintun et al., 2006). This suggests that PiB alone is not a sufficient marker for AD,
although it may indicate individuals who will subsequently develop the disease. Longitudinal
follow-up of cognitively normal PiB positive individuals will be required to verify this suggestion.
(a) Healthy individuals
(b) AD patients
Figure 1.13: Transverse sections from PiB-PET images of (a) healthy individuals, and (b) AD
patients. These images demonstrate that AD patients typically show cortical PiB retention,
while healthy individuals typically show non-specific retention in the white matter.
Significant amyloid plaque deposition occurs before the onset of clinical symptoms (Mintun
et al., 2006), continuing at a slower rate as AD progresses. Progression may therefore be better
assessed by considering measures of neurodegeneration. A study of ADNI MRI and PiB-PET
found the rate of ventricular expansion greater in MCI patients that were PiB positive at
baseline than in those that were PiB negative (Jack Jr. et al., 2009). This supports other
studies suggesting that PiB negative MCI patients may not have early AD (Archer et al., 2006;
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Forsberg et al., 2008). Additional follow-up data will again be required for verification.
1.6 Research contributions and thesis outline
The research presented in this thesis contributes to the growing body of literature surrounding
the image-based classification of MCI and AD. In particular, a framework for multi-modality
classification, based on the combination of similarity measures derived from random forest
classifiers, is presented. In addition, early signs of neurodegeneration are identified in cognitively
normal individuals at high risk of developing AD, based on multi-region analysis of MR images
from two independent cohorts.
Relevant concepts from the fields of image analysis and machine learning are first described in
Chapters 2 and 3, respectively. Chapter 2 describes image analysis techniques including regis-
tration, anatomical segmentation, and statistical parametric mapping. Chapter 3 then provides
an overview of machine learning concepts relevant to image-based classification, including clas-
sification algorithms, and methods with which to assess their performance. A review of the
current state-of-the-art for image-based classification of AD is additionally presented.
In terms of the classification of AD and MCI, there are many more studies based on structural
MR imaging data than on FDG-PET imaging data. This is because anatomical imaging with
either MRI or CT is routinely used in clinical practice for dementia patients. Investigations
of the potential utility of multi-region FDG-PET features for image-based classification of AD
and MCI are described in Chapters 4 and 5. In particular, attempts are made to distinguish
between MCI patients who subsequently progress to AD and those who remain stable. Chapter
4 demonstrates that regional information extracted from FDG-PET images acquired at a single
timepoint can be used to achieve classification results in line with those obtained using data
from MRI, or biomarkers obtained invasively from the CSF. Chapter 5 then demonstrates
the additional benefit of incorporating longitudinal FDG-PET information for classification.
By combining cross-sectional and longitudinal multi-region FDG-PET features, classification
results in line with the current state-of-the-art are achieved. The findings described in these
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chapters support the use of FDG-PET for the early diagnosis of AD and for monitoring its
progression.
Changes in multiple neuroimaging and biological measures may provide complementary infor-
mation for the diagnosis and prognosis of AD. Chapter 6 presents a multi-modality classification
framework in which manifolds are constructed based on pairwise similarity measures derived
from random forest classifiers. Similarities from multiple modalities are combined to generate
an embedding that simultaneously encodes information about all the available features. Multi-
modality classification is then performed using coordinates from this joint embedding. Random
forests provide consistent pairwise similarity measures for multiple modalities, thus facilitating
the combination of different types of feature data. Classification results based on the com-
bination of regional MRI volumes, voxel-based FDG-PET signal intensities, CSF biomarker
measures, and ApoE allele status are comparable with those obtained in other studies using
multi-kernel learning. Since random forest classifiers extend naturally to multi-class problems,
the framework described here could be used for other applications in the future, such as the
differential diagnosis of AD.
Novel findings of early signs of neurodegeneration in cognitively normal individuals at high risk
of developing AD are presented in Chapter 7. Multi-region analysis of MR images acquired
at a single timepoint is used to show volumetric differences in cognitively normal individuals
differing in amyloid-based risk status for the development of AD. Reduced volumes in temporo-
parietal and orbito-frontal regions in high-risk individuals from two independent cohorts could
be indicative of very early changes associated with AD. These findings suggest that volumetric
MRI can reveal structural brain changes that precede the onset of clinical symptoms. It may
therefore be useful in identifying early signs of neurodegeneration in healthy elderly individuals,
potentially providing a useful early screening tool, or outcome measure for clinical trials.
Chapter 2
Background: PET and MR image
analysis
2.1 Introduction
This chapter describes state-of-the-art techniques relevant to the PET and MR image analysis
presented in this work. Image registration is first described in Section 2.2. This allows the
alignment of different images so that they share a common coordinate system. Anatomical
segmentation techniques are then reviewed in Section 2.3. Much of the work presented in this
thesis involves the use of multi-region imaging features obtained by using segmentation to label
anatomically defined structures in the brain. The initial focus of this research was FDG-PET
image analysis, and an overview of statistical parametric mapping is given in Section 2.4. This
provides a voxel-based analysis method for studying group differences amongst PET images.
2.2 Image registration
The goal of image registration is to estimate a spatial correspondence between two images.
Approaches can be broadly divided into those based on image intensity values, and those
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which instead rely on image features such as lines or contours. The focus for this work is on
intensity-based approaches. These typically comprise several related components: a transfor-
mation model, optimisation method, similarity metric, regularisation method, and interpolation
method. A transformation model defines the way in which one image (the source) should be
deformed into the coordinate system of another (the target). Having selected a transformation
model, the spatial correspondence between the two images is estimated by applying an optimi-
sation method to find the transformation which maximises the image similarity. To ensure that
the transformation is plausible, regularisation may be incorporated into the registration pro-
cess. Finally, intensities may need to be interpolated to compensate for any mismatch between
the deformed voxel grid of the source image and the target grid.
Several applications of image registration will be described in this thesis: alignment of images of
a subject acquired at a single timepoint using different modalities (MRI and PET), alignment
of images of a subject acquired serially using a single modality, and alignment to a standard
template space of images of a group of subjects acquired using a single modality. Registration
also forms part of an image segmentation procedure in which the labels from a set of manually
segmented images are propagated to the target.
The components of the voxel-based registration method used throughout this research are de-
scribed in detail in the following subsections. A more comprehensive review of image registration
techniques may be found in Hajnal et al. (2001).
2.2.1 Transformation model
A transformation T defines a parametric representation mapping a voxel in the target image
to a location in the source image, T : (x, y, z) → (x′, y′, z′). Transformations may be broadly
divided into linear and nonlinear models. Linear models include both rigid transformations,
which preserve distances between points, and affine transformations, which preserve colinearity
of points. Linear transformations are global in nature, and cannot model local geometric differ-
ences between images. Nonlinear (or nonrigid) transformations, however, can represent varying
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local deformations, thus allowing the source image to be locally warped into the coordinate
system of the target.
The choice of transformation model is dependent on the application of interest. For example, a
rigid transformation may be sufficient for the registration of serially acquired brain MR images
of a healthy adult, since there should be very little change in the shape of the cranium. An
affine transformation may be more appropriate for the intra-subject registration of brain MR
and PET images acquired at a single timepoint, where some global scaling may be required.
A nonrigid transformation may be applied following a global transformation to reduce any
residual differences remaining between images. For example, local differences are likely to
remain following global registration of serially acquired brain MR images of an AD patient.
Rigid transformations
A rigid transformation can be represented by the application of translations and rotations, as
illustrated in Figure 2.1.
(a) Original image (b) Translate (c) Translate+Rotate
Figure 2.1: Illustration of possible rigid transformations applied to (a) the original image,
showing the effect of (b) translation, and (c) both translation and rotation.
In 2-D, a translation in the xy-plane can be represented by a vector t, and rotations may be
made about an axis perpendicular to the plane. An anti-clockwise rotation about the z-axis by
an angle θ can be expressed as
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Rz(θ) =
cos θ − sin θ
sin θ cos θ
 .
The effect of applying a rigid transformation comprising a rotation matrix R and translation
vector t to a point x can be written as Trigid(x) = Rx+t. This may alternatively be represented
by the following single transformation matrix using homogenous coordinates:
Trigid(x) =
Rx + t
1
 =
R t
0 1

x
1
 ,
where Trigid can be decomposed into the following block form rotation and translation matrices:
Trigid =
R t
0 1
 =
I t
0 1

R 0
0 1
 .
In 3-D, a general rotation can be decomposed into rotations about each of the coordinate axes.
In a right-handed frame, these rotations may be expressed as
Rx(θ1) =

1 0 0 0
0 cos θ1 − sin θ1 0
0 sin θ1 cos θ1 0
0 0 0 1

Ry(θ2) =

cos θ2 0 sin θ2 0
0 1 0 0
− sin θ2 0 cos θ2 0
0 0 0 1

Rz(θ3) =

cos θ3 − sin θ3 0 0
sin θ3 cos θ3 0 0
0 0 1 0
0 0 0 1

.
A general rotation comprising sequential rotations about the x-, y- and z-axes can be expressed
as R = Rz(θ3)Ry(θ2)Rx(θ1). The single matrix representation for the rigid transformation
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Trigid is therefore the same as for the 2-D case. A general 3-D rigid transformation can therefore
be represented using six parameters, three describing translation, and three rotation.
Affine transformations
An affine transformation can be represented by the application of translations and rotations,
as well as scales and shears, which are illustrated in Figure 2.2.
(a) Original image (b) Scaling (c) Shear
Figure 2.2: Illustration of possible affine transformations applied to (a) the original image,
showing the effect of (b) scaling, and (c) shear.
In 3-D, scale factors sx, sy and sz can be applied independently along each of the coordinate
axes, such that a general scaling transformation may be expressed as
Tscale =

sx 0 0 0
0 sy 0 0
0 0 sz 0
0 0 0 1

.
In 2-D, shear along the x-direction describes the translation of a point x = (xx, xy) parallel to
the x-axis by an amount shxxy, where shx is a scalar shear coefficient. Shear in the y-direction
can be similarly described by a scalar shear coefficient shy. The general shear matrix can then
be expressed as
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Tshear =

1 shy 0
shx 1 0
0 0 1
 .
In 3-D, shears can be characterised as either beam shears or slice shears, although these two
representations are equivalent. A beam shear is defined as the translation of a point x parallel
to one axis by an amount equal to a linear combination of the other two coordinate values. A
slice shear involves translation of the point x along a pair of axes by an amount proportional
to the coordinate value of the third. For example, shear along the x- and y-axes due to z is
described by scalar shear coefficients shzx and shzy respectively. A general shear can therefore
be expressed as
Tshear =

1 shxy shxz 0
shyx 1 shyz 0
shzx shzy 1 0
0 0 0 1

.
A general affine transformation may be expressed as Taffine = TshearTscaleTrigid. In 3-D,
translation, rotation and scale can each be represented using three parameters, and shear using
six. It therefore appears that 15 parameters are required to specify an affine transformation.
However, the parameters are not independent, and a general 3-D affine transformation may be
expressed as
Taffine =

a11 a12 a13 a14
a21 a22 a23 a24
a31 a32 a33 a34
0 0 0 1

.
Only 12 independent parameters are required to represent a 3-D affine transformation.
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Nonrigid transformations
A nonrigid transformation represents local deformations which can vary across the image, as
illustrated in Figure 2.3. There are various possible ways to characterise nonrigid transforma-
tions because they require many more parameters than global transformations and therefore
cannot be simply represented using a single matrix.
(a) Original image (b) Deformed image
Figure 2.3: Illustration of a nonrigid transformation applied to (a) the original image, showing
the effect of (b) a locally varying deformation.
A brief description of the relevant mathematical terminology is now presented. A function f
on a domain Ω is described as continuous if an infinitesimal change in the input results in
an infinitesimal change in the output. The class of all such continuous functions, whose nth
derivatives are also continuous, is denoted Cn(Ω). If all derivatives of a continuous function f
are also continuous, the function is described as smooth, and it belongs to the class C∞(Ω).
In practice, when modelling transformations, functions belonging to classes C2(Ω) and C1(Ω)
may be considered sufficently smooth. A function f which maps points from a set X to a set
Y is described as a homeomorphism if it is a bijection, and both f and its inverse f−1 are
continuous. A bijection describes an exact pairing of the sets X and Y , such that each element
in X is paired with exactly one element in Y , and vice-versa. A homeomorphic transformation
preserves topology, and should therefore be used if the underlying topology between two images
is assumed to be identical. Enforcing the additional restriction that both f and its inverse f−1
must belong to the class Cn(Ω) defines f as a Cn-diffeomorphism. The term diffeomorphism
is typically used to refer to the case of C∞-diffeomorphism. If the anatomical structures rep-
resented within a pair of images are assumed to be smooth, the transformation between them
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must be a diffeomorphism of the appropriate order. Diffeomorphic transformations are often
used as a theoretical basis for the nonrigid registration of medical images.
A nonrigid transformation can be represented by a smooth displacement field, which requires
the smooth assignment of vectors to every location in the image. In 3-D, this requires that
a displacement vector is specified for every voxel, and the number of parameters is therefore
three times the number of voxels. It is possible to reduce the number of parameters required
by either using a model, or exploiting a property of the transformation. For example, a smooth
transformation may be globally defined based on displacement vectors assigned to each of a set
of control points defined within the image. For the free-form deformation (FFD) model used
in this work (Rueckert et al., 1999), the control points are arranged on a regular nx × ny × nz
axis-aligned lattice with spacings δx, δy, δz along each coordinate axis. A FFD can then be
parametrised by a set of vectors {Φ}, each of which is associated with one of the control
points. Displacement vector φi,j,k, for example, represents the control point located at position
x = (i, j, k). The nonrigid transformation is thus parametrised by the displacement vectors
at the locations of the control points, but must also be defined at general locations within
the image. This is achieved by convolving {Φ} with a suitable basis function, resulting in a
smoothly varying displacement field across the entire image. In this work, the control points
are convolved using 1-D cubic B-splines, which are expressed as
B0(u) =
(1− u)3
6
B1(u) =
(3u3 − 6u2 + 4)
6
B2(u) =
(−3u3 + 3u2 + 3u+ 1)
6
B3(u) =
u3
6
.
The local displacement at the general location x = (x, y, z) can then be written as the 3-D
tensor product over the control point vectors, as
Tlocal(x, y, z) =
3∑
l=0
3∑
m=0
3∑
n=0
Bl(u)Bm(v)Bn(w)φi+l,j+m,k+n,
where i = bx/δxc − 1, j = by/δyc − 1, k = bz/δzc − 1, u = x/δx− bx/δxc, v = y/δy− by/δyc,
w = z/δz − bz/δzc, and bxc = floor(x), which gives the largest integer not greater than x.
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B-splines are computationally efficient because the displacement at a particular control point
affects the transformation only in its local neighbourhood. Similarly, its displacement depends
only on control points within the neighbourhood.
When performing nonrigid registration using FFDs, it is possible to employ a hierarchical,
coarse-to-fine strategy (Schnabel et al., 2001) to reduce the likelihood of convergence to a local
optimum. Using this approach, the FFD parameters are first optimised based on a relatively
sparse control point lattice with a large spacing. This results in a transformation that captures
large-scale local differences between the two images being registered. The control point lattice is
then sub-divided to generate a lattice with half the spacing of the original (Forsey and Bartels,
1988). The FFD parameters are re-optimised based on this new, denser lattice of control points.
This process of lattice sub-division and parameter optimisation may be repeated as required,
with smaller-scale local differences between the images being captured at each iteration. It
is important to ensure that the scale of the image features is appropriate for the selected
control point spacing. The images should be blurred and resampled at each step so that
information relating to structures smaller than a certain size is neglected. Images may be
blurred by convolution with a Gaussian kernel of width σ. For capturing large-scale differences,
a relatively wide Gaussian kernel is appropriate. Successively smaller values of σ may then be
selected as smaller-scale differences are captured by the FFD.
Combining global and local transformations
In the work presented in this thesis, nonrigid image registration is performed as a multi-stage
process. Global transformation parameters are estimated, and used as the starting point for
the nonrigid registration step. The global transformation itself is performed in two steps, with
rigid transformation parameters estimated first, and used as the starting point for an affine
registration. Rigid transformation parameters make up a sub-set of the affine parameters, and
their combination is therefore straightforward. The affine transformation is simply initialised
with the translation and rotation parameters from the rigid registration, and the scales and
shears set to one and zero respectively. The global transformation is thus obtained following
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the affine registration step, and the subsequent nonrigid registration aims to estimate the
local residual displacements required to accurately align the images. This means that the
global and local components of the final transformation are combined by addition, such that
T(x) = Tglobal(x) + Tlocal(x).
2.2.2 Optimisation method
The goal of an optimisation method, as applied to the registration of medical images, is to
select transformation parameters which maximise the similarity between the two images being
registered. In the work presented in this thesis, global transformations are optimised using
downhill descent, and nonrigid transformations using steepest gradient descent. Both meth-
ods consider the optimisation as a minimisation problem, and therefore aim to minimise the
difference between the two images. This is equivalent to maximising their similarity.
In downhill descent, the transformation parameters are initialised, and the similarity between
the two images is determined using the chosen metric. Each parameter is then perturbed by the
chosen step size, the image similarity re-evaluated, and the parameter providing the greatest
increase in similarity is modified. This process is repeated until no further increase in similarity
is achieved following perturbation. A large step size is selected for the earliest iterations, and
successively reduced to obtain an accurate global alignment.
In steepest gradient descent, the set of transformation parameters Φ are updated by moving
along the direction of maximum increase in similarity. For a similarity metric C and step size
δ, this may be expressed as Φ→ Φ + δ∇ΦC. As for the downhill descent method, successively
smaller step sizes may be applied at each iteration. The gradient term ∇ΦC can be evaluated
analytically for certain similarity metrics, or estimated using a finite difference method.
2.2.3 Similarity metric
A similarity metric which measures the correspondence between a pair of images must be defined
in order to optimise the transformation parameters of a registration. For a transformation T,
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which maps locations {x} in the target image It to locations {T(x)} in the source image Is,
the set of intensity pairs {(It(x), Is(T(x)))} is used to calculate the similarity metric. In the
following section, this set of intensity pairs will be more compactly represented by {(t, s)} =
{(t1, s1), . . . , (tn, sn)}.
The simplest similarity metric, which penalises differences in intensity between corresponding
voxels in two images, is the sum of squared differences, defined as
SSD =
1
n
n∑
i=1
(ti − si)2.
This actually provides a measure of the distance between images, and −SSD is therefore used
to measure the image similarity. This metric should be used only when the correct alignment of
two images would result in them having identical intensities, bar Gaussian noise. If this is not
the case, cross-correlation may be an appropriate similarity metric if it can be assumed that
the intensities at corresponding voxels in the two images would have a linear relationship when
correctly aligned, again allowing for residual Gaussian noise. Cross-correlation is a general
measure of statistical agreement, and is defined as
CC =
∑
n(ti − t¯)(si − s¯)√∑
n(ti − t¯)2
√∑
n(si − s¯)2
,
where t¯ and s¯ represent the mean intensities of It and Is respectively.
For cases such as multi-modality image registration, where a linear relationship between the
intensities in corresponding voxels cannot be assumed, an appropriate similarity metric can be
defined using measures from the field of information theory. By allocating the intensities in
images It and Is to a series of bins, the joint histogram of the image pair is constructed. This
histogram consists of a matrix of values h(t, s), each of which represents the number of times
a binned intensity pair (t, s) has co-occurred at the same voxel in the two images. The joint
probability p(t, s) of co-occurence of the intensity pair (t, s) may be estimated as
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p(t, s) =
h(t, s)
N
,
where N is the total number of samples in the joint histogram. The marginal probabilities of
the occurence of intensity t in image It, p(t), and of the occurence of intensity s in image Is,
p(s), may then be estimated as p(t) =
∑
s p(t, s) and p(s) =
∑
t p(t, s), respectively.
Using these probability estimates, the Shannon entropy (Shannon, 1949) of the target image It
can be expressed as
H(It) = −
∑
t
p(t) log(p(t)),
with a corresponding expression for the source image Is. The Shannon entropy describes the
information content of an image. It is maximal if all possible intensities have equal probability,
and minimal (zero) if p(t) = 1 for a single intensity value, such that the image is completely
uniform. The joint entropy of the image pair can be expressed in a similar way as
H(It, Is) = −
∑
t
∑
s
p(t, s) log(p(t, s)).
A similarity metric can then be defined such that it maximises the information content of
each image, while minimising their shared information content. Mutual information (Collignon
et al., 1995; Viola and Wells III, 1995), defined by MI = H(It)+H(Is)−H(It, Is), thus describes
the extent to which one image can be explained by another. The two images are aligned when
their mutual information is maximal. Normalised mutual information, defined by
NMI =
H(It) +H(Is)
H(It, Is)
,
is a more robust metric with respect to changes in the overlap of the two images during the
registration process (Studholme et al., 1999).
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2.2.4 Regularisation method
Nonrigid image registration requires the optimisation of a large number of parameters. It is
therefore an ill-posed problem to which multiple solutions may exist. Restricting the possible
solutions to those considered plausible transformations can be beneficial. For example, if a
pair of images represent the same topology, a plausible transformation between them should
not alter this topology. The smoothness of a transformation is often an appropriate measure
of its plausibility (Rueckert et al., 1999). The term regularisation refers to the process of
providing smooth, and therefore plausible, transformations. Regularisation methods include
the application of a processing step to obtained deformations (Karac¸ali and Davatzikos, 2004),
incorporation of models describing the mechanical properties of tissues into the registration
step (Soza et al., 2004), and modification of the optimisation step such that it maximises both
the image similarity and transformation smoothness. The final approach is the method used
throughout this research.
For a similarity metric Csim and regularisation term Creg, the overall objective function can
be expressed as C = Csim + λCreg, where λ determines the relative contribution of each term.
There is a trade-off between maximising the image similarity and maximising the transformation
plausibility, and it is important that an appropriate value is selected for λ. A value that is too
low could result in an implausible transformation, whereas a value that is too high could prevent
the registration from achieving accurate alignment. For the nonrigid registrations presented in
this work, high curvature solutions were penalised by using the bending energy associated with
the transformation as a regularisation term (Rueckert et al., 1999).
2.2.5 Interpolation method
The computation of the similarity metric for a transformation T is based on the correspondence
between intensities at voxels x in the target image It, and those at voxels T(x) in the source
image Is. It is unlikely that locations in the target image should exactly coincide with voxels in
the deformed source image. Intensity values in the source image must therefore be interpolated
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to coincide with locations in the target image before calculating the image similarity.
There are several choices of interpolation method. The simplest is nearest neighbour interpola-
tion, in which the source image intensity at a location in the target image is assigned the value
of its nearest neighbour in the source image. This method is appropriate for image data with
intensity values on a nominal or ordinal scale, such as label maps for anatomical structures.
For images with a continuous distribution of intensities, tri-linear interpolation may be more
appropriate, in which the source image intensity at a location in the target image is determined
from a linear combination of its neighbours in the source image.
2.3 Anatomical segmentation
Anatomical image segmentation describes the process of assigning labels to voxels in an image
according to the anatomically defined structures they represent. In the work presented in this
thesis, segmentations are defined on structural MR images and propagated to the corresponding
PET images. Regional imaging features may then be extracted, such as volumes and average
PET signal intensities. The following subsections provide an overview of relevant image seg-
mentation concepts, including manual segmentation, brain atlas generation, and multi-atlas
segmentation.
2.3.1 Manual segmentation
An experienced human rater can produce accurate manual segmentations of structural brain
images. This requires a detailed segmentation protocol which clearly defines the way in which
each structure should be delineated. Manual segmentation is the gold-standard method, but it
is a challenging and time-consuming process. Its use is often not practical, particularly for a
large set of images.
An automated, or semi-automated, approach could present a valuable alternative, provided
that the resulting segmentations are of sufficiently high quality. Automated approaches may
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also be more robust to sources of error occurring between segmentations of different images. For
manual segmentation, these can include human factors such as inter- and intra-rater variation,
and differences in the interpretation of the segmentation protocol. Both manual and automated
segmentation methods may be affected by image acquisition effects such as image contrast
characteristics, motion artefacts, and scanner calibration issues.
2.3.2 Brain atlases
The term brain atlas refers to the pairing of a brain image, or series of histological sections of a
post-mortem brain, with a corresponding set of anatomical labels. The Talairach and Tournoux
atlas of 1988 (Talairach and Tournoux, 1988) is additionally associated with a corresponding
coordinate system, allowing the alignment of other brains with the atlas. This coordinate
system is defined by requiring that the anterior and posterior commissures lie on a straight
horizontal line, known as the AC-PC line, as illustrated in Figure 2.4. The anterior and posterior
commissures lie in the mid-sagittal plane, and the coordinate system is therefore fully defined
by requiring this plane to be vertical.
Figure 2.4: Schematic sagittal brain view showing the anterior commissure (AC) and posterior
commissure (PC), and construction of the AC-PC line (Rorden, 2002).
The Talairach and Tournoux atlas is based on post-mortem sections of one hemisphere of a
single brain. The Montreal Neurological Institute (MNI) aimed to define a more representative
template based on a large set of MR images of normal controls. The International Consortium
for Brain Mapping (ICBM) adopted one such template as their standard in 2001 (Mazziotta
et al., 2001), and it remains the most commonly used today. This template is known as the
ICBM152, since it was generated by averaging 152 normal MR images that had been affinely
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aligned to the Talairach and Tournoux atlas.
In the work presented in this thesis, a set of 30 manually delineated brain atlases is used.
Each atlas consists of the 83 anatomically defined structures described in Appendix A. The
MR images used for atlas creation were acquired from 30 young, healthy adults (age range 20–
54, median age 30.5 years), as described in Hammers et al. (2003). Protocols for the manual
delineation are described in Hammers et al. (2003) and Gousias et al. (2008). An example of
one of the manual segmentations overlaid onto the corresponding MRI is shown in Figure 2.5.
(a) Transverse view (b) Coronal view (c) Sagittal view
Figure 2.5: One of the manually delineated brain atlases used in this work shown overlaid onto
the corresponding MR image.
2.3.3 Automated multi-atlas segmentation
There are numerous ways to approach automated image segmentation. The focus for this
work is on atlas-based methods, in which expert manual segmentations are propagated to new
(unseen) images. For example, the MR image of a single brain atlas may be registered to the
MR image of a new subject, and the resulting transformation used to propagate the atlas label
volume into the space of the unseen image. An atlas-based segmentation of the unseen image
is thus automatically generated. If a set of atlases is available, multiple label volumes can be
propagated to the unseen image. These transformed label volumes may then be viewed as
classifiers, whose outputs can be combined to generate a consensus segmentation for the new
subject. This procedure is illustrated in Figure 2.6.
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Figure 2.6: Schematic representation of the multi-atlas segmentation procedure. A set of atlas
anatomical images Ii is registered to the unseen image U , and the corresponding atlas label
volumes Li propagated to the unseen image. The transformed label volumes L
′
i are then fused
to generate the consensus segmentation L∗ for the unseen image.
An overview of classifier fusion methods is provided in Kittler et al. (1998). A simple approach
is to consider the multiple labels assigned to a voxel as votes. A majority voting rule may then
be applied, such that the consensus label for a voxel is defined as the mode of the distribution
of its individual labels. Classifier fusion according to such a majority voting rule performs
well in comparison with other fusion approaches in the general pattern recognition context
(Kittler et al., 1998). It has also been shown to be both robust and accurate for medical image
segmentation, using a database of bee brain confocal microscopy images (Rohlfing et al., 2004),
as well as human brain MR images (Heckemann et al., 2006). The key benefit of fusing the
propagated labels from multiple atlases is that the effect of non-systematic errors associated
with the propagation of any single atlas may be reduced. For brain MR images, the fused
consensus segmentation has greater accuracy than that of any individual segmentation based
on the propagation of a single atlas label volume (Heckemann et al., 2006).
If a sufficiently large set of atlases is available, it can be beneficial to apply a strategy in
which multi-atlas segmentation of a new subject is based on only the most suitable atlases.
The STAPLE algorithm (Warfield et al., 2004) generates a probabilistic final segmentation by
computing a weighted combination of the propagated label volumes, in which the weighting
factor for an individual label volume is based on its estimated performance. Alternatively, an
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intensity-based similarity metric may be used to rank each atlas according to its suitability for
segmenting a new subject. Multi-atlas segmentation may then be performed using only the
top-ranked atlases (Aljabar et al., 2009).
2.4 Statistical parametric mapping
Statistical parametric mapping (SPM) is a technique for testing hypotheses about functional
neuroimaging data, such as PET. The software was first made available to the research commu-
nity in 1991 (Friston et al., 1991, 1990), and there have since been many theoretical and technical
advances. The latest versions of the SPM software are available from the Wellcome Trust Cen-
tre for Neuroimaging at University College London (http://www.fil.ion.ucl.ac.uk/spm),
along with detailed documentation, background information, and related publications.
The current SPM8 software incorporates various image processing tools as well as the statistical
interface. In the work presented in this thesis, SPM is used to investigate voxel-wise differences
in PET signal intensities between two groups. The aspects of the software that are relevant to
this particular type of analysis are described in the following subsections. The images must first
undergo several processing steps, including alignment to a standard template space, smoothing,
and intensity normalisation (if required). A general linear model is applied at each voxel in
the processed images, and the resulting parameters are used to compute t-statistics (Student,
1908). Voxels for which the PET signal intensities are significantly different between the two
groups can then be identified. Finally, since statistical tests are performed independently at
each voxel, a correction for multiple comparisons is required.
2.4.1 Image processing
Before voxel-wise statistical analyses may be performed, spatial correspondences between voxels
must be established across the set of images. This is achieved by alignment to a standard
template space. The images are then smoothed, both to reduce residual anatomical variation,
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and to improve the signal-to-noise ratio. Intensity normalisation is additionally performed to
account for inter-subject variability in overall radioactivity. This can arise from physiological
differences in metabolic rate, as well as variations in, for example, the injected dose or time
allowed for tracer uptake before scanning. Intensity normalisation is often performed using
proportional scaling relative to the cerebral global mean.
2.4.2 Statistical analyses
A general linear model is applied at each voxel in the processed images. This model describes
the signal intensities at a voxel Y in terms of the parameters B and residual variability E. For
investigating differences in the PET signal intensities between two groups, this can be expressed
as the multiple linear regression Y = XB + E. The design matrix X = (XP,XC) contains
variables indicating to which group each image belongs, as illustrated in Figure 2.7 (a).
(a) Design matrix (b) Significant voxels
Figure 2.7: Illustrative example of the SPM analysis procedure, showing (a) the design ma-
trix for investigating differences between two groups, and (b) an example maximum intensity
projection image depicting voxels whose adjusted signal intensities are significantly different
between two groups. The vectors XP and XC indicate the group to which each image belongs.
The parameters B = (BP , BC) are determined for each voxel from the analysis of variance, and
then hypothesis testing is performed using classical statistical inference. To identify voxels with
significantly higher adjusted PET signal intensities in a patient group than a group of healthy
individuals, voxel-wise t-statistics are computed as
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t =
(BP −BC)
SE
,
where SE is the standard error, which may be determined from E. In SPM, a contrast vector
C = (1,−1) is defined, such that the t-statistic may be expressed as t = CB/SE. A threshold α
for the t-statistic can be set to define the significance level at which the null hypothesis, that the
adjusted PET signal intensity at a voxel is no higher in the patient group than in the healthy
group, can be rejected. An image depicting the significant voxels may then be produced, as
illustrated in Figure 2.7 (b).
2.4.3 Multiple comparison correction
Multiple comparison correction is an integral part of SPM. If the large number of voxels which
make up medical imaging data were treated independently, it would be likely that a number
of individual voxels would reach statistical significance by chance, even if the null hypothesis
were true. The significance level can be corrected to account for the number of voxels, thus
controlling the family-wise error (FWE). This is the likelihood of the chance observation of a
family of statistically significant voxels across the entire brain.
One standard method for controlling the FWE is the Bonferroni correction (Bonferroni, 1936,
1935), in which the significance level is adjusted to pFWE =
α/n, where n is the number of
independent statistical tests. However, the Bonferroni correction generally sets too conservative
a threshold for functional neuroimaging data, since the spatial correlations in the images mean
that the statistical tests at each voxel are not independent.
Random field theory provides a way to define a corrected threshold which takes these spatial
correlations into account, based on the Euler characteristic of the t-statistic image. This can be
considered as the number of “blobs” present in the image after thresholding. At high thresholds,
the expected Euler characteristic is a good approximation for the FWE, and a corrected voxel-
level threshold which permits a known false positive rate across the entire brain may thus
be determined. The Euler characteristic depends only on the number of resolution elements
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(resels) in an image (Worsley et al., 1992), which itself depends on the image smoothness, and
the number of voxels. A more detailed description of the application of random field theory
to functional neuroimaging data is provided in Worsley et al. (1996). Voxel-level tests identify
the individual voxels which reach statistical significance based on the corrected threshold. In
addition, cluster-level tests identify regions comprising a number of significant voxels, while
set-level tests identify the number of significant clusters.
2.5 Conclusion
This chapter has provided an overview of methods relevant to the analyses of PET and MR
imaging data which are presented in this thesis. Using these methods, multi-region and voxel-
based imaging features will be extracted from MR and PET images. Image registration and
anatomical segmentation techniques are important processing steps used throughout this work.
Statistical parametric mapping is applied for FDG-PET image intensity normalisation, which
is described in detail in Chapter 4. The following chapter presents additional background
information about the use of machine learning techniques for image-based classification.
Chapter 3
Background: machine learning
3.1 Introduction
Machine learning is a branch of artificial intelligence involving the design of algorithms whose
performance automatically improves through experience. Such algorithms can learn to make
intelligent decisions based on their recognition of complex patterns, with applications includ-
ing handwriting recognition, stock market analysis, and medical diagnosis. The focus of this
research is medical diagnosis. This is a classification problem in which the aim could be, for
example, to use neuroimaging data to determine whether a newly presenting patient has AD.
This chapter provides an overview of machine learning concepts that are relevant to the image-
based classification analyses presented in this thesis. Details of various classification algorithms
are first presented in Section 3.2, followed by a description of methods with which to assess
their performance in Section 3.3. Finally, a review of literature relating to the use of machine
learning for image-based classification of AD is provided in Section 3.4.
3.2 Classification algorithms
An image consisting of D voxels may be represented by the D-dimensional feature vector
x = (x1, x2, . . . , xD). The overall goal of a classification algorithm is to assign this feature
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vector to one of K discrete classes Ck. For the purposes of this work, only the case of K = 2
is considered, and the classes C1 and C2 are taken to be disjoint, such that each feature vector
belongs to one, and only one, of the two classes. A classification algorithm could therefore
take the form of a function y(x) which returns a value that indicates the class to which the
feature vector x should be assigned. The parameters of the function y(x) are optimised during
a training phase in which the algorithm is presented with a set of N training examples for
which the correct diagnoses are known,
{
(xi, ti) | xi ∈ RD, ti ∈ {−1, 1}
}N
i=1
. After training,
the classification performance may be assessed using new data. There are a large number of
classification algorithms, and details of those relevant to this work are now provided.
3.2.1 Linear discriminant functions
The two-class Fisher linear discriminant function classifier (Fisher, 1936) aims to determine the
linear combination of features that results in the maximum separation between the class means
relative to the sum of the within-class variances, and therefore with the minimum possible class
overlap. This linear combination may be expressed as y(x) = wTx − b, where the decision
surface y(x) = 0 is a (D − 1)-dimensional hyperplane, as illustrated in Figure 3.1. A feature
vector x belongs to class C1 if y(x) ≥ 0, and to class C2 if y(x) < 0. The value of y(x) gives
a signed measure of the distance from the decision surface, which may be interpreted as a
measure of the certainty with which the feature vector x is assigned to a class.
Figure 3.1: A 2-D illustration of the decision surface obtained using a Fisher linear disciminant
function. Feature vectors belonging to class C1 are shown in red, and those belonging to class
C2 are shown in blue. The decision surface is defined by its orthogonality to the feature weight
vector w and its distance from the origin, which depends on the threshold b.
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The maximisation criterion described above may be written as
max
w
J(w) = max
w
wTSBw
wTSWw
,
where SB is the between-class scatter matrix, and SW the within-class scatter matrix. For two
classes C1 and C2, the scatter matrices are defined as
SB =
2∑
i=1
Ni(µi − µ)(µi − µ)T = N1N2
N
(µ1 − µ2)(µ1 − µ2)T
SW =
2∑
i=1
∑
j∈Ci
(xj − µi)(xj − µi)T ,
where Ni is the number of feature vectors in class Ci, N the total number of feature vectors, µi
the mean of class Ci, and µ the overall mean. Since only the direction of w is important, not
its magnitude, the maximisation may equivalenty be expressed as the constrained optimisation
max
w
wTSBw
subject to wTSWw = 1.
By using Lagrange multipliers (Fletcher, 1987), this may be re-expressed as the unconstrained
optimisation of the Lagrangian L(w, α) = wTSBw−α(wTSWw−1). By finding the stationary
point, the feature weight vector may be expressed as w ∝ SW−1(µ1 − µ2), and the threshold
as b = wTµ.
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3.2.2 Support vector machines
A two-class support vector machine (SVM) classifier aims to construct a hyperplane that max-
imises the margin, which is the distance between the closest points on either side of the bound-
ary. These points are known as the support vectors, and their role in the construction of a
maximum-margin hyperplane is illustrated in Figure 3.2. The original SVM algorithm was a
linear classifier (Vapnik and Lerner, 1963), but there have since been modifications to deal
with data that are not linearly separable. A soft-margin formulation, which allows for misla-
belled data, has been proposed (Cortes and Vapnik, 1995), as well as a way to use the kernel
trick (Aizerman et al., 1964) to create nonlinear classifiers (Boser et al., 1992). These three
formulations are described in further detail in the following subsections.
Figure 3.2: 2-D illustration of the construction of a maximum-margin hyperplane. This decision
surface maximises the distance between the support vectors, indicated by the arrow.
Before the application of a SVM classifier, it is important that both the training and test data
are scaled so that features with high variance do not dominate those with lower variance (Hsu
et al., 2010; Juszczak et al., 2002). For the work presented in this thesis, all features are linearly
scaled to the range [−1,+1].
Linear SVM
The decision surface of a linear SVM classifier is described by y(x) = wTx − b = 0, as for
the Fisher linear discriminant function classifier. The feature weight vector w and threshold b
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are then chosen such that the margin, or distance between the support vectors, is maximised.
As illustrated in Figure 3.2, the support vectors lie on two parallel hyperplanes described by
y(x) = 1 and y(x) = −1, such that the distance between them is 2/‖w‖. The maximisation of
the margin can therefore be expressed as the constrained optimisation
min
w,b
1
2
wTw
subject to ti(w
Txi − b) ≥ 1,
where the constraint ensures that no feature vectors fall within the margin. By using Lagrange
multipliers, this may be re-expressed as the unconstrained optimisation
min
w,b
max
α
{
1
2
wTw −
N∑
i=1
αi[ti(w
Txi − b)− 1]
}
subject to αi ≥ 0,
from which an expression for the feature weight vector w can be derived in terms of a linear
combination of the feature vectors,
w =
N∑
i=1
αitixi.
The decision surface is thus expressed in terms of the support vectors, since only their corre-
sponding αi are non-zero. A robust solution for the threshold b may then be found by averaging
over the Nsv support vectors,
b =
1
Nsv
Nsv∑
i=1
(wTxi − ti).
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The primal form of the Lagrangian L(w, b,α) may be equivalently written in dual form by
substituting the above expression for w. The dual form,
max
α
L˜(α) = max
α
{
N∑
i=1
αi − 1
2
∑
i,j
αiαjtitjx
T
i xj
}
subject to αi ≥ 0 and
N∑
i=1
αiti = 0,
expresses the optimisation criterion in terms of inner products of the feature vectors. This is
an important property for the creation of nonlinear SVM classifiers.
Soft-margin SVM
The soft-margin SVM formulation may be applied in cases where no linear hyperplane exists
which can separate the data. Slack variables ξ are introduced, which measure the degree of
misclassification of the feature vectors. The optimisation becomes a trade-off between max-
imising the margin and minimising the degree of misclassification. This trade-off is controlled
by the penalty parameter C, such that the constrained optimisation may be expressed as
min
w,ξ,b
{
1
2
wTw + C
N∑
i=1
ξi
}
subject to ti(w
Txi − b) ≥ 1− ξi and ξi ≥ 0.
By using Lagrange multipliers, the problem may be re-expressed as the unconstrained optimi-
sation
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min
w,ξ,b
max
α,β
{
1
2
wTw + C
N∑
i=1
ξi −
N∑
i=1
αi[ti(w
Txi − b)− 1 + ξi]−
N∑
i=1
βiξi
}
subject to αi, βi ≥ 0,
which may be written in dual form as
max
α
L˜(α) = max
α
{
N∑
i=1
αi − 1
2
∑
i,j
αiαjtitjx
T
i xj
}
subject to 0 ≤ αi ≤ C and
N∑
i=1
αiti = 0.
The only change from the linear SVM optimisation is the upper bound on the αi.
Nonlinear SVM
In cases where the data are not linearly separable in the input feature space, a nonlinear function
φ(x) may be used to map each feature vector into a higher-dimensional space. As illustrated
in Figure 3.3, the data are separated by a linear hyperplane in this new space.
Figure 3.3: A nonlinear boundary in the input feature space becomes a linear hyperplane in a
higher-dimensional space to which feature vectors are mapped using the nonlinear function φ.
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The linear SVM algorithm may then be solved in the transformed feature space by optimising
the dual form Lagrangian
L˜(α) =
N∑
i=1
αi − 1
2
∑
i,j
αiαjtitjφ(xi)
Tφ(xj).
The optimisation criterion is thus expressed in terms of inner products of the transformed
feature vectors. By choosing the nonlinear mapping φ such that these inner products can be
expressed in terms of a kernel function k(xi,xj) ≡ φ(xi)Tφ(xj), it is not necessary to explicitly
perform the mapping. The optimisation problem may therefore be solved even in very high-
dimensional spaces. The most commonly used kernel is the Gaussian radial basis function,
given by k(xi,xj) = exp(−γ‖xi − xj‖2), where γ > 0 describes the width.
3.2.3 Boosting
Boosting is an ensemble method which aims to generate a single strong classifier by combining
a number of weak classifiers. A weak classifier is defined as having an accuracy little better
than 50%, whereas a strong classifier may achieve an arbitrarily good accuracy. In this work,
weak classifiers are simple thresholds on each of the D features.
The majority of boosting algorithms work by iteratively selecting weak classifiers, and then
combining them to form a single strong classifier using a weighted summation, in which each
weak classifier is weighted according to its performance. All feature vectors are initially assigned
equal weightings. They are then re-weighted at every iteration, after the inclusion of a new weak
classifier, such that the weights for incorrectly classified examples are increased, while those
for correctly classified examples are decreased. Later weak classifiers therefore focus more on
those cases which were most difficult to classify during the earlier iterations. Some boosting
algorithms, however, decrease the weightings of repeatedly mis-classified examples in order to
reduce the influence of outliers. An overview of the boosting process is illustrated in Figure
3.4.
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(a) First iteration (b) Second iteration
Figure 3.4: Illustration of the first two iterations in a typical boosting procedure. At the first
iteration (a), all feature vectors are weighted equally and a weak classifier selected. At the
second iteration (b), the weights of incorrectly classified examples are increased and a second
weak classifier selected.
There are a number of boosting algorithms available, of which adaptive boosting (AdaBoost) (Fre-
und and Schapire, 1997) is one of the most popular. The AdaBoost algorithm begins by as-
signing equal weightings to all N feature vectors, such that D1(i) =
1/N . At each iteration
(j = 1, 2, . . . , J), the weak classifier hj resulting in the minimum classification error is selected
from the set of weak classifiers H, such that
hj = argmax
hj∈H
|0.5− j| ,
where the error j is the sum of the weights of the incorrectly classified examples. The selected
weak classifier hj is assigned a weighting αj =
1/2 ln((1− j)/j) according to its performance,
and the weightings are then updated such that
Dj+1(i) =
Dj(i) exp(−αjtihj(xi))
Zj
where Zj =
N∑
i=1
Dj(i) exp(−αjtihj(xi))
= 2
√
j(1− j).
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The final strong classifier is constructed from the selected weak classifiers as y(x) = sign
J∑
j=1
αjhj(x).
3.2.4 Random forests
A random forest is an ensemble classifier consisting of many decision trees, where the final pre-
dicted class for a test example is the mode of the predictions of all individual trees, as illustrated
in Figure 3.5. Random forests, developed by Leo Breiman and Adele Cutler (Breiman, 2001),
combine bootstrap aggregation (bagging) (Breiman, 1996) and random feature selection (Amit
and Geman, 1997; Ho, 1998) in order to construct a collection of decision trees exhibiting con-
trolled variation. The training set for each individual tree in a random forest is constructed
by sampling N examples at random with replacement from the N available examples in the
dataset. This is known as bootstrap sampling, and bagging describes the aggregation of pre-
dictions from the resulting collection of trees. As a result of the bootstrap sampling procedure,
approximately one third of the available N examples are not present in the training set of each
tree. These are referred to as the out-of-bag data of the tree, for which internal test predictions
can be made. By aggregating the predictions of the out-of-bag data across all trees, an internal
estimate of the generalisation error of the random forest can be determined.
Figure 3.5: Illustration of a random forest, showing two trees in detail. Each node is partitioned
based on a single feature, and each branch ends in a terminal node which provides a prediction
for the class of a test example based on the path taken through the tree. The colour of a
terminal node indicates its class prediction. The final predicted class for a test example is the
mode of the predictions of all individual trees.
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At each node in a tree, d << D features are randomly selected, and the node is partitioned
using the best possible binary split. It has been shown (Breiman, 2001) that the random forest
error rate depends on both the correlation between trees ρ¯ and the strength of the collection
of trees s, such that an upper bound for the generalisation error is given by ρ¯(1 − s2)/s2. A
reduction in the selected value of d results in a corresponding reduction in both ρ¯ and s. An
optimal range for d therefore exists, which is generally quite wide. The recommended default
value for most applications is d =
√
D (Liaw and Wiener, 2002).
A parent node np is partitioned into child nodes nl and nr according to an impurity criterion
which aims to maximise the homogeneity of the child nodes with respect to the parent node.
Impurity is assessed using the Gini index IG, which measures the likelihood that an example
would be incorrectly labelled if it were randomly classified according to the distrbution of labels
within the node. For two classes C1 and C2, the Gini index of a node n may be expressed as
IG(n) = 1−
2∑
K=1
p2K ,
where pK is the relative proportion of examples belonging to class K present in the node n.
The Gini index therefore ranges from a minimum of zero to a maximum value of (1− 1/K). A
value of zero indicates that the node contains only examples belonging to a single class, and the
maximum value indicates that the node contains examples belonging to both classes in equal
proportions. The best possible binary split is the one which maximises the improvement in
the Gini index ∆IG(np) = IG(np)− plIG(nl)− prIG(nr), where pl and pr are the proportions of
examples in node np that are assigned to child nodes nl and nr, respectively. The Gini index
can also be used to assess the relative importances of the various features for classification. A
measure of the importance of an individual feature may be computed by summing the decreases
in the Gini index ∆IG occuring at all nodes in the forest which are partitioned based on that
feature.
Random forests can also provide pairwise measures of the similarities between examples in the
dataset. All N feature vectors are passed down each tree in the forest, and if feature vectors
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xi and xj finish in the same terminal node in a tree, their similarity sij is increased by one.
The final similarity measures are normalised by the total number of trees in the forest. The
similarities form anN×N matrix with elements sij, and corresponding distance matrix elements
dij = 1 − sij (Cox and Cox, 2001). The matrix is symmetric, positive-definite, bounded from
above by one, and has diagonal elements equal to one.
Manifold learning techniques may be applied to the pairwise similarity measures to find an
appropriate coordinate embedding for the feature vectors, such that the similarity relationships
between them are preserved. A review of the most popular manifold learning techniques, as
applied to medical imaging, is provided in Aljabar et al. (2012). Classical multidimensional
scaling (MDS) (Torgerson, 1952) is used for the work presented in this thesis, and is now
described. Using MDS, the matrix of coordinates X is derived by performing an eigenvalue
decomposition on the matrix of scalar products
B = XTX = −1
2
{
d2ij −
1
N
N∑
i=1
d2ij −
1
N
N∑
j=1
d2ij +
1
N2
N∑
i=1
N∑
j=1
d2ij
}
.
Retaining only the eigenvectors corresponding to the k largest-valued eigenvalues leads to a
lower-dimensional embedding for the data, which can be useful for visualising its structure. A
goodness-of-fit parameter G, describing the extent to which the selected k eigenvectors represent
the full N × N similarity matrix, can be useful in selecting an appropriate dimensionality for
the lower-dimensional embedding. One possible measure of goodness-of-fit is given by
G =
∑k
j=1 λj∑N
j=1 max(λj, 0)
,
where the eigenvalues λj are sorted in decreasing order (Mardia et al., 1979).
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3.3 Classifier performance
Measures of classifier performance are required to assess the applicability of a trained algorithm
using independent test data, as well as for the optimisation of parameters during training.
The simplest performance metric is accuracy, the proportion of examples that are correctly
labelled by the classifier. However, this does not always provide an appropriate measure of
performance, and other relevant metrics are described in Section 3.3.1. The technique of cross-
validation may be used to assess the generalisation performance of a classifier, as there is often
no appropriate independent dataset available for testing. A single round of cross-validation
involves partitioning the data into two subsets, so that it may be trained using one and tested
using the other. Results are generally reported as the average over multiple rounds in which
different partitions of the data are used. Details of the most common cross-validation methods
are provided in Section 3.3.2.
3.3.1 Performance metrics
The performance of a binary classifier can be visualised using a confusion matrix, as shown in
Table 3.1. The number of examples correctly labelled by the classifier are located on the diag-
onal. These may be divided into true positives TP, representing correctly identified patients,
and true negatives TN, representing correctly identified controls. The number of examples
incorrectly labelled by the classifier may be divided into false positives FP, representing con-
trols incorrectly classified as patients, and false negatives FN, representing patients incorrectly
classified as controls.
True class Predicted class
C1 (patients) C2 (controls)
C1 (patients) TP FN
C2 (controls) FP TN
Table 3.1: Confusion matrix for a binary classifier which aims to distinguish between classes
C1 (patients) and C2 (controls).
The accuracy measures the proportion of examples that are correctly labelled by a classifier,
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accuracy =
TP + TN
TP + TN + FP + FN
.
This may not be a good performance metric if the class distribution of the dataset is unbalanced.
For example, if class C1 is much larger than C2, a high accuracy value could be obtained by a
classifier which labels all examples as belonging to class C1. The sensitivity and specificity,
sensitivity =
TP
TP + FN
and specificity =
TN
TN + FP
,
may provide a better assessment of the overall performance of a classifier. Sensitivity mea-
sures the proportion of correctly identified patients, and specificity measures the proportion
of correctly identified controls. The balanced accuracy, which treats both classes with equal
importance, may then be expressed as
balanced accuracy =
sensitivity + specificity
2
.
An ideal classifier would achieve 100% sensitivity and specificity, but in general there is a
trade-off between these two measures. This can be investigated using a receiver operating char-
acteristic (ROC) curve. As shown in Figure 3.6, a ROC curve shows the relationship between
the true positive rate (sensitivity) and false positive rate (1− specificity) as the discrimination
threshold of the binary classifier is varied. This curve could be used to select the optimal
threshold for a particular application. For example, to identify patients in the earliest stages
of disease, it may be desirable to select a threshold which results in high sensitivity, at the
expense of reduced specificity. The area under a ROC curve (AUC) may be interpreted as an
aggregated measure of classifier performance (Flach et al., 2011).
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Figure 3.6: Illustration of the ROC curve for a binary classifier. The solid line shows the rela-
tionship between the sensitivity and specificity as the discrimination threshold of the classifier
is varied. This may be compared with the dashed line of no-discrimination, and the red line
depicting an ideal classifier.
3.3.2 Cross-validation
The parameters of a classifier are optimised based on the training data. An independent test
set is therefore required for making a reliable assessment of the applicability of the classifier to
new data. Cross-validation provides a way to measure this generalisation performance when no
such test data are available. One commonly used method is k-fold cross-validation, in which
the data are randomly partitioned into k subsets. A single cross-validation fold involves using
(k − 1) subsets for training the classifier, and the remaining data for testing. This process
is repeated k times, such that each of the subsets is used once for testing, and the results
are averaged over the folds. An alternative method is repeated random sampling, in which
the dataset is randomly partitioned into training and test sets of fixed sizes. For example, a
single round may involve randomly selecting 75% of the data for training, with the remaining
25% used for testing. This process can then be repeated, and the results averaged over the
repetitions. Repeated random sampling has the advantage that the proportions of the training
and test sets are not dependent on the number of repetitions. However, there may be some
overlap between test sets, and the method also exhibits Monte Carlo variation. This means
that the results will vary if the analysis is repeated using different partitions of the data. If
two classes C1 and C2 are not of equal sizes, the training and test sets should be selected such
that they contain examples from the two classes in approximately equal proportions to the full
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dataset. This is known as stratified cross-validation, and has been shown to produce results
with a lower variance than regular cross-validation (Kohavi, 1995).
Both the k-fold and repeated random sampling cross-validation methods generate a distribution
of performance values which may be averaged across the folds or repetitions. The statistical
significance of differences between the results of two classifiers may be assessed by performing
unpaired t-tests between these distributions. In addition, permutation testing may be applied
to assess whether the results of a classifier are significantly different from chance. Permutation
testing involves performing cross-validation on data for which the diagnostic labels have been
randomly permuted. This results in a distribution of classification results under the null hy-
pothesis that the classifier cannot accurately predict the clinical labels from the data. Unpaired
t-tests between the distribution of observed results and that obtained from permutation testing
indicate whether the observed results are significantly different from chance.
3.4 Application to Alzheimer’s disease
Automated image-based classification of individual patients could provide valuable diagnostic
support for clinicians, when considered alongside cognitive assessment scores and traditional
visual image analysis. The ADNI study provides an ideal dataset for classification experiments,
since it approximates a clinical population due to its large size and diversity. The gender
ratio of ADNI participants is, however, not that expected of a general clinical population.
Approximately 43% of ADNI participants are females, compared with the 57% which would
be expected based on the gender ratio observed amongst adults aged over 65 in the United
States (Central Intelligence Agency, 2012).
Three recent studies which have performed image-based AD classification using cross-sectional
ADNI FDG-PET data are summarised in Table 3.2. Salas-Gonzalez et al. (2010) additionally
report an accuracy of 83% for discriminating between MCI patients and healthy controls (HC).
Machine learning techniques using FDG-PET images from other datasets have also been suc-
cessful in distinguishing AD patients from HC, as well as from patients with frontotemporal
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dementia (Kippenhan et al., 1994; Xia et al., 2008).
Study Results (%)
Acc. Sens. Spec.
Haense et al. (2009) - 83 78
sum of abnormal t-values in predefined areas (Herholz et al., 2002)
Hinrichs et al. (2009) 84 - -
boosting applied to voxel-wise features
Salas-Gonzalez et al. (2010) 87 - -
linear SVM applied to selected voxel-wise features
Table 3.2: Summary of classification results based on cross-sectional ADNI FDG-PET data.
Studies report either the accuracy (acc.), or sensitivity (sens.) and specificity (spec.) for
distinguishing AD patients from healthy controls.
There are, however, many more classification studies based on structural MR imaging data,
since anatomical imaging with either MRI or CT is routinely used in clinical practice for demen-
tia patients. For example, a recent study (Cuingnet et al., 2011) compares ten high-dimensional
classification methods applied to 509 baseline ADNI 1.5 T MR images. Two methods use only
the hippocampal shape or volume, while the remainder are whole-brain approaches. These use
either cortical thickness measures, or voxel-wise tissue class probabilities for grey matter, white
matter and CSF. High accuracies in distinguishing AD patients from HC (up to 81% sensitivity
and 95% specificity) are reported for whole-brain approaches. Four of the ten methods were
able to distinguish MCI patients who later progressed to AD (pMCI) from those who remained
stable over 18 months (sMCI) slightly more accurately than a random classifier. However, the
results were not significantly different from chance (p > 0.05).
SVM classifiers have been successfully applied by several groups for discriminating between AD
patients and HC based on structural MRI. Reported accuracies generally fall between 80% and
95% (Duchesne et al., 2008; Klo¨ppel et al., 2008; Magnin et al., 2009). Vemuri et al. (2008)
achieve an accuracy of 89% based on a large cohort of 190 AD patients and 190 age- and gender-
matched HC. Three studies performed using other machine learning techniques are summarised
in Table 3.3. Davatzikos et al. (2008a) have additionally applied their high-dimensional pattern
classification approach in a small study comparing 15 HC with 15 MCI patients, at least 10 of
whom later converted to AD. They report an accuracy of 90% for discriminating between MCI
patients and HC. Colliot et al. (2008) perform classification based on automatically segmented
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hippocampal volumes, achieving accuracies of 84% between AD patients and HC, 73% between
MCI patients and HC, and 69% between AD and MCI patients.
Study No. AD patients No. HC Accuracy (%)
Davatzikos et al. (2008b) 37 37 100
high-dimensional pattern classification
Plant et al. (2010) 32 18 92
data mining
Aljabar et al. (2008) 8 18 84
spectral clustering
Table 3.3: Summary of classification results based on MR imaging data.
There is increasing interest in using multi-modality imaging and non-imaging data for classifica-
tion. For example, Zhang et al. (2011) apply a multi-kernel learning approach to cross-sectional
FDG-PET and MR imaging data and CSF biomarker measures. They report classification ac-
curacies of 93% between AD patients and HC, and 76% between MCI patients and HC, when
using all three modalities in combination. These results are superior to those obtained when
using any one modality independently. Hinrichs et al. (2011) have also investigated the applica-
tion of kernel combination methods. They apply these to both cross-sectional and longitudinal
FDG-PET and MR imaging data, as well as CSF biomarker measures, neuropsychological sta-
tus examination scores, and ApoE genotype information. They also report that the use of
multi-modality data leads to superior classification performance compared with that based on
any individual modality.
3.5 Conclusion
This chapter has provided details of the machine learning algorithms applied as part of the work
presented in this thesis, as well as descriptions of the methods with which their performance may
be assessed. In addition, an overview of recent research related to the image-based classifiction
of AD and MCI has been presented. The later chapters incorporate more focussed and detailed
reviews of the most recent related research. The following four chapters present the main
contributions of the thesis.
Chapter 4
Multi-region baseline FDG-PET for
classification
Work in this chapter has, in part, been presented in:
K. R. Gray, R. Wolz, S. Keihaninejad, R. A. Heckemann, P. Aljabar, A. Hammers, and D.
Rueckert. Regional analysis of FDG-PET for use in the classification of Alzheimer’s disease.
(In Proceedings) IEEE 8th International Symposium on Biomedical Imaging (ISBI’11), 1082–
1085, 2011.
4.1 Introduction
This chapter presents a regional analysis of baseline FDG-PET imaging data from the ADNI
study. Whole-brain segmentations into 83 anatomically defined regions were automatically gen-
erated in the native MRI space of each subject, and used to extract regional signal intensities
from the corresponding FDG-PET images. The resulting regional FDG-PET data were used
to investigate group differences between AD and MCI patients and HC, as well as in binary
classification experiments. Part of this work involved the investigation of image intensity nor-
malisation methods with which to account for non-disease related inter-subject variations in
the CMRgl.
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The ADNI participants whose imaging data are used in this work are first described in Sec-
tion 4.2, followed by the image acquisition and pre-processing steps in Section 4.3, and the
anatomical segmentation procedure in Section 4.4. Investigations into image intensity normal-
isation methods are then presented in Section 4.5. FDG-PET intensity normalisation is often
performed relative to the cerebral global mean (CGM). Recent research, based on a study of
36 AD patients, 11 MCI patients and 15 HC, suggests that using regions of the brain which are
relatively preserved in AD may provide improved group discrimination (Yakushev et al., 2009).
These two intensity normalisation approaches were compared using ADNI FDG-PET imaging
data from 71 AD patients, 147 MCI patients and 69 HC. The superior group discrimination
observed in this large cohort using the method proposed by Yakushev et al. (2009) supports
the previously reported findings.
Multi-region analyses of group differences are described in Section 4.6. The findings are consis-
tent with previously reported voxel-based group differences amongst the ADNI subjects (Lang-
baum et al., 2009). Binary classification experiments are presented in Section 4.7. In particular,
the most challenging, but clinically significant, comparison between pMCI and sMCI patients
was investigated. Classification was performed using a SVM classifier, as well as an algorithm
which combines feature extraction using AdaBoost with a linear discriminant function classifier.
The value for image-based classification of regional information extracted from FDG-PET im-
ages acquired at a single timepoint was thus investigated using two classifiers exhibiting different
behaviours. Classification results are comparable with those obtained using data from MRI, or
biomarkers obtained invasively from the CSF. These findings support the use of FDG-PET for
the early diagnosis of AD and for monitoring its progression.
4.2 Imaging data
Clinical and imaging data used in this chapter were obtained from the ADNI database (http:
//adni.loni.ucla.edu), which was briefly introduced in Section 1.5. The ADNI was launched
in 2003 by the National Institute on Aging (NIA), the National Institute of Biomedical Imaging
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and Bioengineering (NIBIB), the Food and Drug Administration (FDA), private pharmaceutical
companies and non-profit organisations, as a $60 million, five-year public-private partnership.
The primary goal of ADNI has been to test whether serial MRI, PET, other biological markers,
and clinical and neuropsychological assessments can be combined to measure the progression of
MCI and early AD. Determination of sensitive and specific markers of very early AD progression
is intended to aid researchers and clinicians to develop new treatments and monitor their
effectiveness, as well as lessen the time and cost of clinical trials. The Principal Investigator of
this initiative is Michael W. Weiner, M.D., VA Medical Center and University of California – San
Francisco. ADNI is the result of efforts of many co-investigators from a broad range of academic
institutions and private corporations (ADNI Data Sharing and Publications Committee, 2012).
ADNI participants were recruited from over 50 sites across the United States and Canada, to
make up a total of 819 adults aged between 55 and 90. These include 229 HC to be followed
for three years, 380 MCI patients to be followed for three years, and 210 mild AD patients
to be followed for two years. The key eligibility criteria for enrolment into one of the three
groups were as follows. HC had a mini mental state examination (MMSE) score (Folstein et al.,
1975) of between 24 and 30 (inclusive), a clinical dementia rating (CDR) (Berg, 1988) of 0, and
no diagnosis of depression, MCI, or dementia. MCI patients had a MMSE score of between
24 and 30 (inclusive), a subjective memory complaint, objective memory loss measured by
education-adjusted scores on the Wechsler memory scale logical memory II (Wechsler, 1987), a
CDR of 0.5, absence of significant levels of impairment in other cognitive domains, essentially
preserved activities of daily living, and an absence of dementia. Mild AD patients had a MMSE
score of between 20 and 26 (inclusive), a CDR of 0.5 or 1.0, and met the NINCDS-ADRDA
criteria for probable AD (McKhann et al., 1984). Further information is available on the ADNI
information website (http://www.adni-info.org).
Approximately 50% of ADNI participants had FDG-PET scans, and 404 baseline images were
available to download in total (as of December 2010). A number of images were excluded from
the analyses presented in this chapter, due to scanner quantification issues, image processing
problems, or because the associated diagnoses did not clearly fall into one of the four clinical
categories (AD, pMCI, sMCI, HC). These exclusions are summarised in Figure 4.1, and will be
4.3. Image acquisition and pre-processing 83
explained in further detail later in the chapter.
Figure 4.1: Summary of exclusions, showing that of the 404 baseline FDG-PET images available
to download, 287 were suitable for the analyses presented in this chapter.
The MCI patients were divided into pMCI and sMCI based on changes in clinical status oc-
curring over 24 ± 11 (range 0 – 36) months. ADNI subject identifiers for all excluded images
are listed in Appendix B, along with the reasons for their exclusion. Groupwise characteristics
are provided in Table 4.1 for the 287 subjects whose imaging data were used in this work. The
mean age does not vary significantly (p > 0.01) on t-test between the clinical groups.
N(F) Age MMSE Score CDR (%)
(mean ± std. dev.) (mean ± std. dev.) 0 0.5 1
AD 71(29) 76.2 ± 7.0 23.3 ± 2.2 0 38 62
pMCI 62(22) 75.2 ± 6.9 26.8 ± 1.7 0 100 0
sMCI 85(23) 76.0 ± 6.9 27.5 ± 1.7 0 100 0
HC 69(27) 75.6 ± 5.0 29.0 ± 1.1 100 0 0
Table 4.1: Clinical and demographic information for the study population (N = 287). For each
clinical group, the total number of subjects (N) and number of females (F) are shown, along
with the average age, average MMSE score, and CDR distribution.
4.3 Image acquisition and pre-processing
The anatomical segmentations required for regional sampling were automatically generated in
the native MRI space of each subject (see Section 4.4). It was therefore necessary to co-register
each FDG-PET image with its corresponding MRI. The following subsections describe the
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acquisition of both the FDG-PET and MR images, the necessary pre-processing steps, and the
inter-modality image registration. These steps are summarised in Figure 4.2.
Figure 4.2: Summary of the FDG-PET and MR image acquisition, pre-processing and co-
registration steps. Those outlined in red were performed by ADNI investigators, while those
outlined in black were performed as part of this work.
4.3.1 ADNI FDG-PET acquisition
Baseline FDG-PET images from 404 ADNI participants, acquired using Siemens, General Elec-
tric (GE) and Philips PET scanners, were available. For this work, all those acquired using
either the Siemens HRRT or BioGraph HiRez scanners (n = 89) were excluded, due to dif-
ferences in the pattern of FDG metabolism that were discovered during the ADNI quality
control process. Further information is available on the ADNI PET Core website (http:
//www.loni.ucla.edu/twiki/bin/view/ADNI/ADNIPETCore). The remaining imaging data
consisted of baseline FDG-PET scans from 315 subjects, acquired using 12 scanner models, as
shown in Figure 4.3.
Figure 4.3: Number of baseline FDG-PET images acquired using each of the 12 scanner models.
FDG-PET images were collected from 40 sites, and acquired according to one of three standard
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protocols. In the majority of cases (n = 263), a 30-minute dynamic scan consisting of six 5-
minute frames was acquired, beginning approximately 30 minutes after the intravenous injection
of 185 ± 19 MBq of FDG. Subjects were instructed to fast for at least four hours prior to
scanning, and then rest in a dimly lit room with their eyes open during the tracer uptake
period. Since dynamic scanning was not available on the Siemens BioGraph, scans performed
using this model consisted of a single 30-minute frame (n = 27). Static acquisitions were also
performed for seven subjects using other models. A limited number of subjects (n = 18) had
60-minute quantitative dynamic scans, including venous sampling, which began simultaneously
with the injection of FDG, and whose final 30 minutes consisted of six 5-minute frames.
Data were corrected for both scatter and measured attenuation, which was determined using
either the CT scan for PET/CT scanners, or a transmission scan with 68Ge or 137Cs rotating
rod sources for PET-only scanners. Images were reconstructed using scanner-specific algo-
rithms, and then sent to the University of Michigan, where they were reviewed for artefacts,
de-identified, and transmitted to the Laboratory of NeuroImaging (LONI) for storage. Further
details are available in the ADNI PET technical procedures manual (ADNI PET Core, 2005).
The 315 baseline FDG-PET scans were downloaded from the LONI image data archive in their
original DICOM or ECAT format. Only 309 images were suitable for further processing, since
three lasted for less than 30 minutes, and three had missing timeframe information in their
ECAT headers (see Appendix B).
4.3.2 FDG-PET pre-processing
The 309 remaining baseline FDG-PET images were converted to NIfTI format using (X)MedCon
(http://xmedcon.sourceforge.net). Each image was examined for major artefacts, and its
orientation adjusted if necessary. In six images, the positioning of the subject in the scanner was
such that the cerebellum, or frontal cortex in one case, was partially excluded from the field of
view (see Appendix B). These images were excluded from further processing. Since FDG-PET
acquisition was performed according to one of three protocols (30-minute static, 30-minute
dynamic, 60-minute dynamic), standardisation was necessary before the images could be com-
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pared. Dynamic scans acquired over 30-60 minutes were corrected for patient motion by using
tools from the Image Registration Toolkit (IRTK; http://www.doc.ic.ac.uk/~dr/software)
to register each of the subsequent frames rigidly to the image’s first frame. Normalised mutual
information was used as the similarity criterion for the registration, and transformations were
performed using linear interpolation. The co-registered frames were then averaged to produce
a single 30-minute static image. For the 60-minute quantitative scans, the final six 5-minute
frames were extracted, and co-registered and averaged into a static image in the same way.
4.3.3 ADNI MRI acquisition and pre-processing
Baseline T1-weighted 1.5 T MRI scans for all 303 subjects with corresponding pre-processed
baseline FDG-PET images were available. MRI and FDG-PET scans had been acquired within
30 ± 16 days of each other. The baseline MR images were downloaded from the LONI image
data archive in NIfTI format. The scans had been acquired according to a standard proto-
col (Jack Jr. et al., 2008a) involving two scans per subject acquired using Siemens, GE and
Philips MR scanners. Further details are available in the ADNI MRI technical procedures
manual (ADNI MRI Core, 2005). Of the two images acquired per subject, the ADNI quality
assurance team selected the best image for pre-processing based on the presence and severity
of common image artefacts, as well as general image quality. Pre-processing involved the appli-
cation of a scanner-specific correction for gradient non-linearity distortion (Gradwarp; Jovicich
et al. (2006)), a correction for image intensity non-uniformity (B1; Jack Jr. et al. (2008a)), and
a histogram peak sharpening algorithm for bias field correction (N3; Sled et al. (1998)). Only
the N3 step was necessary for images acquired on Philips scanners, since B1 correction was
already implemented and their gradient systems tended to be linear (Jack Jr. et al., 2008a).
4.3.4 Co-registration of FDG-PET with MRI
Each of the 303 pre-processed FDG-PET images was co-registered with its corresponding pre-
processed native space MRI, again using tools from IRTK. Rigid registration parameters were
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estimated, and used as a starting point for the estimation of a twelve-parameter affine regis-
tration, using normalised mutual information as the similarity criterion. The resulting affine
registration parameters were applied to transform the FDG-PET image into the higher reso-
lution space of its corresponding MRI using linear interpolation. An affine transformaton was
preferred over a rigid one because it can account for any scaling or voxel size errors which may
remain after phantom correction of the MRI (Clarkson et al., 2009). There is currently no
established method with which to assess the accuracy of PET-MRI co-registration. The trans-
formed images were therefore interactively visually reviewed before further processing. The
image registration process is illustrated in Figure 4.4.
(a) Native space MRI (b) Native space PET (c) MRI-space PET
Figure 4.4: Illustration of the PET-MRI co-registration process, showing (a) the native space
MR image overlaid with (b) the native space FDG-PET image, and (c) the MRI-space FDG-
PET image.
4.4 MRI anatomical segmentation
Automatic whole-brain segmentations of all available baseline ADNI MR images had been
prepared in native MRI space as part of the work described in Heckemann et al. (2011), in
which full details of both the segmentation procedure and subsequent morphometric analyses
are presented. Each MRI was segmented into 83 anatomically defined regions using multi-
atlas propagation with enhanced registration (MAPER) (Heckemann et al., 2010). This is a
refined version of a previously validated segmentation approach (Heckemann et al., 2006), whose
accuracy was shown to be only slightly inferior to that of expert manual segmentation. MAPER
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was the first automatic whole-brain multi-region segmentation method shown to produce robust
results in subjects with anatomical variations often seen in neurodegenerative disease, such
as ventricular enlargement (Heckemann et al., 2010). MAPER is an atlas-based method, as
described in Section 2.3.3, and the required atlas data consisted of the 30 manually segmented
MRI described in Section 2.3.2. The additional image processing steps, segmentation procedure,
and tissue class masking are described in the following subsections.
4.4.1 Additional image processing
Additional image processing was applied for brain extraction and tissue classification. For
brain extraction, binary masks covering intracranial white and grey matter were available as
the starting point. These had been generated as part of a separate project using MIDAS, a
semi-automatic procedure that is described elsewhere (Freeborough et al., 1997). Each mask
was extended to cover the intracranial region generously, and FSL FAST (http://www.fmrib.
ox.ac.uk/fsl) applied to identify CSF within the pre-masked region. The original MIDAS
mask was then extended by the resulting CSF to obtain a complete intracranial mask, as
illustrated in Figure 4.5.
(a) MR image (b) MIDAS mask (c) Intracranial mask
Figure 4.5: Illustration of the brain masking process in which (a) the MRI is processed using
MIDAS, resulting in (b) a binary mask covering the intracranial white and grey matter. This
mask is further processed to generate (c) the final intracranial mask required for segmentation.
One image for which a MIDAS mask was not available was excluded from further processing
(see Appendix B). For the remaining 302 images, individual tissue probability maps for CSF,
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grey matter and white matter were obtained using FSL FAST, as illustrated in Figure 4.6.
These were combined into a single multi-spectral volume.
(a) CSF (b) Grey matter (c) White matter
Figure 4.6: Illustration of the tissue classification results, showing individual tissue probability
maps for (a) CSF, (b) grey matter, and (c) white matter.
4.4.2 Segmentation procedure
MAPER follows the multi-atlas segmentation approach described in Section 2.3.3. A target
MRI was paired with each atlas to generate a set of atlas-based segmentations, which were then
fused. The steps used to align the target MRI with a single atlas are summarised in Table 4.2.
Transformation model Image data Similarity criterion
Global (rigid) mstprob CC
Global (affine) mstprob CC
Coarse nonrigid (20 mm) mstprob CC
Detailed nonrigid (10, 5, 2.5 mm) masked MRI NMI
Table 4.2: MAPER steps for aligning a single atlas MRI with the target MRI. Image data
consisted of the multi-spectral tissue probability map (mstprob), or MR intensities within the
intracranial mask (masked MRI). Cross correlation (CC) or normalised mutual information
(NMI) was used as the similarity criterion. For the nonrigid transformations, numbers indicate
the control point spacings.
The transformation obtained from the final nonrigid registration step was applied to the atlas la-
bel volume using nearest-neighbour interpolation, resulting in a single atlas-based segmentation
of the image in native MRI space. For a single target MRI, the registration and transformation
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steps were performed using each atlas, producing 30 propagated label volumes in the space
of the original image. The labels from these independent segmentations were combined using
vote-rule decision fusion to produce a fused segmentation for the target image.
4.4.3 Tissue class masking
For FDG-PET image analysis, the grey matter portion within each cortical label is more relevant
than the full label which covers both grey and white matter. Masked segmentations were
therefore employed, in which all regions except ventricles, central structures, cerebellum and
brainstem have been masked with a grey matter label, and the lateral ventricles with a CSF
label. Typical examples of both the full and masked segmentations are shown in Figure 4.7.
(a) Full (axial) (b) Full (coronal) (c) Full (sagittal)
(d) Masked (axial) (e) Masked (coronal) (f) Masked (sagittal)
Figure 4.7: Typical examples of (a-c) a full segmentation, and (d-f) a masked segmentation
shown overlaid onto the corresponding MR image.
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4.5 FDG-PET intensity normalisation
When performing comparisons of FDG-PET images across subjects, intensity normalisation is
required to account for inter-subject variability in overall radioactivity. Such variability can
arise from both physiological differences in metabolic rate, as well as variations in, for example,
the injected dose or time allowed for tracer uptake before scanning. An additional incentive for
normalisation is provided by reports showing that relative values of the CMRgl are less variable
than absolute values in both HC and AD patients (Wang et al., 1994; Minoshima et al., 1995).
FDG-PET intensity normalisation is often performed relative to the CGM. However, due to
the nature of the disease, both MCI and AD patients have a lower CMRgl than HC across the
whole brain. CGM normalisation therefore artificially scales up the CMRgl from patients, while
scaling down those from HC. This results in under-estimation of the relative hypometabolism
in patients compared to HC (Yakushev et al., 2008), as well as the semblance of hyperme-
tabolism in relatively preserved regions of the brain, including the cerebellum, brainstem, basal
ganglia, and sensorimotor cortex (Herholz et al., 2002). Recent work suggests that improved
group discrimination can be achieved by using these relatively preserved regions for FDG-PET
image intensity normalisation (Yakushev et al., 2009; Borghammer et al., 2009). Although
normalisation relative to regions such as the cerebellum or sensorimotor cortex has been used
in other previous studies, a key feature of the method proposed in Yakushev et al. (2009) is
that preserved regions are extracted directly from the image data. The following subsections
present results of investigations into FDG-PET intensity normalisation methods.
4.5.1 Additional image processing
FDG-PET image intensity normalisation is investigated using the SPM software described in
Section 2.4. To perform voxel-wise comparisons, the images first had to be aligned with the
MNI template described in Section 2.3.2. Each pre-processed ADNI MRI was linearly and non-
linearly deformed (Ashburner and Friston, 2005) to the MNI template using the “Segment”
module of SPM 5. The resulting transformation parameters were applied to the corresponding
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MRI-space FDG-PET image using tri-linear interpolation. This process is illustrated in Figure
4.8. Full inclusion of the cerebellum was ensured by extending the bounding box in the z-
direction to cover -75 mm to +85 mm from the position of the anterior commissure in MNI
space. Upon visual inspection, three images for which SPM Segment was unable to provide
satisfactory transformations were excluded from further processing (see Appendix B).
(a) MRI-space MRI (b) MRI-space PET
(c) MNI-space MRI (d) MNI-space PET
Figure 4.8: Example images showing alignment of MRI and FDG-PET to the MNI template.
The MNI-space FDG-PET images were smoothed to increase their signal-to-noise ratios, as
well as compensate for any residual inter-subject variability remaining after the transformation
to MNI space. Since the images had been acquired using one of 12 scanner models, they were
first smoothed to a common isotropic spatial resolution of 8 mm full-width-at-half-maximum
(FWHM) by applying scanner-specific Gaussian kernels. These kernels had been determined
from the Hoffman brain phantom PET scans (Hoffman et al., 1990) acquired during the scanner
certification process. The FWHM of these kernels are provided in Joshi et al. (2009), and
summarised in Table 4.3. The FDG-PET images were then smoothed by an additional isotropic
Gaussian kernel of 8 mm FWHM. The smoothing process is illustrated in Figure 4.9.
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Scanner FWHM
Manufacturer Model In-plane (mm) Axial (mm)
GE Advance 5 3
GE Discovery LS - -
GE Discovery RX 5 4
GE Discovery ST 4 3
Philips Allegro - -
Philips Gemini 3 3
Philips Gemini GXL - -
Philips Gemini TF - -
Siemens Accel 2 3
Siemens BioGraph - -
Siemens Exact - -
Siemens HR+ 5 5
Table 4.3: In-plane and axial FWHM of the scanner-specific Gaussian kernels required to
obtain an isotropic spatial resolution of 8 mm FWHM for the 12 ADNI PET scanner models
from which images used in this work were acquired. Scanner models for which no FWHM
values are provided did not require smoothing to reach the common lowest spatial resolution.
(a) Original (b) Smoothed (c) Re-smoothed
Figure 4.9: Typical example images illustrating the smoothing process, in which (a) the original
MNI-space FDG-PET image is (b) smoothed with a scanner-specific Gaussian kernel, followed
by (c) smoothing with a further isotropic Gaussian kernel.
4.5.2 Cerebral global mean intensity normalisation
The smoothed MNI-space FDG-PET images were first used to replicate the findings reported
in Langbaum et al. (2009), in which SPM analyses were performed on ADNI-processed images.
The aim was to verify that the processing applied as part of this work was comparable with that
performed by the ADNI PET core. The ADNI-processed FDG-PET images were not used in
this work because the intermediate re-orientation of each image, such that its anterior-posterior
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axis was parallel to the AC-PC line, was not desirable for region-based analyses performed in
native MRI space. The incorporation of unnecessary re-orientation steps would have resulted
in degraded image quality due to the additional interpolation.
The SPM methods described in Section 2.4 were applied to identify voxels for which the FDG-
PET signal intensities were significantly reduced in AD patients compared with HC. The two-
sample t-test factorial design was applied, and inclusion of voxels outside the brain was avoided
using a combination of relative threshold, explicit, and implicit masking. For relative threshold
masking, only voxels for which all images exceeded 80% of their mean value were retained for
analysis. The explicit mask specified was the SPM brain mask, which covers white and grey
matter in MNI space. The implicit masking removed any voxels with “NaN” (not a number)
values. The images were normalised for inter-subject global variations using proportional scaling
to the CGM. The voxels identified as significantly (p < 0.001, uncorrected) reduced in AD
patients compared with HC are shown in Figure 4.10.
(a) SPM 5 glass-brain (b) Volume rendering
Figure 4.10: Voxels for which the FDG-PET signal intensity was significantly reduced in AD
patients compared with HC when using CGM normalisation shown as (a) maximum intensity
projections onto the SPM 5 glass-brain, and (b) a volume rendering. Red arrows on the glass-
brain indicate the location of the voxel with the highest t-value (t = 8.59).
The same methods were applied to identify voxels with significantly (p < 0.001, uncorrected)
reduced signal intensities in MCI patients compared with HC. These are shown in Figure 4.11.
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(a) SPM 5 glass-brain (b) Volume rendering
Figure 4.11: Voxels for which the FDG-PET signal intensity was significantly reduced in MCI
patients compared with HC when using CGM normalisation shown as (a) maximum intensity
projections onto the SPM 5 glass-brain, and (b) a volume rendering. Red arrows on the glass-
brain indicate the location of the voxel with the highest t-value (t = 5.57).
The results of these two SPM analyses are comparable with those reported in Langbaum et al.
(2009). Both AD and MCI patients display significantly reduced FDG-PET signal intensities
in brain regions preferentially affected by AD, including the parietal and posterior temporal
lobes, and posterior cingulate cortices. The reductions are of greater magnitude and spatial
extent in AD patients compared with MCI patients.
4.5.3 Reference cluster intensity normalisation
The data-driven intensity normalisation approach proposed in Yakushev et al. (2009) was next
investigated. Regions of the brain that are relatively preserved throughout AD were extracted
from the ADNI FDG-PET images by identifying voxels in which there was a semblance of
hypermetabolism in patients compared with HC. These regions form a so-called reference cluster
which can be used for intensity normalisation. Voxels for which the FDG-PET signal intensities
were significantly increased in the whole patient group (both AD and MCI patients) compared
with the HC group were identified using the SPM methods described in Section 4.5.2. The
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voxels identified as significantly (p < 0.05, FWE corrected for multiple comparisons at the
voxel-level) increased are shown in Figure 4.12 (a). From these, a cluster was defined which
contained the voxel with the highest t-value in the search space, as shown in Figure 4.12 (b).
(a) All preserved regions (b) Reference cluster
Figure 4.12: Voxels for which the FDG-PET signal intensity was significantly increased in AD
and MCI patients compared with HC shown as maximum intensity projections onto the SPM 5
glass-brain. Both (a) all voxels, and (b) only voxels in the selected cluster are shown. Red
arrows indicate the location of the voxel with the highest t-value (t = 5.98).
The results of this SPM analysis are comparable with those presented in Yakushev et al.
(2009), with significant clusters observed bilaterally in regions of the cerebellum, brainstem
and primary sensorimotor systems. The spatial extent of the significant regions is greater in
both the cerebellum and sensorimotor cortex, possibly reflecting the potential for detecting more
subtle changes when using such a large cohort. Apparent hypermetabolism was additionally
observed in the putamen in Yakushev et al. (2009), which does not show up as significant in
this study. This is most likely due to the different demographic characteristics of the two study
populations. For example, the study reported in Yakushev et al. (2009) included no sMCI
patients. The reference cluster identified using the ADNI FDG-PET images is located mostly
in the cerebellum, but also extends to a small region of the brainstem, consistent with the
findings of Yakushev et al. (2009).
Having defined the reference cluster for normalisation, the methods described in Section 4.5.2
were again applied to identify voxels for which the FDG-PET signal intensities were signifi-
cantly reduced in AD patients compared with HC. Inter-subject global variations were now
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accounted for by proportional scaling to the reference cluster mean. The voxels identified as
significantly (p < 0.001, uncorrected) reduced in AD patients compared with HC, and MCI
patients compared with HC are shown in Figures 4.13 and 4.14, respectively.
(a) SPM 5 glass-brain (b) Volume rendering
Figure 4.13: Voxels for which the FDG-PET signal intensity was significantly reduced in AD
patients compared with HC when using reference cluster normalisation shown as (a) maximum
intensity projections onto the SPM 5 glass-brain, and (b) a volume rendering. Red arrows on
the glass-brain indicate the location of the voxel with the highest t-value (t = 11.96).
(a) SPM 5 glass-brain (b) Volume rendering
Figure 4.14: Voxels for which the FDG-PET signal intensity was significantly reduced in MCI
patients compared with HC when using reference cluster normalisation shown as (a) maximum
intensity projections onto the SPM 5 glass-brain, and (b) a volume rendering. Red arrows on
the glass-brain indicate the location of the voxel with the highest t-value (t = 7.24).
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The results of these two SPM analyses demonstrate that the reference cluster intensity normali-
sation method proposed in Yakushev et al. (2009) provides superior discrimination of the ADNI
AD and MCI patients from the HC, compared with CGM normalisation. Both AD and MCI
patients display significantly reduced FDG-PET signal intensities across most of the brain, and
at higher significance levels than were observed for the CGM-normalised images.
The use of a normalisation region derived directly from the imaging data may introduce bias
into classification studies. The validity of using the reference cluster derived in Yakushev et al.
(2009) for normalisation of the ADNI FDG-PET images was therefore assessed. A MNI space
image of the cluster used in Yakushev et al. (2009) was obtained from the author, and the FDG-
PET signal intensity per mm3 was determined from each image in both this independently-
derived cluster, and in the ADNI-derived cluster. The intraclass correlation coefficient (ICC)
between the two sets of values was calculated using the “one-way random” model implemented
in SPSS. The “single measures” ICC was 0.95, a value high enough to suggest that the areas
of the brain identified are reliably preserved across early AD and MCI.
4.6 Multi-region image analysis
Many image-based classification methods rely on voxel-wise comparisons in which each voxel
is considered as a feature that may be exploited for group discrimination. As well as requiring
that all images be transformed into a common space, these methods can fail to account for
the spatial structure of the imaging data which results from correlations between neighbouring
voxels. A feature selection process may therefore be required which, as well as reducing the
dimensionality of the feature-space, requires that selected voxels form spatially contiguous
regions, thus exploiting the underlying spatial structure. The multi-region analysis used in this
work instead makes use of subject-specific anatomical segmentations into 83 regions that are
automatically generated in the native space of each subject, rather than in the space of a single
reference image. Exploiting the spatial structure of the imaging data in this way results in a
greatly reduced number of available features for group discrimination and classification.
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4.6.1 Region-based feature extraction
Each of the MRI-space FDG-PET images described in Section 4.3.4 was overlaid with its
corresponding masked anatomical segmentation, and the FDG-PET signal intensity per mm3
determined for all 83 regions. Global inter-subject variations were accounted for by normali-
sation to the signal intensity per mm3 in the independently-derived reference cluster described
in Section 4.5.3. This cluster was provided in MNI space, and the inverse transformation pa-
rameters obtained using SPM Segment, as described in Section 4.5.1, were used to transform
the cluster into the native MRI space of each subject using tri-linear interpolation. Examples
of the images required for regional FDG-PET feature extraction are shown in Figure 4.15.
(a) FDG-PET (b) Segmentation (c) Cluster
Figure 4.15: Typical examples of the images required for regional FDG-PET feature extrac-
tion, showing (a) the FDG-PET image overlaid onto its corresponding MRI, (b) the masked
anatomical segmentation, and (c) the independently-derived normalisation cluster overlaid onto
the FDG-PET image. All images are shown in native MRI space.
4.6.2 Region-based group differences
Boxplots based on the normalised signal intensity per mm3 in two regions known to be affected
in AD are shown in Figure 4.16. Comparisons by t-test were also performed between pairs
of clinical groups to identify the regional features giving significant differences (p < 0.01,
uncorrected for multiple comparisons). Regional t-values for comparisons between AD patients
and HC, as well as between MCI patients and HC are shown in Figure 4.17.
100 Chapter 4. Multi-region baseline FDG-PET for classification
(a) Hippocampus (b) Middle & inferior temporal gyri
Figure 4.16: Boxplots showing group differences based on the normalised signal intensity per
mm3 in the (a) hippocampus and (b) middle and inferior temporal gyri. In each boxplot,
the central red line represents the median, the edges of the blue box represent the 25th and
75th percentiles, and the black whiskers extend to the most extreme data points not considered
outliers. Outliers are plotted individually in red for points outside of ±1.5× interquartile range.
(a) AD/HC (ax.) (b) AD/HC (cor.) (c) AD/HC (sag.)
(d) MCI/HC (ax.) (e) MCI/HC (cor.) (f) MCI/HC (sag.)
Figure 4.17: Regional t-values for comparisons between (a-c) AD patients and HC and (d-f)
MCI patients and HC, superimposed onto a maximum probability brain atlas masked according
to the same procedure as the anatomical segmentations. Axial (ax.), coronal (cor.) and sagittal
(sag.) views are shown. A: anterior, P: posterior, S: superior, I: inferior, L: left, R: right.
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The majority of regions differ significantly between AD patients and HC (74/83 regions), as
well as between MCI patients and HC (54/83 regions). The magnitude and spatial extent of the
significant regions is greater between AD patients and HC. The ten most significantly different
regions between AD patients and HC are the bilateral posterior cingulate gyrus, hippocampus,
posterior temporal lobe and parietal lobe, and left parahippocampal gyrus and middle and
inferior temporal gyri. The ten most significantly different regions between MCI patients and
HC are the bilateral hippocampus and parietal lobe, and left parahippocampal gyrus, amygdala,
posterior temporal lobe, posterior cingulate gyrus, insula, and pre-subgenual frontal cortex.
These findings are consistent with the voxel-based group differences described in Section 4.5.3.
4.7 Classification experiments
The potential use of multi-region FDG-PET information for image-based classification of the
ADNI participants was next investigated. Other relevant classification studies based on imaging
data acquired at baseline have been described in Section 3.4. The majority of research sur-
rounding the classification of AD and MCI focuses on the discrimination of AD patients from
HC and, in fewer cases, MCI patients from HC. In this work, all eight possible binary classifica-
tion experiments (AD/HC, MCI/HC, pMCI/HC, sMCI/HC, AD/MCI, AD/pMCI, AD/sMCI,
pMCI/sMCI) were performed, of which the potential to discriminate between pMCI and sMCI
patients is the most interesting in terms of monitoring the progression of AD.
4.7.1 Methods
The normalised signal intensities per mm3 in each of the 83 anatomically defined regions formed
a feature vector for each of the 287 ADNI participants (71 AD, 62 pMCI, 85 sMCI, 69 HC). Two
binary classifiers were investigated: a SVM classifier, and an algorithm which combines feature
extraction using AdaBoost with a linear discriminant function classifier (Ada-LDA). Robust
estimates of the performance of the two classifiers were obtained via the stratified repeated
random sampling approach described in Section 3.3.2. The mean classification accuracy, sensi-
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tivity and specificity for pairs of clinical groups were evaluated over 1,000 runs, in which 75%
of the subjects were randomly selected for training, with the remaining 25% used for testing.
SVM classifier
The SVM classifier was applied using LIBSVM, an integrated software for support vector clas-
sification (http://www.csie.ntu.edu.tw/~cjlin/libsvm). Since the data were unlikely to be
linearly separable, the soft-margin SVM formulation described in Section 3.2.2 was used. This
is the “C-SVC” option in LIBSVM (Chang and Lin, 2011). The radial basis function kernel
described in Section 3.2.2 was selected to map the data into a higher dimensional space.
As part of the training process, it was necessary to optimise the penalty parameter C, and
kernel width γ. This was achieved by performing a grid-search using five-fold cross-validation.
Various (C, γ) pairs were considered, and the pair resulting in the highest cross-validation
accuracy was selected. The SVM classifier was then trained using the full set of training data,
before having its performance assessed on the test data.
Ada-LDA classifier
The Ada-LDA classifier combines feature extraction using AdaBoost, described in Section 3.2.3,
with the linear discriminant function described in Section 3.2.1. Although AdaBoost itself
may be applied as a classifier, in this work it was employed solely as a feature selection tool,
iteratively selecting the best unique features to pass to the linear discriminant function. A
particular strength of this feature selection method is its consideration of previously selected
features in the determination of the next, since features which individually provide good group
discrimination may not necessarily work well in combination.
As part of the training process, it was necessary to determine the optimal number of features to
pass to the linear discriminant function. This was again achieved using five-fold cross-validation,
with the number of features resulting in the highest cross-validation accuracy selected. The
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final classifier was then trained using the selected number of features from the full set of training
data, before having its performance assessed on the test data.
4.7.2 Results
Classification results are presented in Table 4.4 for both the SVM and Ada-LDA classifiers.
For each clinical group pair, unpaired t-tests between the distributions of classification results
obtained from the 1,000 leave-25%-out repetitions were performed to assess the significance of
differences in performance between the two classifiers. The SVM classifier achieves a signifi-
cantly (p < 0.05) higher accuracy than the Ada-LDA classifier for the MCI/HC experiment,
but no other differences in accuracy reach significance. All accuracies are significantly different
from chance, as assessed using the permutation testing procedure described in Section 3.3.2.
SVM Ada-LDA
acc. (%) sens. (%) spec. (%) acc. (%) sens. (%) spec. (%)
AD/HC 81.6 (0.2) 82.7 (0.3) 80.4 (0.3) 83.3 (0.2) 80.5 (0.3) 86.2 (0.3)
MCI/HC 70.2∗ (0.2) 73.8 (0.3) 62.3 (0.6) 63.6 (0.2) 58.5 (0.3) 74.4 (0.3)
pMCI/HC 71.8 (0.2) 71.8 (0.4) 71.8 (0.3) 73.1 (0.2) 72.8 (0.4) 73.4 (0.3)
sMCI/HC 63.7 (0.2) 62.6 (0.3) 63.0 (0.4) 59.6 (0.2) 58.1 (0.3) 61.3 (0.4)
AD/MCI 68.2 (0.2) 58.3 (0.6) 73.0 (0.3) 66.6 (0.2) 70.3 (0.3) 64.8 (0.3)
AD/pMCI 57.1 (0.2) 58.3 (0.6) 50.7 (0.5) 59.1 (0.3) 55.8 (0.4) 62.8 (0.4)
AD/sMCI 74.2 (0.2) 72.1 (0.3) 76.0 (0.3) 72.5 (0.2) 70.8 (0.3) 73.8 (0.3)
pMCI/sMCI 56.4 (0.2) 51.6 (0.6) 60.1 (0.4) 57.6 (0.2) 59.5 (0.4) 56.2 (0.3)
Table 4.4: Classification accuracy (acc.), sensitivity (sens.), and specificity (spec.) for the SVM
and Ada-LDA classifiers, expressed as mean (standard error) over the 1,000 leave-25%-out
repetitions. The single case where the difference in classifier performance reaches significance
(p < 0.05) is indicated by an asterisk (∗).
While the SVM classifier makes use of all 83 features, the Ada-LDA classifier instead employs
feature selection to suppress redundancies. The first selected feature is maximally able to dis-
criminate the clinical groups. For AD/HC, the features most commonly selected first across the
1,000 repetitions were the hippocampus and posterior cingulate cortices. The parahippocam-
pal gyrus was most commonly selected first for MCI/HC and pMCI/HC, and the hippocampus
for sMCI/HC. The middle and inferior temporal gyri were most commonly selected first for
AD/MCI, AD/pMCI, and pMCI/sMCI, and the posterior temporal lobe for AD/sMCI.
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4.7.3 Discussion
Multi-region features extracted from baseline FDG-PET images of ADNI participants have been
used to achieve classification results comparable with other studies based on FDG-PET data,
as well as with those obtained using data from MRI. For the discrimination of AD patients from
HC, both the SVM and Ada-LDA classifiers achieve results that are in line with the studies
reviewed in Section 3.4. Classification results may be converging on a glass ceiling for this task,
since diagnostic consensus criteria themselves have an accuracy of around 90% (Ranginwala
et al., 2008). Although higher accuracies have been reported in some studies, these tend to be
in smaller, or more selective, patient cohorts. For FDG-PET in particular, it is important to
consider the further confounding factor that approximately 10% of the ADNI AD patients have
a pattern of glucose metabolism that is more consistent with frontotemporal dementia than
with AD (Thiele et al., 2009; Jagust et al., 2010).
With the SVM classifier, good discrimination is achieved between MCI patients and HC (ac-
curacy 70%), and slightly less good discrimination between AD and MCI patients (accuracy
68%). These results are again comparable with those of other published studies, such as Colliot
et al. (2008). The Ada-LDA classifier performs less well, particularly in distinguishing MCI
patients from HC (accuracy 64%). This is possibly because the heterogeneous nature of the
MCI group means that a linear classifier is not optimal, even if it is applied to only a selected
set of features.
In discussing the remaining comparisons, in which pMCI and sMCI patients are considered
separately, it is important to note that clinical follow-up data are still being acquired for the
ADNI participants. Subjects currently in the sMCI group may yet convert to AD. Even the
three years of clinical follow-up that will eventually be available for these subjects is likely
to be insufficient to allow the identification of all those who will develop AD in the future.
Progression from MCI to AD is reported to occur at a rate of 10-15% per year (Petersen et al.,
1999), with up to 80% of MCI patients developing AD over a six year period (Petersen, 2004).
Following sub-division of the MCI group, both classifiers achieved good discrimination between
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pMCI patients and HC, as well as between AD and sMCI patients. However, neither classifier
was able to achieve particularly good discrimination between sMCI patients and HC. The
causes for memory impairment in sMCI patients are, perhaps, too heterogeneous in nature to
be reliably distinguished from the changes associated with normal ageing. The relatively poor
performance of both classifiers in distinguishing AD from pMCI patients is to be expected,
since many of the changes associated with AD will have already begun in pMCI patients. The
discrimination between pMCI and sMCI patients is also relatively poor with both classifiers,
but significantly different from chance. This result corroborates other published studies, such
as Cuingnet et al. (2011). The discrimination of pMCI from sMCI patients is the most clinically
interesting, and subsequent studies will aim to improve on these results by incorporating follow-
up FDG-PET data, or information obtained using other modalities.
The aim of this work was to investigate the utility of multi-region FDG-PET information ac-
quired at baseline for image-based classification of AD and MCI patients. Two readily available
classifiers which exhibit different behaviours were therefore applied. There was little apprecia-
ble difference in their performance, but the Ada-LDA classifier provides valuable information
about the features that best distinguish between various clinical groups. The features selected
first by the Ada-LDA classifier all have highly significant regional t-values, as shown in Section
4.6.2. AdaBoost was applied for feature selection, rather than a simple t-test, because the fea-
tures selected by AdaBoost are complementary, in the sense that previously selected features
are considered in the determination of the next.
The findings presented here support the use of FDG-PET, in conjunction with other neuroimag-
ing methods, clinical assessments and measures of non-imaging biomarkers, as a tool for the
early diagnosis of AD and for monitoring its progression. However, an important consideration
of the described regional FDG-PET analysis approach is its requirement for MR imaging data.
Structural imaging, either with MRI or CT, is routinely used in clinical practice to exclude focal
brain lesions that could lead to a clinical picture mimicking AD. Both MRI and FDG-PET are
mentioned in the revised AD diagnostic criteria (McKhann et al., 2011; Albert et al., 2011;
Sperling et al., 2011) as providing potentially useful biomarkers. The recent development of
hybrid MRI-PET technology means that the simultaneous acquisition of both modalities could
106 Chapter 4. Multi-region baseline FDG-PET for classification
become a practical solution for dementia imaging in the future. For example, one such system
has been approved for use in clinical practice in both Europe and the USA, and its clinical ap-
plication in oncology has already been demonstrated (Drzezga et al., 2012). The requirement
for MR data has the key benefit that regional volumes and volume changes are also available for
each patient, and these data could potentially be combined with the FDG-PET information.
4.8 Conclusion
This chapter has presented a multi-region analysis of baseline FDG-PET imaging data from
the ADNI study. Whole-brain segmentations into 83 anatomically defined regions were auto-
matically generated in the native MRI space of each subject, and used to extract regional signal
intensities from the corresponding FDG-PET images. Image intensity normalisation methods
were investigated, and an independently-derived cluster of relatively preserved regions was used
to normalise the FDG-PET images prior to region-based analyses of group differences and bi-
nary classification experiments. The classification results are comparable with other studies,
but it is expected that they might be improved by the inclusion of additional data. The work
presented in the following chapter will focus on the incorporation of follow-up FDG-PET data.
Chapter 5
Multi-region longitudinal FDG-PET
for classification
Work in this chapter has, in part, been presented in:
K. R. Gray, R. Wolz, R. A. Heckemann, P. Aljabar, A. Hammers, D. Rueckert, for the
Alzheimer’s Disease Neuroimaging Initiative. Multi-region analysis of longitudinal FDG-PET
for the classification of Alzheimer’s disease. Neuroimage, 60(1):221–229, 2012.
and:
K. R. Gray, R. Wolz, R. A. Heckemann, A. Hammers, and D. Rueckert. Classification
of ADNI subjects based on longitudinal analysis of the hippocampal FDG-PET signal. (Ab-
stract) Alzheimer’s Association International Conference on Alzheimer’s Disease (ICAD’10).
Alzheimer’s and Dementia, 6(4, Supplement):S288–S289, 2010.
5.1 Introduction
This chapter presents a regional analysis of longitudinal FDG-PET imaging data from the
ADNI study. Both cross-sectional and longitudinal FDG-PET and MR imaging data were
used by Hinrichs et al. (2011) in their investigations into the application of kernel combina-
tion methods for multi-modality AD classification. They observed that longitudinal FDG-PET
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features performed relatively poorly in distinguishing AD patients from HC, compared with
using the raw signal intensities at either timepoint. They suggested that two-year changes in
FDG-PET signal intensity alone are not sufficient for image-based classification of individual
patients. However, highly significant group differences between AD or MCI patients and HC
have been reported by Chen et al. (2010) in their longitudinal analysis of 12-month metabolic
declines in ADNI subjects. These two studies suggest that while longitudinal FDG-PET data
alone may not be sufficient for AD classification, they may provide valuable complementary in-
formation which can enhance the results achievable using cross-sectional FDG-PET. This work
investigates the value of combining cross-sectional and longitudinal multi-region FDG-PET in-
formation for classification. Whole-brain segmentations into 83 anatomically defined regions
were automatically generated in the native MRI space of each subject for both baseline and
12-month images. These were used to extract regional signal intensities from the corresponding
FDG-PET images, and their combined use for image-based AD classification was investigated.
The effect on classification of the subjects’ gender and age at time of scanning was additionally
investigated.
The ADNI participants whose imaging data are used in this work are first described in Section
5.2, followed by the image acquisition and pre-processing steps in Section 5.3. Preliminary stud-
ies involving only the hippocampal region are presented in Section 5.4. These studies found
that increases in classification accuracy could be achieved by combining cross-sectional and
longitudinal FDG-PET features. The additional benefit of using multi-region information was
then investigated. The extension of the multi-region MRI segmentation procedure described
in Section 4.4 to the follow-up images is presented in Section 5.5, followed by multi-region
analyses of group differences in Section 5.6, and binary classification experiments in Section
5.7. Longitudinal FDG-PET features were found to provide complementary information which
enhanced classification performance when used in conjunction with cross-sectional features, re-
sulting in classification results in line with the current state-of-the-art. This work demonstrates
that information extracted from serial FDG-PET through regional analysis can accurately dis-
criminate diagnostic groups, even at the early symptomatic stages of AD. This finding may be
usefully applied for AD diagnosis and prognosis.
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5.2 Imaging data
Clinical and imaging data used in this chapter were obtained from the ADNI database, which
has been described in Section 4.2. Baseline and 12-month FDG-PET and 1.5 T MR images
were available to download for 321 ADNI participants (as of March 2011). A number of images
were excluded from the analyses presented in this chapter. These exclusions are summarised
in Figure 5.1, and will be explained in further detail later in the chapter.
Figure 5.1: Summary of exclusions, showing that of the 321 baseline and 12-month FDG-PET
and MRI available to download, 221 were suitable for the analyses presented in this chapter.
The MCI patients were divided into pMCI and sMCI based on changes in clinical status occur-
ring over 19 ± 10 (range 6 – 48) months. ADNI subject identifiers for all excluded images are
listed in Appendix B, along with the reasons for their exclusion. Groupwise characteristics are
provided in Table 5.1 for the 221 subjects whose imaging data were used in this work.
N(F) Age ∆T (months) CDR (%) MMSE ∆MMSE
(mean ± sd) (mean ± sd) 0 0.5 1 (mean ± sd) (mean ± sd)
AD 50 (20) 75.8 ± 6.1 11.5 ± 0.8 0 36 64 23.5 ± 2.0 -2.76 ± 3.96
pMCI 53 (20) 75.1 ± 7.1 11.5 ± 1.1 0 100 0 26.7 ± 1.7 -1.79 ± 2.57
sMCI 64 (18) 76.6 ± 7.1 11.8 ± 0.8 0 100 0 27.5 ± 1.7 0.05 ± 1.79
HC 54 (18) 75.2 ± 4.6 11.5 ± 0.9 100 0 0 28.9 ± 1.2 0.30 ± 1.47
Table 5.1: Clinical and demographic information for the study population (N = 221). For
each clinical group, the total number of subjects (N) and number of females (F) are shown,
along with the average age, average time between baseline and 12-month FDG-PET scans
(∆T ), baseline CDR distribution, average baseline MMSE score, and average change in MMSE
score over the 12-month follow-up period (∆MMSE). Standard deviation (sd) values are also
provided.
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The mean age at baseline and mean time between baseline and 12-month FDG-PET scans do
not vary significantly (p > 0.01) on t-test between the clinical groups.
5.3 Image acquisition and pre-processing
The anatomical segmentations required for regional sampling were automatically generated in
the native MRI space of each subject and timepoint (see Section 5.5). It was therefore necessary
to co-register each FDG-PET image with its corresponding MRI. FDG-PET image intensity
normalisation was performed using a cluster of relatively preserved regions that were provided
in MNI space and then transformed into the native MRI space of each subject and timepoint.
These image acquisition and pre-processing steps are summarised in Figure 4.2.
Figure 5.2: Summary of the FDG-PET and MR image acquisition and pre-processing steps.
Those outlined in red were performed by ADNI investigators, while those outlined in black
were performed as part of this work. The reference cluster outlined in green was provided in
MNI space by Yakushev et al. (2009).
The FDG-PET images were acquired as described in Section 4.3.1. Baseline and 12-month
FDG-PET images were available for 321 ADNI participants. For this work, all those acquired
using either the Siemens HRRT or BioGraph HiRez scanners (n = 78) were excluded, again
due to the scanner quantification issues described in Section 4.3.1. The 243 remaining baseline
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FDG-PET scans were downloaded from the LONI image data archive in their original DICOM
or ECAT format. These were pre-processed to produce 30-minute statics as described in Section
4.3.2. Three images were excluded due to missing timeframe information in their ECAT headers,
and five because the positioning of the subject in the scanner was such that either the cerebellum
or frontal cortex was partially excluded from the field of view (see Appendix B).
Baseline and 12-month T1-weighted 1.5 T MRI scans for all 235 subjects with corresponding
pre-processed FDG-PET images were downloaded from the LONI image data archive in NIfTI
format. These had been acquired and pre-processed as described in Section 4.3.3. For each
subject and timepoint, the pre-processed FDG-PET image was affinely co-registered with the
corresponding pre-processed MR image, and re-sampled to the higher resolution of the MRI.
Registration was performed as described in Section 4.3.4.
FDG-PET image intensity normalisation was performed using the reference cluster method
described in Section 4.5.3. The independently-derived cluster from Yakushev et al. (2009) was
again used for normalisation to avoid the introduction of bias. This cluster was provided in MNI
space, and transformed into the baseline and 12-month MRI space of each subject. The pre-
processed MR images were linearly and non-linearly deformed to the MNI template using SPM
Segment, as described in Section 4.5.1. The resulting inverse transformation parameters were
then applied to transform the MNI-space cluster into the native MRI space of each subject
and timepoint using tri-linear interpolation. The cluster was also re-sampled to the higher
resolution of the MRI. Two images for which SPM Segment was unable to provide satisfactory
transformations were additionally excluded from the analysis (see Appendix B).
5.4 Preliminary studies
Before proceeding with a multi-region analysis of the longitudinal ADNI FDG-PET imaging
data, preliminary studies involving only the hippocampal region were performed. Section 5.4.1
describes the automatic generation of hippocampal segmentations for both baseline and 12-
month MR images. Section 5.4.2 describes the subsequent extraction of hippocampal FDG-
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PET signal intensities at both imaging timepoints, as well as investigations of group differences.
Binary classification experiments are then described in Section 5.4.3.
5.4.1 Hippocampal segmentation
The 12-month MR images were affinely co-registered with their corresponding baseline MR
images. Rigid registration parameters were estimated, and used as a starting point for the
estimation of a twelve-parameter affine registration, using normalised mutual information as
the similarity criterion. The 12-month MR images and their corresponding co-registered 12-
month FDG-PET images were then transformed into the space of the baseline MR images using
linear interpolation. The follow-up MRI and both baseline and follow-up FDG-PET images
were thus all aligned with the baseline MRI, as illustrated in Figure 5.3. Affine registration
was used to obtain brain-wide alignment while maintaining local changes such as atrophy.
(a) Bl MRI (b) M12 MRI (c) Bl PET (d) M12 PET
(e) Bl MRI (f) M12 MRI (g) Bl PET (h) M12 PET
Figure 5.3: Typical examples showing the affine alignment to baseline (Bl) MRI space of the
12-month (M12) MRI and FDG-PET images at both timepoints. Images are shown for a HC
(a-d), as well as an AD patient (e-h). FDG-PET images are shown after intensity normalisation.
Hippocampal segmentations for both the baseline and follow-up images were generated simul-
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taneously in baseline MRI space using multi-atlas segmentation followed by a 4D graph-cut
method. These segmentations were prepared as part of a project involved with measuring
hippocampal atrophy, described in Wolz et al. (2010). Since both timepoints were segmented
simultaneously, the segmentations were both consistent and sensitive to atrophy. Typical ex-
amples of the hippocampal segmentations are shown in Figure 5.4.
(a) Baseline (b) Month 12
(c) Baseline (d) Month 12
Figure 5.4: Typical examples of the hippocampal segmentations at both timepoints for a HC
(a-b), as well as an AD patient (c-d).
5.4.2 Image analysis
Each of the MRI-space FDG-PET images described in Section 5.4.1 was overlaid with its
corresponding segmentation, and the signal intensity per mm3 in the hippocampus determined
at each timepoint. Global inter-subject variations were accounted for by normalisation to the
signal intensity per mm3 in the independently-derived reference cluster described in Section
5.3. Normalised hippocampal signal intensities were thus extracted from both the baseline and
12-month FDG-PET images, and the relative changes in signal intensity over the 12-month
follow-up period were additionally determined. These feature data are illustrated in Figure 5.5.
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(a) Baseline (b) Month 12 (c) 12-month change
Figure 5.5: Boxplots showing group differences based on the normalised FDG-PET signal
intensity per mm3 in the hippocampus at (a) baseline and (b) month 12, as well as based on
(c) the intensity change over the follow-up period.
The FDG-PET signal intensity in small structures such as the hippocampus can be influenced
by the partial volume effect. This is a consequence of the limited PET detector resolution, and
results in an apparent loss of intensity in structures that are smaller than twice the scanner’s
FWHM resolution (Hoffman et al., 1979). The partial volume effect can result in the under-
estimation of FDG-PET signal intensities in small hippocampi. It therefore works in the favour
of classification studies, since signal intensities in the smaller hippocampi of AD patients appear
even further reduced compared with those in the larger hippocampi of HC. It is possible to
correct for the effects of partial volume (Rousset et al., 2007; Aston et al., 2002), but this is
generally not feasible as part of routine clinical pratice. Partial volume correction is therefore
not applied for the studies presented in this thesis.
5.4.3 Classification experiments
The potential use of the hippocampal FDG-PET features for classification was next investi-
gated. Two sets of cross-sectional features had been extracted for each subject (hippocampal
signal intensities at each timepoint). Longitudinal features had also been evaluated as the rela-
tive changes in signal intensity over the 12-month follow-up period. Two additional feature sets
which combined the cross-sectional and longitudinal information were formed by concatenating
the longitudinal change features with the signal intensities at either timepoint. Classifica-
tion rates were assessed between four clinically relevant pairs of diagnostic groups (AD/HC,
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pMCI/HC, AD/sMCI, pMCI/sMCI) using the linear discriminant function classifier described
in Section 3.2.1. This simple linear classifier was sufficient for these preliminary investigations
in which only a small number of features were available. Robust estimates of classifier perfor-
mance were obtained via the stratified repeated random sampling approach described in Section
3.3.2. The mean classification accuracy, sensitivity and specificity for pairs of groups were eval-
uated over 1,000 runs in which 75% of the subjects were randomly selected for training, with
the remaining 25% used as test data. For each group pair, unpaired t-tests between the distri-
butions of classification results obtained from the 1,000 leave-25% out runs were performed to
assess the significance of differences in performance between the five feature sets. Results are
shown in Table 5.2.
Bl M12 Ch Bl & ch M12 & ch
AD/HC Acc (%) 76.2 (0.3) 80.4 (0.2) 69.5 (0.3) 81.0 (0.2) 81.1 (0.2)
Sens (%) 77.5 (0.4) 75.8 (0.4) 68.3 (0.4) 75.7 (0.4) 75.5 (0.4)
Spec (%) 75.1 (0.4) 84.3 (0.3) 70.6 (0.4) 85.5 (0.3) 85.7 (0.3)
pMCI/HC Acc (%) 70.9 (0.3) 74.1 (0.2) 44.1 (0.3) 75.6 (0.3) 76.2 (0.3)
Sens (%) 74.6 (0.4) 75.6 (0.3) 42.9 (0.4) 79.1 (0.3) 79.6 (0.4)
Spec (%) 67.8 (0.4) 77.8 (0.4) 45.0 (0.4) 72.6 (0.4) 73.3 (0.4)
AD/sMCI Acc (%) 62.3 (0.3) 70.1 (0.2) 68.2 (0.3) 69.5 (0.3) 71.3 (0.2)
Sens (%) 58.2 (0.5) 67.6 (0.4) 75.6 (0.4) 70.7 (0.4) 71.3 (0.4)
Spec (%) 65.3 (0.4) 74.8 (0.3) 62.7 (0.4) 68.6 (0.4) 69.9 (0.3)
pMCI/sMCI Acc (%) 58.3 (0.3) 60.1 (0.2) 50.9 (0.3) 60.6 (0.3) 61.3 (0.3)
Sens (%) 60.7 (0.5) 61.7 (0.4) 50.4 (0.4) 58.5 (0.5) 59.8 (0.5)
Spec (%) 56.6 (0.4) 62.2 (0.4) 51.2 (0.4) 62.1 (0.4) 61.5 (0.4)
Table 5.2: Classification accuracy (acc), sensitivity (sens) and specificity (spec) expressed as
mean (standard error) over the 1,000 leave-25%-out runs. Results are provided for baseline
signal intensities (Bl), 12-month signal intensities (M12), relative changes in signal intensity
over 12 months (Ch), baseline signal intensities concatenated with 12-month changes (Bl & ch),
and 12-month signal intensities concatenated with 12-month changes (M12 & ch).
Significant (p < 0.05) increases in classification accuracy were achieved when using 12-month
hippocampal signal intensities compared with using baseline signal intensities for all clinical
group pairs except pMCI/sMCI. Classification based on longitudinal information alone had
significantly (p < 0.05) lower accuracy compared with using either of the two cross-sectional
feature sets, except for AD/sMCI. Consistent increases in accuracy were achieved when combin-
ing longitudinal information with 12-month data, compared with its combination with baseline
data, although differences do not reach significance. Classification based on the combination
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of longitudinal data with 12-month signal intensities was consistently improved compared with
using 12-month signal intensities alone, although again differences do not reach significance.
5.4.4 Discussion
Similarly to Hinrichs et al. (2011), it was observed that the relative changes in signal intensity
over 12 months alone did not provide particularly good classification performance. Increases in
classification accuracy were achieved by combining the cross-sectional and longitudinal features,
with the highest accuracies achieved for all group pairs when using the combination of 12-month
signal intensities and changes over 12 months. Although not all differences in classification
performance reached significance, these results suggest that longitudinal FDG-PET features
may provide some complementary information which can enhance classification when used in
conjunction with cross-sectional FDG-PET features. The additional benefit of using multi-
region information was therefore investigated.
5.5 Multi-region segmentation
Automatic whole-brain segmentations into 83 anatomical regions had been prepared in the
native space of each baseline MRI using MAPER as described in Section 4.4. To obtain com-
parable segmentations for the follow-up images, the baseline segmentations were nonrigidly
propagated to the native space of their corresponding 12-month MRI. Although incorrectly
labelled voxels in the baseline segmentation were thereby propagated to the follow-up image,
this method produced consistent segmentations for each subject. Intra-subject segmentation
consistency is important for measuring longitudinal change (Crum et al., 2001) since uncorre-
lated errors lead to greater measurement uncertainty. The MAPER segmentation procedure
was therefore not used directly to generate independent segmentations for the follow-up images.
The intracranial portion of each 12-month MRI was determined by rigid propagation of the
baseline intracranial mask that had been used for brain extraction during the MAPER segmen-
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tation procedure described in 4.4. This process is illustrated in Figure 5.6.
(a) Baseline (b) Month 12
Figure 5.6: An illustration of the rigid propagation of the intracranial brain mask from (a)
baseline MRI space to (b) 12-month MRI space.
The rigidly aligned intracranial-masked baseline and 12-month MRI were then affinely aligned,
followed by a series of nonrigid registrations. Nonrigid registration was performed using control
point spacings of 10, 5, and 2.5 mm. The unmasked baseline anatomical segmentation was
nonrigidly propagated to 12-month MRI space using nearest neighbour interpolation. Individual
tissue probability maps for CSF, grey matter and white matter were obtained for the 12-month
MRI using FSL FAST, and the segmentation masked as described in Section 4.4.3. Typical
examples of the masked segmentations at both timepoints are shown in Figure 5.7.
(a) Baseline (b) Month 12
Figure 5.7: Typical examples of the masked multi-region segmentations in (a) baseline MRI
space, and (b) 12-month MRI space.
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5.6 Multi-region image analysis
Each of the native MRI-space FDG-PET images described in Section 5.3 was overlaid with
its corresponding masked anatomical segmentation. The FDG-PET signal intensity per mm3
was determined for each of the 83 anatomically defined regions at both imaging timepoints.
Global variations in the cerebral metabolic rate of glucose between subjects were accounted
for by normalisation to the signal intensity per mm3 in the independently-derived reference
cluster also described in Section 5.3. Normalised regional signal intensities were thus extracted
from both the baseline and 12-month FDG-PET images. Additionally, the regional changes in
FDG-PET signal intensity over the 12-month follow-up period were determined.
To verify that the regional features to be used for classification were biologically plausible, t-tests
were performed to identify the features which gave significant differences between diagnostic
groups (p < 0.01, uncorrected for multiple comparisons). Both sets of cross-sectional features
(baseline and 12-month regional signal intensities) were considered, as well as the regional
changes in signal intensity over the 12-month follow-up period. Regional t-values between AD
patients and HC based on the cross-sectional features indicated significant differences across
most of the brain. This finding was consistent with the voxel-wise t-tests reported in Yakushev
et al. (2009). The most significantly different regions between groups included those known to
be affected in AD for all three feature sets, consistent with previous voxel-wise t-tests performed
on the ADNI FDG-PET data (Langbaum et al., 2009; Chen et al., 2010).
The majority of regions differed significantly between AD patients and HC for both baseline
intensities (65/83 regions), and 12-month intensities (73/83 regions). In addition to more
regions reaching significance, significance levels were also higher in the 12-month data than
in the baseline data. Far fewer regions reached significance for the change features (26/83
regions), and significance levels were lower than for either of the cross-sectional feature sets.
These results are illustrated in Figure 5.8, and similar patterns were consistently observed
across the remaining three clinical group pairs (pMCI/HC, AD/sMCI, pMCI/sMCI). For these
pairs of groups, fewer regions reached significance than between AD patients and HC, and at
reduced significance levels. The fewest significant regions and lowest significance levels were
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found between pMCI and sMCI patients.
Figure 5.8: Regional t-values for comparisons between AD patients (n = 50) and HC (n = 54)
superimposed onto sagittal (top row) and coronal (bottom row) slices of a maximum probability
brain atlas which has been masked according to the same procedure as the anatomical segmen-
tations. The feature sets tested are, from left to right: baseline signal intensities; 12-month
signal intensities; changes in signal intensity over 12 months. To allow all three feature sets
to be visualised using the same colour scale, so that their spatial patterns may be compared,
all t-values greater than 5.5 have been set to the maximum value. A: anterior, P: posterior, S:
superior, I: inferior, R: right, L: left.
For both sets of cross-sectional features, the five most significantly different regions between AD
patients and HC were the bilateral hippocampus, left parietal lobe, left posterior temporal lobe,
and right posterior cingulate gyrus. However, only one of these regions (right hippocampus)
was among the five most significantly different regions for the change features, along with the
right amygdala, right middle and inferior temporal gyri, right posterior part of the superior
temporal gyrus, and right posterior temporal lobe. For the remaining three group pairs, the five
most significantly different regions for each of the three feature sets contained some combination
of the regions identified between AD patients and HC, with the parahippocampal gyrus also
identified in some cases.
Interestingly, the amygdala was consistently identified among the five most significantly differ-
ent regions for the change features, but not for either of the cross-sectional feature sets. It was
the only region reaching significance for the change features between pMCI and sMCI patients.
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5.7 Classification experiments
The potential use of combining multi-region cross-sectional and longitudinal FDG-PET data
for image-based AD classification was next investigated. Two sets of cross-sectional features
had been extracted for each subject (regional signal intensities at each of the timepoints).
Longitudinal features had also been evaluated as the relative changes in signal intensity over
the 12-month follow-up period. Two additional feature sets which combined the cross-sectional
and longitudinal information were formed by concatenating the longitudinal change features
with the signal intensities at either timepoint.
5.7.1 Methods
Classification rates were assessed between four clinically relevant pairs of diagnostic groups
(AD/HC, pMCI/HC, AD/sMCI, pMCI/sMCI) using the SVM classifier described in Section
3.2.2. The SVM classifier was applied using the soft-margin formulation from LIBSVM with
a radial basis function kernel, as described in Section 4.7.1. Robust estimates of classifier
performance were obtained via the stratified repeated random sampling approach described in
Section 3.3.2. The mean classification accuracy, sensitivity and specificity for pairs of groups
were evaluated over 1,000 runs in which 75% of the subjects were randomly selected for training,
with the remaining 25% used as test data. For each group pair, unpaired t-tests between the
distributions of classification results obtained from the 1,000 leave-25% out runs were performed
to assess the significance of differences in performance between the five feature sets.
To demonstrate that classification was truly based on disease-specific imaging information,
rather than the intrinsic age and gender information captured in the images, classification
was additionally performed after accounting for these effects. A linear regression step was
incorporated into the classification procedure for every clinical group pair such that, for each of
the 1,000 repetitions, a regression model was estimated from the training data, and the SVM
trained on the residuals. The regression model was then applied to the test data, and the SVM
tested on the resulting residuals.
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5.7.2 Results
For all four clinical group pairs, highly significant (p < 0.001) increases in classification ac-
curacy were achieved when using 12-month signal intensities compared with using baseline
signal intensities. Classification based on the longitudinal information alone had significantly
(p < 0.05) lower accuracy compared with using either of the two cross-sectional feature sets.
Highly significant (p < 0.001) increases in classification accuracy were achieved when combin-
ing longitudinal information with 12-month data, compared with its combination with baseline
data. In addition, classification based on the combination of longitudinal data with 12-month
signal intensities was significantly (p < 0.05) improved compared with using 12-month signal in-
tensities alone. All classification accuracies were significantly different from chance, as assessed
using the permutation testing procedure described in Section 3.3.2.
The above results are illustrated as boxplots in Figure 5.9, with numerical results provided
in Table 5.3. ROC curves, as described in Section 3.3.1, for classification based on the best-
performing combined feature set (longitudinal change concatenated with 12-month signal in-
tensities) are displayed in Figure 5.10.
Figure 5.9: Classification accuracies for the four clinical group pairs based on the five feature
sets studied. From left to right for each boxplot: (a) baseline signal intensities, (b) 12-month
signal intensities, (c) change over 12 months, (d) combined baseline intensities and change, (e)
combined 12-month intensities and change.
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Bl M12 Ch Bl & ch M12 & ch
AD/HC Acc (%) 80.9 (0.2) 86.1 (0.2) 73.7 (0.3) 85.9 (0.2) 88.4 (0.2)
Sens (%) 79.6 (0.3) 81.2 (0.3) 66.4 (0.4) 81.2 (0.3) 83.2 (0.3)
Spec (%) 82.3 (0.3) 91.0 (0.3) 81.0 (0.4) 90.6 (0.3) 93.6 (0.3)
pMCI/HC Acc (%) 70.7 (0.3) 79.2 (0.3) 70.0 (0.3) 77.7 (0.3) 81.3 (0.2)
Sens (%) 70.5 (0.4) 77.2 (0.4) 63.0 (0.4) 75.1 (0.4) 79.8 (0.3)
Spec (%) 71.0 (0.4) 81.4 (0.3) 77.5 (0.4) 80.4 (0.3) 82.9 (0.3)
AD/sMCI Acc (%) 72.7 (0.3) 79.3 (0.2) 67.2 (0.3) 78.5 (0.2) 83.5 (0.2)
Sens (%) 65.6 (0.4) 77.9 (0.3) 56.6 (0.5) 73.9 (0.4) 79.9 (0.3)
Spec (%) 78.5 (0.3) 80.5 (0.3) 75.8 (0.3) 82.2 (0.3) 86.4 (0.3)
pMCI/sMCI Acc (%) 58.4 (0.3) 62.3 (0.3) 58.4 (0.3) 61.8 (0.3) 63.1 (0.3)
Sens (%) 51.5 (0.4) 53.2 (0.4) 50.2 (0.5) 52.5 (0.5) 52.2 (0.5)
Spec (%) 64.8 (0.5) 70.8 (0.4) 68.5 (0.4) 70.5 (0.4) 73.2 (0.4)
Table 5.3: Classification accuracy (acc), sensitivity (sens) and specificity (spec) expressed as
mean (standard error) over the 1,000 leave-25%-out runs. Results are provided for baseline
signal intensities (Bl), 12-month signal intensities (M12), relative changes in signal intensity
over 12 months (Ch), baseline signal intensities concatenated with 12-month changes (Bl & ch),
and 12-month signal intensities concatenated with 12-month changes (M12 & ch).
Figure 5.10: ROC curves for the combined feature set of relative changes concatenated with
12-month signal intensities. AUC values for each clinical group pair are provided in brackets.
Linear regression for age and gender had no significant effect on the classification accuracy for
the majority of experiments. Classification results after linear regression are shown in Table
5.4, in which cases where regression did significantly affect the accuracy are indicated.
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Bl M12 Ch Bl & ch M12 & ch
AD/HC 81.2 (0.2) 85.9 (0.2) 73.6 (0.3) 84.8 (0.2) 87.1 (0.2)
pMCI/HC 73.7 (0.3)∗ 80.2 (0.3) 68.9 (0.3) 78.4 (0.3) 81.6 (0.2)
AD/sMCI 74.2 (0.3) 78.8 (0.3) 67.8 (0.3) 79.1 (0.2) 83.5 (0.3)
pMCI/sMCI 61.5 (0.3)∗ 62.2 (0.3) 58.9 (0.3) 62.7 (0.3) 64.0 (0.3)
Table 5.4: Classification accuracy (%) after regression for age and gender expressed as mean
(standard error) over the 1,000 leave-25%-out runs. Results are provided for baseline signal
intensities (Bl), 12-month signal intensities (M12), relative changes in signal intensity over 12
months (Ch), baseline signal intensities concatenated with 12-month changes (Bl & ch), and
12-month signal intensities concatenated with 12-month changes (M12 & ch). Cases where the
regression significantly (p < 0.05) affected the accuracy are indicated by asterisks (∗). In both
these cases, regression improved the accuracy.
5.7.3 Discussion
Classification results in line with the current state-of-the-art have been achieved by using a
combination of cross-sectional and longitudinal multi-region FDG-PET information. For the
most commonly reported classification task of separating AD patients from HC, the accuracy of
88% is comparable with other recent classification results based on multi-modality imaging and
non-imaging data (for example, Hinrichs et al. (2011): 92% accuracy, Zhang et al. (2011): 93%
accuracy), and also with the results of high-dimensional pattern recognition methods applied
to cross-sectional MR imaging data (for example, Cuingnet et al. (2011): up to 81% sensitivity,
95% specificity). As explained in Section 4.7.3, classification results may be converging on a
glass ceiling of around 90% for this task. The less commonly reported, but more clinically
significant, task of separating pMCI from sMCI patients was also investigated. The accuracy of
63% is encouraging compared with the most directly comparable studies based on MR imaging
data (for example, Cuingnet et al. (2011): up to 62% sensitivity, 69% specificity), Wolz et al.
(2010): 64% accuracy). However, as explained in Section 4.7.3, to properly assess the utility of
any classification method in predicting progression, longer clinical follow-up would be required
than is currently available for the ADNI participants.
Similarly to Hinrichs et al. (2011), it was observed that the percentage change in signal intensity
over 12 months alone did not provide particularly good classification performance between AD
patients and HC (74% accuracy). Although the longitudinal change data alone appear insuffi-
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cient for matching state-of-the-art classification performance, the results of experiments based
on combined feature sets show that they provide some complementary information which can
enhance classification when used in conjunction with cross-sectional features. This suggestion is
supported by the t-test results displayed in Section 5.6, which show that the pattern of regional
significances differs between cross-sectional and longitudinal data. For example, the amygdala
was identified among the best five features for group discrimination only for the longitudinal
data. The two cross-sectional feature sets, on the other hand, had similar patterns of regional
significances, although improved group discrimination was achieved with the 12-month data.
This is to be expected, since patients that are 12 months further along the disease process
should be more easily distinguished from HC. Rather than relying on t-tests to explore the rel-
ative feature importances, a direct visualisation of the SVM weight vector would be desirable.
However, because of the nonlinearity of the kernel used, it was not possible to map the weight
vectors learned in the transformed feature space back to the original feature space.
The aim of this work has not been to introduce a novel classification approach, but instead
to use a readily available SVM classifier and simple feature combination approach (direct con-
catenation) to demonstrate the utility of longitudinal FDG-PET information for improving
classification amongst four clinically relevant pairs of diagnostic groups. All classification ex-
periments were also performed after accounting for the effects of age and gender by linear
regression. The lack of significant effect on accuracy observed in the majority of cases indicates
that the classification results were truly based on disease-specific imaging information, rather
than the intrinsic age and gender information also captured in the images.
This work demonstrates that information extracted from serial FDG-PET through regional
analysis can accurately discriminate diagnostic groups, even at the early symptomatic stages
of AD. This finding may be usefully applied in the diagnosis of AD, predicting disease course
in MCI patients, and in the selection of participants for clinical trials. Importantly, the utility
of serial regional FDG-PET for patient classification is demonstrated in a realistic multi-centre
setting. Although the use of longitudinal data for the clinical diagnosis of AD is not necessarily
practical, its use for stratification of pMCI versus sMCI patients could still be valuable. For
clinical trial recruitment, it may be acceptable to use longitudinal information acquired over
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12 months to gain additional certainty about whether a candidate fits the selection criteria.
5.8 Conclusion
This chapter has presented a multi-region analysis of longitudinal FDG-PET imaging data
from the ADNI study. Whole-brain segmentations into 83 anatomically defined regions were
automatically generated in the native MRI space of each subject for both baseline and 12-month
images. These were used to extract regional signal intensities from the corresponding FDG-
PET images, and their combined use for image-based AD classification was investigated. The
effect on classification of the subjects’ gender and age at scan were additionally considered.
The classification results are in line with the current state-of-the-art, but there are several
areas for further research. For example, a more sophisticated method could be used for data
combination, and the information from both the FDG-PET and MR images could be combined.
The work presented in the following chapter will focus on these issues, as well as investigating
the incorporation of non-imaging data such as CSF biomarkers and genetic information.
Chapter 6
Random forest-based similarities for
multi-modality classification
Work in this chapter has, in part, been presented in:
K. R. Gray, P. Aljabar, R. A. Heckemann, A. Hammers, and D. Rueckert. Random forest-based
manifold learning for classification of imaging data in dementia. (In Proceedings) Machine
Learning in Medical Imaging Workshop at 14th International Conference on Medical Image
Computing and Computer Assisted Intervention (MICCAI’11). Lecture Notes in Computer
Science, 7009:159–166, 2011.
6.1 Introduction
This chapter presents a multi-modality classification framework evaluated using imaging and
biological data from the ADNI study. As described in Section 1.5, changes in multiple neu-
roimaging and biological measures may provide complementary information for the diagno-
sis and prognosis of AD. Automated classification of individual patients based on multiple
biomarkers could provide valuable support for clinicians, when considered alongside cognitive
assessment scores and traditional visual image analysis. Two independent studies investigating
multi-modality classification using multi-kernel learning have reported that classification based
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on multi-modality data was superior to that based on any individual modality (Zhang et al.,
2011; Hinrichs et al., 2011).
This work presents an alternative approach for multi-modality classification, based on pair-
wise similarity measures derived from random forest classifiers. The similarities were used to
construct a manifold representation from labelled training data and then to infer the diagnos-
tic labels of test data mapped into this space. This method facilitates the incorporation of
multi-modality data, since similarities derived from several datasets may be readily combined
to generate an embedding that simultaneously encodes information from all features. Clas-
sification based on the combination of regional MRI volumes, voxel-based FDG-PET signal
intensities, CSF biomarker measures, and ApoE allele status is superior to that based on any
individual modality for comparisons between AD patients and HC, as well as between MCI
patients and HC. Results are comparable with those obtained using multi-kernel learning in
Zhang et al. (2011) and Hinrichs et al. (2011). Since random forest classifiers extend naturally
to multi-class problems, the framework described here could be used for other applications in
the future, such as the differential diagnosis of AD.
Manifold learning techniques based on pairwise similarities between images have been applied in
a variety of neuroimaging studies. For example, Laplacian eigenmaps (Belkin and Niyogi, 2003)
have been used to generate an embedding of brain MR images based on similarities derived
from overlaps of their structural segmentations (Aljabar et al., 2008). Isomap (Tenenbaum
et al., 2000) has also been used to estimate the manifold structure of brain MR images, using
distance measures based on nonrigid transformations between image pairs (Gerber et al., 2009).
A framework for fusing manifold learning steps based on multiple pairwise similarity measures
has been presented in Aljabar et al. (2010). The method described here uses random forests
to derive consistent pairwise similarity measures for multiple modalities, thus facilitating the
combination of different types of feature data.
The ADNI participants whose imaging and biological data are used in this chapter are first de-
scribed in Section 6.2. Details of the multi-modality classification framework are then presented
in Section 6.3. The results of preliminary experiments based on the combination of voxel-based
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FDG-PET and region-based MR imaging data are presented in Section 6.4, followed by results
based on the combination of imaging and biological data in Section 6.5.
6.2 Imaging and biological data
Clinical, imaging, and biological data used in this chapter were obtained from the ADNI
database, which has been described in Section 4.2. Baseline FDG-PET and MR imaging data
from the 287 participants described in Section 4.2 were used for the preliminary experiments
presented in Section 6.4. ApoE genotype information was available for all 287 participants, but
baseline CSF measures were only available for a subset of 147. Groupwise characteristics are
provided in Table 6.1 for this subset of participants, whose imaging and biological data were
used for the experiments presented in Section 6.5. The MCI patients in this subset were divided
into pMCI and sMCI based on changes in clinical status occurring over 20 ± 11 (range 6 – 36)
months. The mean age at baseline does not vary significantly (p > 0.01) on t-test between the
clinical groups.
N(F) Age MMSE Score CDR (%)
(mean ± std. dev.) (mean ± std. dev.) 0 0.5 1
AD 37(14) 76.8 ± 6.6 23.5 ± 2.0 0 49 51
pMCI 34(12) 76.1 ± 7.3 26.5 ± 1.7 0 100 0
sMCI 41(12) 75.7 ± 6.5 27.3 ± 1.8 0 100 0
HC 35(12) 74.5 ± 5.2 28.9 ± 1.2 100 0 0
Table 6.1: Clinical and demographic information for the subset of participants for whom CSF
data were available. For each clinical group, the total number of subjects (N) and number of
females (F) are shown, along with the average age, average MMSE score, and CDR distribution.
The four imaging and biological feature sets used for evaluation of the multi-modality classifi-
cation framework presented in this chapter are described in the following subsections.
6.2.1 Region-based MRI features
Automatic whole-brain segmentations into 83 anatomical regions had already been prepared in
the native space of each baseline MRI using MAPER, as described in Section 4.4. Since AD
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is characterised by cortical neuronal loss, the masked segmentations described in Section 4.4.3
were employed for feature extraction. Regional volumes were computed for all 83 structures,
and normalised by the total intracranial volume (ICV) computed from the masks described
in Section 4.4.1. ICV normalisation has been shown to substantially reduce variation, remove
gender-related differences (Whitwell et al., 2001), and eliminate inaccuracies arising from scaling
or voxel size errors remaining after phantom correction of the MRI (Clarkson et al., 2009).
6.2.2 Voxel-based FDG-PET features
Voxel-based features were extracted from the FDG-PET images to enable demonstration that
the proposed multi-modality classification approach could readily combine different types of
features. The FDG-PET images were aligned with the MNI template and smoothed, as de-
scribed in Section 4.5.1. Global inter-subject variations were accounted for by normalisation to
the signal intensity per mm3 in the independently-derived reference cluster described in Section
4.5.3. The SPM brain mask, which covers white and grey matter in MNI space, was thresholded
at 50% probability, and applied to each normalised FDG-PET image to exclude voxels outside
the brain. Signal intensities were then extracted from all remaining voxels, resulting in 239,304
voxel-based features per image.
6.2.3 Biological CSF and ApoE genotype features
The ADNI Biomarker Core, based at the University of Pennsylvania, provides biological data
for the study participants. These data include CSF measures of Aβ, tau and phosphorylated
tau (ptau), as well as ApoE genotype information determined from a blood sample. Details of
the biofluid collection and processing are provided in Trojanowski et al. (2010). The genetic
feature data for each participant consist of a single categorical variable describing their ApoE
genotype. This categorical feature takes one of five possible values: (3, 3), (3, 4), (4, 4),
(2, 3), (2, 4). Groupwise CSF measures and genotype information are provided in Table 6.2
for the 147 participants for whom biological data were available.
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CSF measures (pg/mL) ApoE genotype (%)
Aβ tau ptau (3, 3) (3, 4) (4, 4) (2, 3) (2, 4)
AD 141 ± 43 127 ± 64 46 ± 24 24 41 30 0 5
pMCI 152 ± 47 96 ± 41 37 ± 12 41 41 18 0 0
sMCI 167 ± 55 105 ± 81 35 ± 22 39 39 12 10 0
HC 208 ± 56 69 ± 28 26 ± 16 48 23 0 26 3
Table 6.2: Groupwise CSF measures and genetic information for the 147 participants for whom
biological data were available. CSF measures are expressed as mean ± standard deviation, and
genetic information is expressed as the proportion of each diagnostic group possessing each of
the five ApoE allele pairs.
6.3 Multi-modality classification framework
A schematic overview of the proposed similarity-based multi-modality classification approach
is shown in Figure 6.1.
Figure 6.1: Schematic overview of the proposed multi-modality classification approach. Each
random forest (RF) step provides a classification result whose performance will be reported.
Random forests are used both to derive the similarity matrices for each feature set, and also to
perform the single- and multi-modality classification experiments.
A random forest classifier, as described in Section 3.2.4, was applied to the feature data from
each modality independently. Single-modality classification results for comparison were thus
obtained, as well as pairwise similarity measures between subjects. These similarities were
used to construct single-modality manifold representations from labelled training data and
then to infer the diagnostic labels of test data mapped into this space. Similarities from
multiple modalities were additively combined to generate an embedding that simultaneously
encodes information from all features. Multi-modality classification was then performed using
coordinates from this joint embedding.
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Classical MDS was applied as described in Section 3.2.4 to learn the manifolds on which to
perform classification. MDS is commonly used to provide low-dimensional visualisations of sim-
ilarity relationships, including those derived from random forests (Hastie et al., 2011). Random
forest-derived similarities have been successfully applied in unsupervised clustering tasks, for
example those involving high-dimensional genetic or tissue microarray data (Shi and Horvath,
2006; Shi et al., 2005). Here, random forests are used to derive supervised similarities, with the
aim of generating manifolds that are optimal for the task of clinical group discrimination.
The multi-modality classification framework described in this chapter has been implemented
using the R package for random forests. This is a port of Leo Breiman and Adele Cutler’s
original Fortran code, by Andy Liaw and Matthew Wiener (Liaw and Wiener, 2002) (http:
//cran.r-project.org/web/packages/randomForest).
6.4 Combining FDG-PET and MR imaging data
The multi-modality classification framework described in Section 6.3 was first applied for the
combination of voxel-based FDG-PET and region-based MR imaging data. These data com-
prised baseline images acquired from the 287 ADNI participants described in Section 4.2. De-
tails of the methodology and results obtained from both single- and multi-modality classification
experiments are presented in the following subsections.
6.4.1 Classification methodology
Classification performance was assessed between two clinically relevant pairs of diagnostic
groups (AD/HC, MCI/HC) based on both single- and multi-modality imaging information.
The mean classification accuracy, balanced accuracy, sensitivity and specificity for both group
pairs were evaluated using the stratified ten-fold cross-validation method described in Section
3.3.2, with the same folds used for all experiments. Classification performance is commonly
reported in terms of accuracy, but here statistical comparisons between experiments are per-
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formed based on the balanced accuracy. This provides a more meaningful performance metric
for groups of unequal sizes, such as the MCI and HC subject groups in this work.
Before performing classification experiments, the number of trees grown in each forest, t, and
the number of features randomly selected at each tree node, d, had to be selected. Stable
estimates of the out-of-bag classification error were consistently observed for t & 1, 000, and
t = 5, 000 was therefore used for all experiments. The value of d was consistently observed
to have little effect on the out-of-bag classification error estimate. The value d =
√
D was
therefore used for all experiments, following the recommendation of Liaw and Wiener (2002).
6.4.2 Single-modality classification results
A random forest classifier was applied to the feature data from each modality independently,
and the single-modality classification results obtained are presented in Table 6.3.
AD vs. HC MCI vs. HC
MRI FDG-PET MRI FDG-PET
Acc. (%) 84.4 (1.6) 87.9 (2.6) 64.4 (3.0) 63.9 (2.3)
Bacc. (%) 84.4 (3.3) 87.9 (4.3) 67.5 (4.9) 66.6 (3.7)
Sens. (%) 83.2 (3.5) 92.0 (3.9) 59.3 (4.5) 59.1 (2.8)
Spec. (%) 85.5 (3.0) 83.8 (4.7) 75.7 (5.2) 74.1 (4.6)
Table 6.3: Single-modality classification accuracy (acc.), balanced accuracy (bacc.), sensitivity
(sens.) and specificity (spec.) based on the application of a random forest classifier to the
original imaging data from 287 ADNI participants. Results are expressed as mean (standard
error).
As described in Section 3.2.4, estimates of the relative importances of the various features
for classification may be extracted from the random forest. Feature importances for the two
imaging modalities are shown in Figure 6.2 for both clinical group pairs. The most important
features for MRI include volumes of the hippocampus, amygdala, and other medial temporal
lobe structures. The most important features for FDG-PET include signal intensities of voxels
located in the posterior cingulate gyrus, parietal lobe, posterior temporal lobe, and around the
hippocampus.
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(a) MRI: AD/HC (b) MRI: MCI/HC
(c) PET: AD/HC (d) PET: MCI/HC
Figure 6.2: Feature importances for distinguishing between clinical groups using (a-b) region-
based MRI, and (c-d) voxel-based FDG-PET. For MRI, regional feature importances are super-
imposed onto sagittal and coronal slices of a maximum probability brain atlas which has been
masked in the same way as the anatomical segmentations. For FDG-PET, important voxels
are overlaid onto sagittal and coronal slices of a MNI-space average MR image.
6.4.3 Single-modality similarity-based classification results
The random forest classifiers described in Section 6.4.2 were additionally used to derive pairwise
similarity measures for each of the modalities, as described in Section 3.2.4. After applying
MDS to the similarity matrix for each modality, the eigenvectors corresponding to the 25
largest-valued eigenvalues were used in generating the embeddings for classification. The value
of 25 was empirically determined to ensure that zero-valued eigenvalues were not included, while
capturing the maximum possible amount of information. Examples of the similarity matrices
are shown later in Section 6.5.3.
A random forest classifier was applied to the embedded feature data from each of the two
modalities independently, and the single-modality classification results obtained are presented
in Table 6.4. The balanced accuracies achieved based on the embedding coordinates do not
differ significantly from those achieved using the original imaging data (paired t-test, p > 0.05).
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AD vs. HC MCI vs. HC
MRI FDG-PET MRI FDG-PET
Acc. (%) 87.2 (2.0) 87.8 (2.6) 64.8 (3.0) 65.3 (1.9)
Bacc. (%) 87.2 (2.9) 87.8 (4.0) 65.2 (5.3) 65.3 (3.4)
Sens. (%) 87.5 (3.2) 91.8 (2.9) 64.8 (3.9) 65.3 (2.9)
Spec. (%) 86.9 (2.6) 83.8 (5.1) 65.5 (6.7) 65.2 (3.8)
Table 6.4: Single-modality classification accuracy (acc.), balanced accuracy (bacc.), sensitivity
(sens.) and specificity (spec.) based on the application of a random forest classifier to the
embedded imaging data from 287 ADNI participants. Results are expressed as mean (standard
error).
6.4.4 Multi-modality similarity-based classification results
To generate a combined embedding that simultaneously incorporated information from both the
FDG-PET and MR imaging data, the similarity matrices from the individual modalities were
additively combined, and MDS applied to the resulting joint similarity matrix. A random forest
classifier was then applied to the embedded feature data, and the multi-modality classification
results obtained are presented in Table 6.5. Results based on the joint embedding out-performed
the corresponding application to the separate embedding coordinates. The improvement in
balanced accuracy was significant for the MCI/HC experiment (paired t-test, p < 0.05).
For comparison, the FDG-PET and MR imaging features were combined by simple concate-
natation, and a random forest classifier applied. The performance based on this feature set is
also shown in Table 6.5. The balanced accuracy based on this feature set does not significantly
differ from that based solely on the FDG-PET imaging features (paired t-test, p > 0.05).
AD vs. HC MCI vs. HC
Joint embedding Concatenation Joint embedding Concatenation
Acc. (%) 90.0 (2.6) 87.9 (2.6) 75.5 (2.2) 64.3 (2.4)
Bacc. (%) 89.4 (3.6) 87.9 (4.3) 74.7 (3.0) 66.9 (3.9)
Sens. (%) 88.9 (3.4) 92.0 (3.9) 76.9 (3.2) 59.8 (3.2)
Spec. (%) 89.8 (3.8) 83.8 (4.7) 72.4 (4.5) 74.0 (4.6)
Table 6.5: Multi-modality classification accuracy (acc.), balanced accuracy (bacc.), sensitivity
(sens.) and specificity (spec.) based on the application of a random forest classifier to the
jointly embedded imaging data from 287 ADNI participants. Classification results based on
the application of a random forest classifier to the concatenated imaging features are also shown.
Results are expressed as mean (standard error).
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6.4.5 Discussion
Classification based on the joint embedding constructed using both FDG-PET and MR imag-
ing data out-performed classification based on either modality alone. This supports previous
suggestions that there is complementary information between MRI and FDG-PET which can
be exploited to produce a more powerful combined biomarker for AD (Walhovd et al., 2010;
Landau et al., 2010). The classification accuracy for discriminating AD patients from HC based
on the joint embedding is comparable with other state-of-the-art machine learning techniques
which use either single-modality (Cuingnet et al., 2011) or multi-modality (Zhang et al., 2011;
Hinrichs et al., 2011) imaging data. The accuracy for discriminating MCI patients from HC
based on the joint embedding is also comparable with state-of-the-art multi-modality methods.
For example, Zhang et al. (2011) report an accuracy of 76% using multi-kernel learning, but
based on the combination of MRI, FDG-PET and CSF biomarkers. The lack of significant dif-
ference between classification performance based on the original imaging data and that based
on the embedding coordinates for each individual modality is expected, since a random forest
is already a nonlinear classifier. The motivation for the embedding step was to facilitate the
incorporation of multi-modality data. It was shown that a simple concatenation of the FDG-
PET and MR imaging features does not optimally combine these data, as this did not improve
classification performance compared with the single modalities.
In the context of a neuroimaging application, one of the key benefits of random forests is that
they provide estimates of the importances of the features for classification (Langs et al., 2011).
This is valuable because it allows verification that the high-dimensional imaging features that
contribute most to the classifier correspond to regions or structures with a biologically plausible
connection to pathology. In this work, the most important features for discriminating between
clinical groups correspond with those known to be visibly affected in AD on both FDG-PET and
structural MR imaging (Hampel et al., 2008; Patwardhan et al., 2004). The important features
for distinguishing between AD patients and HC are localised to affected regions, with the more
challenging distinction between MCI patients and HC requiring features spread across a larger
portion of the brain. The motivation for extracting voxel-based features from the FDG-PET
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and region-based features from the MRI was to demonstrate that these two different types of
imaging features could be readily combined using the proposed method.
6.5 Combining imaging and biological data
Following the success of the preliminary experiments described in Section 6.4, the multi-
modality classification framework described in Section 6.3 was next applied for the combination
of imaging and biological data. These data comprised ApoE genotype information and baseline
FDG-PET, MRI and CSF measures acquired from the 147 ADNI participants described in Sec-
tion 6.2. As well as extending the application of the method to biological data, improvements
were made to the cross-validation and embedding steps, and an additional classification exper-
iment (pMCI/sMCI) was included. Details of the methodology and results obtained from both
single- and multi-modality classification experiments are presented in the following subsections.
6.5.1 Classification methodology
Classification performance was assessed between three clinically relevant pairs of diagnostic
groups (AD/HC, MCI/HC, pMCI/sMCI) based on both single- and multi-modality imaging and
biological data. Robust estimates of classifier performance were obtained using the stratified
repeated random sampling approach described in Section 3.3.2, with the same folds used for all
experiments. The mean accuracy, balanced accuracy, sensitivity and specificity were evaluated
over 100 runs in which 75% of the data were selected for training, with the remaining 25% used
as test data. Values of t = 5, 000 and d =
√
D were selected as described in Section 6.4.1.
6.5.2 Single-modality classification results
A random forest classifier was applied to the feature data from each modality independently,
and the single-modality classification results obtained are presented in Table 6.6. As described
in Section 3.2.4, estimates of the relative importances of the various features for classification
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may be extracted from the random forest. Feature importances for the two imaging modalities
are shown in Figure 6.3 for all three clinical group pairs. The most important features for both
MRI and FDG-PET are as described in Section 6.4.2.
CSF MRI FDG-PET Genetic
AD/HC Acc. (%) 76.5 (0.8) 81.6 (0.8) 86.0 (0.7) 72.6 (0.9)
Bacc. (%) 76.8 (1.3) 81.8 (1.3) 86.0 (1.2) 72.7 (1.3)
Sens. (%) 73.0 (1.3) 79.8 (1.3) 86.8 (1.1) 71.3 (1.3)
Spec. (%) 80.5 (1.3) 83.8 (1.3) 85.1 (1.3) 74.1 (1.4)
MCI/HC Acc. (%) 63.1 (0.8) 66.9 (0.9) 66.5 (0.8) 73.8 (0.5)
Bacc. (%) 63.8 (1.4) 68.9 (1.3) 66.9 (1.3) 60.7 (0.9)
Sens. (%) 62.0 (1.1) 63.7 (1.2) 65.7 (1.1) 94.7 (0.5)
Spec. (%) 65.5 (1.7) 74.0 (1.4) 68.1 (1.5) 26.6 (1.2)
pMCI/sMCI Acc. (%) 52.9 (1.0) 55.1 (1.0) 52.6 (1.0) 47.3 (0.9)
Bacc. (%) 53.5 (1.6) 55.5 (1.7) 53.1 (1.7) 42.4 (2.4)
Sens. (%) 58.1 (1.6) 59.1 (1.8) 57.4 (2.0) 32.1 (2.1)
Spec. (%) 48.8 (1.5) 51.9 (1.6) 48.8 (1.5) 52.6 (2.7)
Table 6.6: Single-modality classification accuracy (acc.), balanced accuracy (bacc.), sensitivity
(sens.) and specificity (spec.) based on the application of a random forest classifier to the
original imaging and biological data from 147 ADNI participants. Results are expressed as
mean (standard error).
(a) MRI: AD/HC (b) MRI: MCI/HC (c) MRI: pMCI/sMCI
(d) PET: AD/HC (e) PET: MCI/HC (f) PET: pMCI/sMCI
Figure 6.3: Feature importances for distinguishing between clinical groups using (a-c) region-
based MRI, and (d-f) voxel-based FDG-PET. For MRI, regional feature importances are super-
imposed onto sagittal and coronal slices of a maximum probability brain atlas which has been
masked in the same way as the anatomical segmentations. For FDG-PET, important voxels
are overlaid onto sagittal and coronal slices of a MNI-space average MR image.
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6.5.3 Single-modality similarity-based classification results
The random forest classifiers described in Section 6.5.2 were additionally used to derive pairwise
similarity measures for each of the four modalities, as described in Section 3.2.4. Examples of
the resulting similarity matrices are shown in Figure 6.4. The categorical nature of the genetic
information results in similarity matrices which have an almost binary structure.
(a) CSF (b) MRI
(c) FDG-PET (d) Genetic
Figure 6.4: Similarity matrices for all three clinical group pairs based on (a) CSF biomarker
measures, (b) regional MRI volumes, (c) voxel-based FDG-PET signal intensities and (d) cat-
egorical ApoE genotype information. The matrices are symmetric, and each entry represents
the similarity between a pair of subjects based on the input feature data.
MDS was applied to each similarity matrix, and a goodness-of-fit value of 90% was used to
determine an appropriate dimensionality for the resulting embeddings, as described in Section
3.2.4. A random forest classifier then was applied to the embedded feature data from each of
the four modalities independently, and the single-modality classification results obtained are
presented in Table 6.7, along with the dimensionality of each embedding.
No consistent differences were observed between the balanced accuracies based on the embedded
imaging and biological feature data shown in Table 6.7, and those based on the original feature
data shown in Table 6.6.
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CSF MRI FDG-PET Genetic
AD/HC Acc. (%) 76.1 (0.8) 82.5 (0.7) 86.4 (0.7) 72.6 (0.9)
Bacc. (%) 76.3 (1.3) 82.1 (1.4) 86.5 (1.2) 72.7 (1.3)
Sens. (%) 72.8 (1.3) 88.6 (1.2) 85.8 (1.2) 71.3 (1.3)
Spec. (%) 79.8 (1.4) 75.6 (1.5) 87.1 (1.3) 74.1 (1.4)
k 13 22 9 2
MCI/HC Acc. (%) 61.7 (0.8) 67.3 (1.0) 53.5 (0.7) 73.8 (0.5)
Bacc. (%) 61.7 (1.3) 69.1 (1.4) 60.2 (1.2) 60.7 (0.9)
Sens. (%) 61.6 (1.1) 64.3 (1.3) 42.3 (1.1) 94.7 (0.5)
Spec. (%) 61.8 (1.5) 73.9 (1.4) 78.0 (1.3) 26.6 (1.2)
k 25 47 35 2
pMCI/sMCI Acc. (%) 52.1 (1.0) 58.4 (1.0) 53.0 (1.0) 43.5 (0.9)
Bacc. (%) 52.7 (1.7) 58.3 (1.7) 52.8 (1.7) 41.2 (2.4)
Sens. (%) 57.9 (1.6) 56.9 (1.6) 50.6 (1.8) 27.4 (2.0)
Spec. (%) 47.5 (1.7) 59.7 (1.8) 54.9 (1.6) 55.0 (2.7)
k 21 38 35 1
Table 6.7: Single-modality classification accuracy (acc.), balanced accuracy (bacc.), sensitivity
(sens.) and specificity (spec.) based on the application of a random forest classifier to the
embedded imaging and biological data from 147 ADNI participants. Results are expressed as
mean (standard error). The mean dimensionality of each embedding (k) is also shown.
6.5.4 Multi-modality similarity-based classification results
A joint similarity matrix S was defined as a linear combination of the similarity matrices from
each of the four modalities Si. Each modality was assigned a weighting factor αi, such that
S =
4∑
i=1
αiSi, where
4∑
i=1
αi = 1.
To ensure the best combination of the four modalities for classification, the αi parameters
were optimised as part of the training process. This was achieved by performing a grid-search
within the training data, and selecting the set of parameters resulting in the highest cross-
validated accuracy. The classifier was then trained using this set of parameters, before having
its performance assessed on the test data. For each of the classification experiments, the
distribution of parameters selected over the 100 runs is illustrated in Figure 6.5.
MDS was applied to the joint similarity matrix constructed using information from all four
modalities, and a goodness-of-fit value of 90% was again used to determine an appropriate
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dimensionality for the resulting embedding. A random forest classifier was applied to the
embedded feature data, and the multi-modality classification results obtained are presented in
Table 6.8.
Acc. (%) Bacc. (%) Sens. (%) Spec. (%)
AD/HC 89.0 (0.7) 89.0 (1.2) 87.9 (1.2) 90.0 (1.1)
MCI/HC 74.6 (0.8) 72.7 (0.8) 77.5 (1.0) 67.9 (1.7)
pMCI/sMCI 58.0 (0.9) 57.9 (1.7) 57.1 (1.8) 58.7 (1.5)
Table 6.8: Multi-modality classification accuracy (acc.), balanced accuracy (bacc.), sensitivity
(sens.) and specificity (spec.) based on the application of a random forest classifier to the jointly
embedded imaging and biological data from 147 ADNI participants. Results are expressed as
mean (standard error).
The balanced accuracies based on multi-modality classification are significantly (paired t-test,
p < 0.01) higher than those based on any individual modality for both the AD/HC and MCI/HC
experiments. For the pMCI/sMCI experiment, however, the balanced accuracy based on multi-
modality classification is not significantly different from that based on MRI information alone.
Figure 6.5: Cobweb plots showing the distribution of parameters selected over the 100 leave-
25%-out runs for all three classification experiments. The four spokes of each plot represent the
four modalities, and each coloured line connecting the four spokes represents a set of parameter
values. The colour and weight of each line represents the percentage of runs in which the
associated parameter set was selected.
6.5.5 Discussion
Classification based on the joint embedding constructed using information from all four modali-
ties was superior to classification based on any individual modality for comparisons between AD
patients and HC, as well as between MCI patients and HC. This lends further support to previ-
ous suggestions that there is some complementary information between these neuroimaging and
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biological measures which can be exploited to produce a more powerful combined biomarker
for AD and MCI (Walhovd et al., 2010; Landau et al., 2010).
In terms of accuracy, 89% classification was achieved between AD patients and HC, and 75%
between MCI patients and HC. These results are comparable with the 92% and 93% accuracies
reported between AD patients and HC in Hinrichs et al. (2011) and Zhang et al. (2011), re-
spectively, as well as the 76% accuracy reported between MCI patients and HC in Zhang et al.
(2011). Both of these studies employ a kernel combination framework for multi-modality clas-
sification, and this work proposes an alternative approach which achieves comparable results.
Random forests provide consistent pairwise similarity measures for multiple modalities, thus
facilitating the combination of different types of feature data. This has been demonstrated
using datasets in which the number of features differ by several orders of magnitude. Since
random forest classifiers extend naturally to multi-class problems, the framework described
here could be used for other applications in the future, such as the differential diagnosis of
AD. In addition, the implementation of random forests used in this work could be easily mod-
ified to produce uncertainty information about the predicted diagnostic labels. This could be
achieved by having each leaf node store a probabilistic distribution of labels, rather than a
point estimate. Criminisi et al. (2012), for example, describes this and other extensions to the
original random forests algorithm, and presents a unified model of random decision forests for
classification, regression, density estimation, manifold learning, and semi-supervised learning.
In Section 6.4, comparable multi-modality classification results were achieved using only infor-
mation extracted from the two imaging modalities (accuracies of 90% for AD/HC and 76% for
MCI/HC). The lack of improvement over these results is likely to be attributable to the consid-
erable reduction in size of the subject group as a result of the requirement for CSF biomarker
information. A total of 287 ADNI participants had both FDG-PET and MR imaging data
available, but CSF biomarker measures were additionally available for only 147. A more robust
form of cross-validation was also applied in this section, which uses stratified repeated random
sampling as opposed to the single round of ten-fold cross-validation employed in Section 6.4.
The motivation for the embedding step was to facilitate the incorporation of multi-modality
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data. A goodness-of-fit parameter of 90% was used to determine an appropriate dimension
for the embeddings which would reduce noise in the data. This method of determining the
dimensionality of the embeddings was more principled than the approach employed in Section
6.4, in which the 25 largest-valued eigenvalues were retained. The lack of significant difference
between classification performance based on the original feature data and that based on the
embedding coordinates for each individual modality was expected, since a random forest is
already a nonlinear classifier. However, a difference was observed for the comparison between
MCI patients and HC based on the voxel-based FDG-PET features. This may be due to the
inhomogeneity of the MCI group, which comprises both pMCI and sMCI patients. It is possible
that the high-dimensional voxel-based FDG-PET features are sensitive to differences in the
pattern of glucose metabolism between these two groups, resulting in a reduced classification
performance based on the associated embedding coordinates.
Random forests are ensemble-based classifiers that are often applied to high-dimensional datasets.
Here, random forests are also applied to low-dimensional biological data so that consistent pair-
wise similarity measures may be obtained for all modalities. In the case of a single feature,
such as the categorical genetic information, a random forest reduces to bootstrap aggregation.
Visualisation of the parameters selected to combine similarities for multi-modality classification
(Figure 6.5) provides some interesting insights into the relationships among the modalities. The
figure indicates the optimum way in which to combine MRI, FDG-PET, CSF and genetic infor-
mation within the framework described. For distinguishing between AD patients and HC, for
example, it appears that FDG-PET and MR imaging features provide the most complementary
information. This indication supports the hypothetical temporal model of biomarker dynamics
shown in Figure 1.10, in which FDG-PET and MRI measures show the greatest difference be-
tween AD patients and cognitively normal individuals. For distinguishing MCI patients from
HC, genetic information appears to have a relatively high importance. However, the optimum
modality weightings for distinguishing between these groups are less stable than those for dis-
tinguishing between AD patients and HC. This may be because the heterogeneity of the MCI
group makes their selection dependent on the proportions of pMCI and sMCI patients in the
training set. The figure suggests an interesting avenue for further research, in that estimates
6.6. Conclusion 143
of inter-modality correlations could help to determine the amount of complementary informa-
tion between them. This could facilitate decisions on how to acquire the maximum amount of
diagnostically relevant information for a patient using a minimum number of assessments.
The classification performance between pMCI and sMCI patients is not significantly improved
by combining multi-modality information in this study. The results presented in Chapter 5
have shown that incorporating longitudinal information can be beneficial to improve the ability
to distinguish between these two groups. This is another avenue for future research. It is also
important to consider, however, that progression from MCI to AD occurs at a rate of 10-15%
per year (Petersen et al., 1999), with up to 80% of MCI patients developing AD over a six year
period (Petersen, 2004). Longer clinical follow-up is therefore required to properly assess the
utility of any classification method in separating pMCI from sMCI patients.
6.6 Conclusion
This chapter has presented a framework for multi-modality classification based on pairwise
similarity measures derived from random forests. Random forests provide consistent pairwise
similarity measures for multiple modalities, thus facilitating the combination of different types
of feature data. The approach has been evaluated using imaging and biological data from
the ADNI study, including voxel-based FDG-PET and region-based MR imaging data, CSF
biomarker measures, and categorical ApoE genotype information. Classification based on mul-
tiple modalities has been shown to out-perform that based on any individual modality. This
finding supports previous suggestions that there is some complementary information between
neuroimaging and biological measures which can be exploited to produce a more powerful
combined biomarker for AD and MCI.
Several areas for further research have been identified. Methodologically, the approach is gen-
eralisable, in that the manifold learning and classification steps could be performed using al-
ternative algorithms, and similarities could be extracted or combined using more sophisticated
metrics. Additionally, longitudinal data could be incorporated, as well as clinical and neuropsy-
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chological information. Since random forest classifiers extend naturally to multi-class problems,
the framework described here could be used for other applications in the future, such as the dif-
ferential diagnosis of AD. In addition, the implementation of random forests used in this work
could be modified to produce uncertainty information about the predicted diagnostic labels.
This may be more useful to clinicians than a simple binary prediction.
Chapter 7
Early identification of Alzheimer’s
disease
Work in this chapter will, in part, be presented in:
K. R. Gray, R. Wolz, R. A. Heckemann, D. Rueckert, and A. Hammers. Structural differ-
ences in cognitively normal elderly individuals with abnormal amyloid biomarkers: detection
using volumetric MRI in ADNI and AIBL. (Abstract) Alzheimer’s Association International
Conference (AAIC’12), 2012 (Accepted).
7.1 Introduction
This chapter presents findings of early signs of neurodegeneration in cognitively normal individ-
uals at high risk of developing AD. The ability to identify individuals in the pre-symptomatic
stages of AD is desirable for early diagnosis, intervention, counselling, and drug discovery.
As described in Section 1.5, pathological changes in the brain precede cognitive symptoms by
several years. Disease-specific imaging biomarkers could potentially detect pre-clinical disease.
The majority of efforts aimed at early detection have either focused on MCI patients, or required
serial imaging over 12 months (for example, Schott et al. (2010)).
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In this work, multi-region analysis of MR images acquired at a single timepoint was used to
identify early signs of neurodegeneration in cognitively normal elderly individuals with evidence
of cortical β-amyloid deposition. Imaging and biological data used in this chapter were ob-
tained from cognitively normal participants in both the ADNI study, and the Australian Imag-
ing, Biomarkers & Lifestyle Flagship Study of Ageing (AIBL; http://www.aibl.csiro.au).
Section 7.2 describes these two cohorts. Section 7.3 presents details of the MRI acquisition,
pre-processing, and anatomical segmentation procedure for both subject groups. Section 7.4
describes the assignment of the participants to risk groups, based on CSF Aβ in ADNI, and
neocortical-to-cerebellar ratios of amyloid deposition on PiB-PET imaging in AIBL. Section
7.5 then presents the results of comparisons between regional MR volumes in the high- and
low-risk sub-sets of each group.
Reduced volumes in temporo-parietal and orbito-frontal regions in high-risk individuals were
observed in both cohorts. These differences could be indicative of very early changes associated
with AD. The consistency of regional differences observed in the two independent groups sug-
gests that volumetric MRI can reveal structural brain changes that precede the onset of clinical
symptoms. It may therefore be useful in identifying early signs of neurodegeneration in healthy
elderly individuals, potentially providing a useful early screening tool, or outcome measure for
clinical trials.
7.2 Imaging and biological data
Clinical, imaging and biological data used in this chapter were obtained from cognitively normal
participants enrolled in both the ADNI and AIBL studies. Groupwise characteristics of these
subjects are presented in Table 7.1. The mean age and MMSE score do not vary significantly
(p > 0.01) on t-test between the ADNI and AIBL groups. Further information about each
cohort is provided in the following subsections, and groupwise characteristics according to
amyloid-based risk status are provided later in Section 7.4.
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N(F) Age MMSE Score CDR (%) M18 conversion
(mean ± std. dev.) (mean ± std. dev.) 0 0.5 1
ADNI 109(55) 75.8 ± 5.2 29.1 ± 1.0 100 0 0 2 (2%)
AIBL 119(63) 73.2 ± 7.2 28.8 ± 1.2 91 8 1 4 (3%)
Table 7.1: Clinical and demographic information for the study populations. For both ADNI
and AIBL, the total number of HC subjects (N) and number of females (F) are shown, along
with the average age, average MMSE score, and CDR distribution. The number and percentage
of subjects who had progressed to either MCI or AD within 18 months (M18 conversion) are
also provided.
7.2.1 ADNI participants
The ADNI database has been described in Section 4.2. Although 3 T MR images are available
for a sub-set of ADNI participants, 1.5 T MR images are available for all. Baseline 1.5 T MR
images and CSF measures of Aβ were available to download for 109 cognitively normal ADNI
participants (as of January 2012). Up to 48 months of clinical follow-up data were available
for these participants, during which eight subjects had progressed to either MCI or AD. Two
subjects progressed during their first 18 months of clinical follow-up.
7.2.2 AIBL participants
The AIBL study aims to improve understanding of the pathogenesis, early clinical manifesta-
tion, and diagnosis of AD, as well as to identify diet and lifestyle factors that influence disease
development. It is a longitudinal study of 1,112 subjects, including 211 AD patients, 133 MCI
patients, and 768 HC. Details of the methodology have been presented in Ellis et al. (2009).
Core funding for AIBL was provided by the Australian Commonwealth Scientific Industrial and
Research Organisation (CSIRO). This was supplemented by contributions from several leading
researchers and research organisations located in the Australian cities of Melbourne and Perth.
AIBL participants have been enrolled at one of five sites in these two cities. At baseline, all
participants underwent a screening interview, had comprehensive cognitive testing, gave blood
for biomarker analysis, and completed health and lifestyle questionnaires. Approximately one
quarter of participants underwent neuroimaging with PiB-PET and structural MRI. Partici-
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pants were recruited between late 2006 and mid 2008, and are being followed up at 18-month
intervals, as described in Ellis et al. (2010). Clinical and imaging data from the AIBL study are
available to download from the LONI image data archive. Baseline PiB-PET and MR images
were available for 119 cognitively normal AIBL participants (as of January 2012). Four subjects
had progressed to either MCI or AD during their first 18 months of clinical follow-up.
7.3 MRI acquisition and anatomical segmentation
The aim of this work was to perform comparisons between regional MR volumes extracted from
groups of HC differing in amyloid-based risk status for the development of AD. Multi-region
anatomical segmentations were therefore required for both the ADNI and AIBL subject groups.
For the ADNI participants, automatic whole-brain segmentations into 83 anatomical regions
had already been prepared in the native space of each baseline MRI using MAPER, as described
in Section 4.4. Details of the acquisition and anatomical segmentation of the AIBL MR images
are presented in the following subsections, as well as computation of the regional MR volumes.
7.3.1 AIBL MRI acquisition
Baseline T1-weighted MRI scans for the 119 cognitively normal AIBL participants were down-
loaded from the LONI image data archive in NIfTI format. As described in Ellis et al. (2010),
the MRI parameters used in the ADNI study had been adopted for the neuroimaging stream
of the AIBL study. However, in contrast with the multi-centre ADNI MRI acquisition, AIBL
MR images had all been acquired at one of two sites, using either a 1.5 T (n = 39) or 3 T (n =
80) Siemens MRI scanner.
7.3.2 AIBL MRI anatomical segmentation
Automatic whole-brain segmentations of the baseline AIBL MR images were prepared in native
MRI space using MAPER as described for the ADNI group in Section 4.4. Additional image
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processing was first required for bias field correction and brain extraction.
Bias field correction
Although the AIBL MR images had been acquired and processed according to the ADNI pro-
cedure described in Section 4.3.3, some images appeared inhomogeneous upon visual review.
Three images were randomly selected, and corrected for field inhomogeneity using the EM seg-
mentation tool from NiftySeg (http://niftyseg.sourceforge.net). The corrected images
were reviewed both directly and after subtraction from the originals. This showed that sub-
stantial amounts of typical field bias had been removed, as illustrated in Figure 7.1. The bias
correction procedure was therefore applied to all images.
(a) Original (b) Bias-corrected (c) Subtraction
Figure 7.1: Illustration of the bias correction procedure applied to the AIBL MR images,
showing (a) the original MRI, (b) the bias-corrected MRI, and (c) the corrected image after
subtraction from the original.
Brain extraction
A coarse brain extraction was performed on each of the bias-corrected MR images using FSL
BET (Smith, 2002). This was iteratively refined using a multi-level, multi-resolution method
named PINCRAM (Pyrimidal INtraCRAnial Masking), developed by Rolf Heckemann. At a
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single iteration, PINCRAM follows a similar approach to the multi-atlas segmentation method
described in Section 2.3.3. The atlases comprised 39 randomly selected baseline ADNI MR
images and their corresponding intracranial masks, which had been generated as described
in Section 4.4.1. The multi-atlas brain masking procedure employed at a single PINCRAM
iteration is illustrated in Figure 7.2.
Figure 7.2: Schematic representation of a single PINCRAM iteration. A set of atlas anatomical
images Ii is registered to the unseen image U , and the corresponding atlas intracranial masks
Mi propagated to the unseen image. The transformed masks M
′
i are then fused to generate the
intermediate consensus mask M∗. Overlap measures between the transformed masks and this
consensus mask are used to determine a sub-set of masks most similar to the consensus. This
sub-set of masks are fused to generate the final consensus mask M∗∗ for the iteration.
A refined extraction of the bias-corrected MR image was performed after each PINCRAM
iteration, based on the consensus brain mask generated. Four iterations of the multi-atlas
brain masking procedure illustrated in Figure 7.2 were employed. As the PINCRAM procedure
progresses, more detailed transformations are applied to align the atlases with the target MR
image, and smaller sub-sets of atlases are retained for generation of the consensus brain mask.
Details of the four iterations used in this work are summarised in Table 7.2.
Images illustrating the refinement of the BET-based brain extraction achieved using the itera-
tive PINCRAM procedure are shown in Figure 7.3. The final consensus brain mask was used
to perform the detailed brain extraction required for multi-atlas segmentation using MAPER.
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Iteration Transformation model Image resolution Number of atlases retained
1 Global affine 4 mm 31
2 Coarse nonrigid (20 mm) 4 mm 27
3 Moderate nonrigid (8 mm) 2 mm 17
4 Detailed nonrigid (3 mm) full 11
Table 7.2: Details of the four PINCRAM iterations employed to generate a refined brain ex-
traction of the bias-corrected MRI. As the PINCRAM procedure progresses, the transformation
models used to register the atlases to the target become more detailed, the images undergo less
smoothing, and a smaller sub-set of atlases is retained for use in the next iteration. For the
nonrigid transformations, numbers in brackets indicate the control point spacings.
(a) BET (b) PINCRAM: affine (c) PINCRAM: final
Figure 7.3: Illustration of the PINCRAM procedure, showing (a) the initial brain mask obtained
using BET, (b) the brain mask obtained following the affine PINCRAM iteration, and (c) the
brain mask obtained following the final PINCRAM iteration. Masks are shown overlaid onto
the corresponding bias-corrected MR images.
7.3.3 Computation of regional MRI volumes
MRI volumes were computed for all 83 anatomically defined regions for both the ADNI and
AIBL groups. To reduce inter-individual variation, regional volumes were normalised by the
total ICV computed from the masks described in Sections 4.4.1 and 7.3.2. This has been shown
to substantially reduce variation, remove gender-related differences (Whitwell et al., 2001),
and eliminate inaccuracies arising from scaling or voxel size errors remaining after phantom
correction of the MRI (Clarkson et al., 2009).
The MAPER segmentation procedure has been shown to produce consistent results across field
strengths of 1.5 T and 3 T in ADNI (Heckemann et al., 2011). However, significant differences
(p < 0.05) in volume were observed in over half of the 83 regions between the 1.5 T and 3 T
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AIBL MR images, both before and after accounting for the effects of subject age using a linear
regression model. These differences could be attributed to a systematic difference in image
processing between scanners, or in the demographic characteristics of the subjects. The AIBL
MR images acquired using the two scanners were therefore not pooled in this work, but divided
into two groups which were analysed independently (see Section 7.4.2).
7.4 Amyloid-based risk status
The cognitively normal ADNI and AIBL participants were assigned to risk groups for the de-
velopment of AD based on evidence of their cortical β-amyloid deposition. This was assessed
using CSF Aβ1−42 measurements in ADNI, and neocortical-to-cerebellar ratios of amyloid de-
position on PiB-PET imaging in AIBL. As described in Section 1.5.4, these two measures show
a highly significant inverse correlation (Fagan et al., 2006). Low CSF Aβ measures and high
neocortical-to-cerebellar ratios of amyloid deposition on PiB-PET imaging are associated with
a high risk for the development of AD.
A CSF Aβ1−42 cutoff of 192 pg/mL has been estimated from an autopsy-confirmed sample as the
best discriminator between AD patients and HC (Shaw et al., 2009). This has been applied to
distinguish between normal and abnormal CSF Aβ measures among ADNI participants (Schott
et al., 2010). An analogous cutoff of 1.5 on a neocortical-to-cerebellar ratio of amyloid deposition
on PiB-PET imaging has also been found useful in ADNI (Weigand et al., 2011). Details of
the assignment of the ADNI and AIBL participants to risk groups for the development of AD
based on these two analogous cutoffs are presented in the following subsections.
7.4.1 ADNI participants
The 109 cognitively normal ADNI participants were assigned to high- and low-risk groups for
the development of AD based on CSF measures of Aβ1−42 (high risk ≤ 192 pg/mL). These data
had been acquired as described in Section 6.2.3, and are summarised in Figure 7.4.
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Figure 7.4: Summary of the ADNI CSF Aβ measures. Ranges containing values associated
with the two subjects who progressed to either MCI or AD within 18 months are indicated by
asterisks (∗).
Following sub-division of the ADNI participants, 39% were classified as having a high risk for
the development of AD. The mean ages of the high- and low-risk sub-sets (76.6 ± 5.1 and 75.3
± 5.2, respectively) were not significantly different (t-test, p > 0.01). The two subjects who
had progressed to either MCI or AD within 18 months were both assigned to the high-risk
group based on their CSF Aβ measures.
7.4.2 AIBL participants
The 119 cognitively normal AIBL participants were assigned to high- and low-risk groups for the
development of AD based on neocortical-to-cerebellar ratios of amyloid deposition on PiB-PET
imaging (high risk > 1.5). The following subsections describe the PiB-PET image acquisition
and processing, as well as computation of the neocortical-to-cerebellar ratios.
AIBL PiB-PET acquisition and pre-processing
Baseline pre-processed PiB-PET images for the 119 cognitively normal AIBL participants were
downloaded from the LONI image data archive in NIfTI format. These had been acquired
according to a standard protocol using a Philips Allegro PET scanner at both neuroimaging
sites. A 30-minute dynamic scan consisting of six 5-minute frames was acquired, beginning
approximately 40 minutes after the intravenous injection of ∼370 MBq of PiB. Data were
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corrected for both scatter and measured attenuation, determined using a transmission scan,
and images were iteratively reconstructed. The six frames were summed to produce a single 30-
minute static image, and these summed images were available to download. PiB-PET imaging
was performed according to the methodology described in Pike et al. (2007).
Co-registration of PiB-PET with MRI
Each of the 119 summed baseline PiB-PET images was affinely co-registered with its corre-
sponding native space baseline MR image, and re-sampled to the higher resolution of the MRI
using linear interpolation. Registration was performed as described in Section 4.3.4, and is
illustrated in Figure 7.5.
(a) Native space MRI (b) Native space PET (c) MRI-space PET
Figure 7.5: Illustration of PET-MRI co-registration, showing (a) the native space MR image
overlaid with (b) the native space PiB-PET image, and (c) the MRI-space PiB-PET image.
Neocortical-to-cerebellar ratios of amyloid deposition
The extent of cortical β-amyloid deposition was assessed on PiB-PET imaging using the SUVR
analysis method described in Section 1.4.1. Each of the MRI-space PiB-PET images was
overlaid with its corresponding masked anatomical segmentation, and the SUVR computed
between a composite neocortical region and the cerebellar grey matter, similarly to the method
described in Rowe et al. (2010).
The neocortical SUV was computed as the volume-weighted average PiB-PET signal intensity
per mm3 across six regions: frontal, superior parietal, lateral temporal, lateral occipital, anterior
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cingulate, and posterior cingulate. These regions were derived from the 83 region anatomical
segmentations as follows. The frontal region comprised the middle, inferior and superior frontal
gyri; anterior, lateral and posterior orbital gyri; precentral and straight gyri; subgenual and
pre-subgenual frontal cortices; and the subcallosal area. The superior parietal region comprised
the postcentral gyrus, and superior parietal gyrus. The lateral temporal region comprised the
lateral part of the anterior temporal lobe; anterior and central parts of the superior temporal
gyrus; middle and inferior temporal gyri, and the posterior temporal lobe.
The cerebellar grey matter was identified by masking the full label with the binary maximum-
probability grey matter map generated using FAST as described in Section 4.4.1. The cerebellar
grey matter provides a suitable reference region due to the lack of PiB accumulation in either
AD patients or HC (Klunk et al., 2004). Examples of the images required for computation of
neocortical-to-cerebellar ratios of amyloid deposition are shown in Figure 7.6.
(a) PiB-PET (b) Neocortical regions (c) Reference region
Figure 7.6: Examples of the images required for assessment of the extent of cortical β-amyloid
deposition, showing (a) the PiB-PET image, (b) the composite neocortical regions, and (c) the
cerebellar grey matter. Images are overlaid onto the corresponding MRI. Neocortical regions
shown comprise frontal (red), superior parietal (blue), lateral temporal (green), lateral occipital
(white), anterior cingulate gyrus (yellow), and posterior cingulate gyrus (purple).
The 119 cognitively normal AIBL participants were divided according to scanner model (1.5 T,
n = 39; 3 T, n = 80) as explained in Section 7.3.3. Participants were then assigned to high-
and low- risk groups for the development of AD based on their PiB-PET SUVR measures (high
risk > 1.5). These are summarised in Figure 7.7 for the 39 participants scanned using the 1.5 T
MR scanner. Following sub-division of these participants, 21% were classified as having a high
risk for the development of AD. The mean ages of the high- and low-risk sub-sets (74.0 ± 6.9
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and 69.3 ± 6.2, respectively) were not significantly different (t-test, p > 0.01). One of the four
subjects who had progressed to either MCI or AD within 18 months was scanned using the
1.5 T MR scanner, and assigned to the low-risk group based on their PiB-PET SUVR measure.
Figure 7.7: Summary of the AIBL PiB-PET SUVR measures for participants scanned using
the 1.5 T MR scanner. Ranges containing values associated with subjects who progressed to
either MCI or AD within 18 months are indicated by asterisks (∗).
PiB-PET SUVR measures are summarised in Figure 7.8 for the 80 participants scanned using
the 3 T MR scanner. Following sub-division of these participants, 34% were classified as having
a high risk for the development of AD. The mean age of the high-risk sub-set (77.7 ± 5.8) was
significantly higher than that of the low-risk sub-set (72.6 ± 7.1) (t-test, p < 0.01). For this
reason, a linear regression model was applied to the MR volumes from both ADNI and AIBL
to account for the effects of age. Three of the four subjects who had progressed to either MCI
or AD within 18 months were scanned using the 3 T MR scanner, and all three were assigned
to the high-risk group based on their PiB-PET SUVR measures.
Figure 7.8: Summary of the AIBL PiB-PET SUVR measures for participants scanned using the
3 T MR scanner. Ranges containing values associated with subjects who progressed to either
MCI or AD within 18 months are indicated by asterisks (∗).
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7.5 Volumetric differences between risk groups
Comparisons by t-test were performed between the ICV-normalised, age-corrected MR volumes
in the high- and low-risk sub-sets of each group (ADNI, 1.5 T AIBL, 3 T AIBL). Correction for
multiple comparisons was performed using the P plot graphical method described in Turkheimer
et al. (2001), which is based on estimating the number of “true” null hypotheses in a set
of statistics. This estimate can be used to sharpen existing multiple comparison correction
approaches, such as the procedure described in Hochberg (1988).
The P plot method takes account of the fact that regional MR volumes are not entirely inde-
pendent, and that differences are therefore expected in more than one brain region. It is a less
conservative approach than the Bonferroni-like corrections described in Section 2.4.3, and has
greater power for detecting true differences.
For a set of N hypotheses, the associated p-values are ranked in descending order, and a P plot
constructed as illustrated in Figure 7.9. Points corresponding to true null hypotheses (large p)
are expected to lie approximately along a straight line passing through the origin, while points
corresponding to false hypotheses should deviate to the right. The slope, β, of the straight line
fitted to the points with large p-values is used to estimate the number of “true” null hypotheses,
N0 = (1/β)− 1.
Figure 7.9: Illustration of a P plot based on p-values computed from t-tests on 43 re-
gions (Turkheimer et al., 2001). The estimated slope of the straight line, β was used to estimate
the number of “true” null hypotheses, N0 = 8.
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7.5.1 ADNI participants
Regional t-values between the high- and low-risk sub-sets of the cognitively normal ADNI
participants are illustrated in Figure 7.10. Five of 83 regions across the brain were significantly
smaller in the high-risk sub-set (p < 0.05, uncorrected). These regions are listed in Table 7.3,
and outlined in blue on Figure 7.10.
Figure 7.10: Regional t-values between age-corrected MR volumes in the high- and low-risk
sub-sets of the cognitively normal ADNI participants are shown superimposed onto a maximum
probability brain atlas which has been masked in the same way as the anatomical segmentations.
The t-value map is overlaid onto a MNI-space average MR image for reference. Sagittal slices
are shown viewed from the right side of the brain, moving towards the left. Regions showing
a significant difference in age-corrected volume (p < 0.05, uncorrected) are outlined in blue.
Since the significance threshold of p < 0.05 is somewhat arbitrary, regions with 0.05 < p < 0.1
are additionally outlined in cyan. All outlined regions were smaller in the high-risk sub-set.
Region p-value
Anterior orbital gyrus (right) < 0.0005
Anterior part of superior temporal gyrus (left) 0.025
Superior parietal gyrus (left) 0.026
Temporal horn of lateral ventricle (left) 0.026
Hippocampus (left) 0.049
Medial orbital gyrus (right) 0.076
Lateral orbital gyrus (left) 0.095
Table 7.3: Regions showing a significant (p < 0.05, uncorrected) difference in age-corrected MR
volume between the high- and low-risk sub-sets of the cognitively normal ADNI participants,
along with the corresponding p-values. Since the significance threshold of p < 0.05 is somewhat
arbitrary, regions are additionally listed down to a significance level of p < 0.1. All regions
listed were smaller in the high-risk sub-set.
One region (right anterior orbital gyrus) remained significantly smaller in the high-risk sub-set
after correction for multiple comparisons using the P plot graphical method (p < 0.05) described
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in Section 7.5. The temporal horn of the left lateral ventricle was among the significantly smaller
regions. This structure is expected to be enlarged in high-risk individuals. However, as shown
in Figure 7.10, it is a very small region. The result could thus be attributed to subject motion
during scanning or inaccuracies in the automatic segmentation procedure.
7.5.2 AIBL 1.5 T participants
Regional t-values between the high- and low-risk sub-sets of the cognitively normal AIBL par-
ticipants scanned using the 1.5 T MR scanner are illustrated in Figure 7.11. Five of 83 regions
across the brain were significantly smaller in the high-risk sub-set (p < 0.05, uncorrected).
These regions are listed in Table 7.4, and outlined in blue on Figure 7.11. One region (left
occipitotemporal gyrus) remained significantly smaller in the high-risk sub-set after correction
for multiple comparisons using the P plot graphical method (p < 0.05).
Figure 7.11: Regional t-values between age-corrected MR volumes in the high- and low-risk
sub-sets of the cognitively normal AIBL participants scanned using the 1.5 T MR scanner are
shown superimposed onto a maximum probability brain atlas which has been masked in the
same way as the anatomical segmentations. The t-value map is overlaid onto a MNI-space
average MR image for reference. The top row shows sagittal slices of the brain viewed from the
right, and the bottom row shows slices from the left. Regions showing a significant difference
in age-corrected volume (p < 0.05, uncorrected) are outlined in blue. Again, regions with
0.05 < p < 0.1 are additionally outlined in cyan. All outlined regions were smaller in the
high-risk sub-set, apart from the corpus callosum.
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Region p-value
Lateral occipitotemporal gyrus (left) < 0.0005
Amygdala (right) 0.005
Lateral occipitotemporal gyrus (right) 0.021
Lateral part of anterior temporal lobe (left) 0.023
Parahippocampal gyrus (left) 0.037
Corpus callosum (spans midline) 0.050
Medial part of anterior temporal lobe (right) 0.056
Superior frontal gyrus (right) 0.058
Middle and inferior temporal gyri (right) 0.062
Middle and inferior temporal gyri (left) 0.066
Pre-subgenual frontal cortex (left) 0.089
Table 7.4: Regions showing a significant (p < 0.05, uncorrected) difference in age-corrected MR
volume between the high- and low-risk sub-sets of the cognitively normal AIBL participants
scanned using the 1.5 T MR scanner, along with the corresponding p-values. Again, regions are
additionally listed down to a significance level of p < 0.1. All regions listed were smaller in the
high-risk sub-set, apart from the corpus callosum.
7.5.3 AIBL 3 T participants
Regional t-values between the high- and low-risk sub-sets of the cognitively normal AIBL par-
ticipants scanned using the 3 T MR scanner are illustrated in Figure 7.12. Four of 83 regions
across the brain were significantly smaller in the high-risk sub-set (p < 0.05, uncorrected).
These regions are listed in Table 7.5, and outlined in blue on Figure 7.12.
Figure 7.12: Regional t-values between age-corrected MR volumes in the high- and low-risk sub-
sets of the cognitively normal AIBL participants scanned using the 3 T MR scanner are shown
superimposed onto a maximum probability brain atlas which has been masked in the same way
as the anatomical segmentations. The t-value map is overlaid onto a MNI-space average MR
image for reference. Sagittal slices are shown viewed from the right side of the brain, moving
towards the left. Regions showing a significant difference in age-corrected volume (p < 0.05,
uncorrected) are outlined in blue. Again, regions with 0.05 < p < 0.1 are additionally outlined
in cyan. All outlined regions were smaller in the high-risk sub-set, apart from the temporal
horn of the right lateral ventricle.
7.5. Volumetric differences between risk groups 161
No regions remained significantly smaller in the high-risk sub-set after correction for multiple
comparisons using the P plot graphical method (p < 0.05).
Region p-value
Pre-subgenual frontal cortex (left) 0.004
Straight gyrus (right) 0.020
Inferior frontal gyrus (left) 0.025
Posterior orbital gyrus (right) 0.036
Subgenual frontal cortex (left) 0.059
Temporal horn of lateral ventricle (right) 0.060
Anterior orbital gyrus (left) 0.062
Table 7.5: Regions showing a significant (p < 0.05, uncorrected) difference in age-corrected MR
volume between the high- and low-risk sub-sets of the cognitively normal AIBL participants
scanned using the 3 T MR scanner, along with the corresponding p-values. Again, regions are
additionally listed down to a significance level of p < 0.1. All regions listed were smaller in the
high-risk sub-set, apart from the temporal horn of the right lateral ventricle.
7.5.4 Discussion
Multi-region analysis of MR images acquired at a single timepoint has been used to identify early
signs of neurodegeneration in cognitively normal elderly individuals with evidence of cortical
β-amyloid deposition. Reduced volumes in temporo-parietal and orbito-frontal regions in high-
risk individuals were observed in two independent cohorts from the ADNI and AIBL studies.
These differences could be indicative of very early changes associated with the development
of AD. The similarity of regional differences observed in the two independent groups suggests
that volumetric MRI can reveal structural brain changes that precede the onset of clinical
symptoms. Variations in significant regions between subject groups can be attributed to the
different demographic characteristics of the participants concerned. For example, the AIBL HC
groups include individuals with subjective, but not objective, memory impairments.
Participants were assigned to risk groups for the development of AD based on evidence of their
cortical β-amyloid deposition. This was assessed based on cutoff values on CSF measures of Aβ
in ADNI (high risk ≤ 192 pg/mL), and neocortical-to-cerebellar ratios of amyloid deposition on
PiB-PET imaging in AIBL (high risk > 1.5). Similar proportions of participants were assigned
to the high-risk sub-set of each group (ADNI, 39%; 1.5 T AIBL, 21%; 3 T AIBL, 34%). It
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has been previously suggested that the cutoff values on CSF Aβ and PiB-PET SUVR are
analogous, and that measures of CSF Aβ may be transformed into calculated PiB units of
cortical β-amyloid (Weigand et al., 2011).
As discussed in Section 1.5.2, many studies have described the structural brain changes as-
sociated with MCI and AD. Far fewer studies have investigated the potential for detecting
structural changes in the pre-symptomatic stages of the disease. It is important to consider
that evidence of cortical β-amyloid deposition in cognitively normal elderly individuals does
not necessarily indicate an increased risk of developing AD. The volumetric differences ob-
served may therefore reflect the amyloid status of participants, rather than directly their risk
for disease development.
Tondelli et al. (2012) used voxel-based morphometry and shape analyses of MR imaging data to
show reduced volumes in temporo-parietal and orbito-frontal regions of the brain in cognitively
normal subjects who were subsequently diagnosed with MCI or AD, in comparison with subjects
who remained cognitively normal over ten years. These results were based on MR images, taken
at least four years before the onset of any cognitive symptoms, from 8 pre-clinical AD patients,
32 pre-clinical MCI patients, and 40 HC. The results presented in this chapter are consistent
with those of Tondelli et al. (2012), supporting the suggestion that these structural changes
may be predictive of the future development of AD. Further clinical follow-up data will become
available for both the ADNI and AIBL participants over the next few years, and one interesting
area for future research would involve performing an analysis similar to that of Tondelli et al.
(2012) based on the large ADNI and AIBL cohorts.
Schott et al. (2010) compared whole-brain, hippocampal and ventricular volumes and atrophy
rates between cognitively normal ADNI participants, stratified into high- and low-risk based
on CSF measures of Aβ. They reported significantly increased whole-brain loss, ventricular
expansion, and hippocampal atrophy in high-risk individuals, but no significant volumetric
differences. The work presented in this chapter has shown that a multi-region analysis approach
can be used to detect significant volumetric differences in certain regions of the brain.
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7.6 Conclusion
This chapter has presented findings of early signs of neurodegeneration in cognitively normal in-
dividuals at high risk of developing AD. Multi-region analysis of MR images acquired at a single
timepoint was used to identify early signs of neurodegeneration in cognitively normal elderly in-
dividuals with evidence of cortical β-amyloid deposition. Reduced volumes in temporo-parietal
and orbito-frontal regions in high-risk individuals were observed in both cohorts. The similarity
of regional differences observed in two independent groups suggests that volumetric MRI can
reveal structural brain changes that precede the onset of clinical symptoms. It may therefore be
useful in identifying early signs of neurodegeneration in healthy elderly individuals, potentially
providing a useful early screening tool, or outcome measure for clinical trials.
Future work will aim to determine whether the observed group differences can be translated
into markers for the prediction of future cognitive decline in individual patients. In addition, it
would be interesting to perform a similar study using multi-region FDG-PET signal intensities
rather than MR volumes, since it is hypothesised that changes in metabolism can be detected
on FDG-PET before corresponding structural changes are visible on MRI (Aisen et al., 2010).
Chapter 8
Overall conclusion
8.1 Contributions
The research presented in this thesis contributes to the growing body of literature surrounding
the image-based classification of MCI and AD. Imaging biomarkers for AD are important
for improved diagnosis and monitoring, as well as drug discovery. Automated image-based
classification of individual patients could provide valuable diagnostic support for clinicians,
when considered alongside cognitive assessment scores and traditional visual image analysis.
This research has investigated machine learning methods aimed at the early identification of
AD, and prediction of progression in patients with MCI. A comparison of the key classification
results from Chapters 4, 5 and 6 is presented in Table 8.1.
Base. PET Long. PET PET, MRI PET, MRI, CSF, Gen.
N/N acc N/N acc N/N acc N/N acc
AD/HC 71/69 81.6% 50/54 88.4% 71/69 90.0% 37/35 89.0%
MCI/HC 147/69 70.2% - - 147/69 75.5% 75/35 74.6%
pMCI/HC 62/69 71.8% 53/54 81.3% - - - -
AD/sMCI 71/85 74.2% 50/64 83.5% - - - -
pMCI/sMCI 62/85 56.4% 53/64 63.1% - - 34/41 58.0%
Table 8.1: Comparison of key classification results from Chapters 4, 5 and 6. The number of
subjects in each diagnostic group (N/N) and classification accuracy (acc) are shown for baseline
(base.) FDG-PET, longitudinal (long.) FDG-PET, FDG-PET combined with MRI, and the
combination of FDG-PET, MRI, CSF and genetic (gen.) data.
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Investigations of the potential utility of multi-region FDG-PET features for image-based clas-
sification of AD and MCI were described in Chapters 4 and 5. In particular, attempts were
made to distinguish between MCI patients who subsequently progressed to AD and those who
remained stable. Chapter 4 demonstrated that regional information extracted from FDG-PET
images acquired at a single timepoint can be used to achieve classification results in line with
those obtained using data from MRI, or biomarkers obtained invasively from the CSF. Chapter
5 then demonstrated the additional benefit of incorporating longitudinal FDG-PET informa-
tion for classification. By combining cross-sectional and longitudinal multi-region FDG-PET
features, classification results in line with the current state-of-the-art were achieved. The find-
ings described in these chapters support the use of FDG-PET for the early diagnosis of AD
and for monitoring its progression.
Chapter 6 presented a multi-modality classification framework in which manifolds are con-
structed based on pairwise similarity measures derived from random forest classifiers. Similar-
ities from multiple modalities were combined to generate an embedding that simultaneously
encoded information about all the available features. Multi-modality classification was then
performed using coordinates from this joint embedding. Random forests provide consistent
pairwise similarity measures for multiple modalities, thus facilitating the combination of dif-
ferent types of feature data. Classification results based on the combination of regional MRI
volumes, voxel-based FDG-PET signal intensities, CSF biomarker measures, and ApoE allele
status are comparable with those obtained in other studies using multi-kernel learning. Since
random forest classifiers extend naturally to multi-class problems, the framework described
could be used for other applications in the future, such as the differential diagnosis of AD.
Novel findings of early signs of neurodegeneration in cognitively normal individuals at high risk
of developing AD were presented in Chapter 7. Multi-region analysis of MR images acquired
at a single timepoint was used to show volumetric differences in cognitively normal individuals
differing in amyloid-based risk status for the development of AD. Reduced volumes in temporo-
parietal and orbito-frontal regions in high-risk individuals from two independent cohorts could
be indicative of very early changes associated with AD. These findings suggest that volumetric
MRI can reveal structural brain changes that precede the onset of clinical symptoms. It may
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therefore be useful in identifying early signs of neurodegeneration in healthy elderly individuals,
potentially providing a useful early screening tool, or outcome measure for clinical trials.
8.2 Future work
The work presented in Chapters 4, 5 and 6 has been focused on the image-based classification
of AD and MCI. As explained in Chapter 4, classification results for distinguishing between AD
patients and HC may be converging on a glass ceiling since the diagnostic consensus criteria
themselves have an accuracy of around 90% (Ranginwala et al., 2008). One interesting area for
further research could be to compare the subjects that are mis-classified using different machine
learning methods based on the various available modalities. It would also be beneficial to further
investigate the case of discriminating pMCI from sMCI patients, since this is one of the most
clinically interesting. As explained in Chapter 4, the three years of clinical follow-up that will
eventually be available for the MCI patients are likely to be insufficient to allow the identification
of all those who will develop AD in the future. However, the ADNI study has been extended in
the form of the ADNI-GO and ADNI-2 studies, which are summarised in Table 8.2. These will
provide additional clinical follow-up for the original ADNI participants. Further information is
available via the ADNI website (http://adni.loni.ucla.edu/about/about-the-study/).
Study Timeline HC eMCI lMCI AD MRI fMRI FDG AV45 Bio.
ADNI-1 2004–2010 200 – 400 200 X 7 X 7 X
ADNI-GO 2009–2011 – 200 – – X X X X X
ADNI-2 2011–2016 150 100 150 150 X X X X X
Table 8.2: Summary of the ADNI studies, including the approximate timelines, number of par-
ticipants in each diagnostic group, and availability of each modality. ADNI-GO and ADNI-2
continue to follow the ADNI-1 participants, as well as recruiting additional subjects as shown.
MCI patients are divided into early (eMCI) and late (lMCI) groups. Available modalities
include structural MRI, resting state functional MRI (fMRI), FDG-PET, AV45-PET, and
biospecimens (bio.). [18F]-AV45 is an amyloid imaging PET tracer developed by Avid Ra-
diopharmaceuticals. Biospecimens include DNA, CSF and blood samples.
As described in Section 1.5, changes in multiple biomarkers may provide complementary infor-
mation for the diagnosis and prognosis of AD. This was demonstrated by the work on multi-
modality classification presented in Chapter 6. It may be interesting to further investigate the
8.2. Future work 167
relationships among the various modalities, since this potentially enables decisions to be made
on how to acquire the maximum amount of diagnostically relevant information for a patient
using a minimum number of assessments. Additional information could also be incorporated
into the described framework, including clinical and neuropsychological assessment scores, and
longitudinal data. It would be particularly interesting to see if incorporating the additional
clinical follow-up information, and longitudinal imaging and biological data enables improved
discrimination between pMCI and sMCI patients. The random forest classifiers applied to de-
rive the similarity measures extend naturally to multi-class problems. It could therefore be
interesting to investigate the use of multi-modality classification for the differential diagnosis of
AD. While it is possible that the ADNI dataset contains some patients with other dementias,
such as frontotemporal dementia or dementia with Lewy bodies, these patients are not clini-
cally labelled as such. To perform a thorough study on differential diagnosis, a large and varied
cohort of dementia patients with autopsy-confirmed clinical diagnoses would be required, such
as that described in Silverman et al. (2001).
The work presented in Chapter 7 is not based on classification, but instead presents novel
findings of early signs of neurodegeneration in cognitively normal individuals at high risk of
developing AD. There is much further research to be done based on these early results. For
example, future work will aim to determine whether the observed group differences can be
translated into markers for the prediction of future cognitive decline in individual patients. The
ability to identify high-risk individuals based on structural MRI would be beneficial, because
it is less invasive than either lumbar puncture or PET imaging. The continuation of the ADNI
study will mean that further clinical follow-up information will be available, and it may then
become possible to replicate the study of Tondelli et al. (2012). In addition, further FDG-PET
data will be acquired, and it would be interesting to perform a similar study using multi-region
FDG-PET signal intensities rather than MR volumes, since it is hypothesised that changes in
metabolism can be detected on FDG-PET before corresponding structural changes are visible
on MRI (Aisen et al., 2010).
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Appendix A
Hammers brain atlases
The Hammers brain atlases comprise 30 T1-weighted MR images which have been manually
segmented into the 83 anatomically defined structures listed in Table A.1. Details of the subject
demographics and MR imaging protocol are provided in Hammers et al. (2003). Protocols for
the manual delineation are described in Hammers et al. (2003) and Gousias et al. (2008).
No. right No. left Structure
1 2 Hippocampus
3 4 Amygdala
5 6 Anterior temporal lobe, medial part
7 8 Anterior temporal lobe, lateral part
9 10 Gyri parahippocampalis et ambiens
11 12 Superior temporal gyrus, posterior part
13 14 Middle and inferior temporal gyri
15 16 Lateral occipitotemporal gyrus, gyrus fusiformis
17 18 Cerebellum
19 Brainstem, spans the midline
21 20 Insula
23 22 Occipital lobe
25 24 Cingulate gyrus, anterior part
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No. right No. left Structure
27 26 Cingulate gyrus, posterior part
29 28 Frontal lobe, becomes middle frontal gyrus after subdivision
31 30 Posterior temporal lobe
33 32 Parietal lobe
35 34 Caudate nucleus
37 36 Nucleus accumbens
39 38 Putamen
41 40 Thalamus
43 42 Pallidum, globus pallidus
44 Corpus callosum, spans the midline
45 46 Lateral ventricle, frontal horn, central part and occipital horn
47 48 Lateral ventricle, temporal horn
49 Third ventricle, spans the midline
51 50 Precentral gyrus
53 52 Straight gyrus, gyrus rectus
55 54 Anterior orbital gyrus
57 56 Inferior frontal gyrus
59 58 Superior frontal gyrus
61 60 Postcentral gyrus
63 62 Superior parietal gyrus
65 64 Lingual gyrus
67 66 Cuneus left
69 68 Medial orbital gyrus
71 70 Lateral orbital gyrus
73 72 Posterior orbital gyrus
75 74 Substantia nigra
77 76 Subgenual frontal cortex
79 78 Subcallosal area
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No. right No. left Structure
81 80 Pre-subgenual frontal cortex
83 82 Superior temporal gyrus, anterior part
Table A.1: Anatomically defined regions manually delineated in the Hammers atlases.
Appendix B
Excluded images
ADNI subject identifiers for all participants whose images were excluded from the analyses
described in Chapter 4 are provided in Table B.1. These participants were additionally excluded
from the analyses described in Chapter 5, either for the same reasons, or because they did not
have longitudinal FDG-PET or MR imaging data available.
Subject ID Reason for Exclusion
005 S 0223 progressed from HC to MCI
006 S 0484 ∗ failed segmentation due to brain mask
010 S 0422 reverted from MCI to HC
011 S 0002 ∗ timeframe information missing in header
011 S 0003 timeframe information missing in header
021 S 0178 cerebellum partially outside field of view
022 S 0096 cerebellum partially outside field of view
024 S 0985 cerebellum partially outside field of view
024 S 1063 progressed from HC to MCI
024 S 1393 frontal cortex partially outside field of view
027 S 0120 transformation to MNI space failed
041 S 0898 progressed from HC to MCI
057 S 0779 progressed from HC to MCI
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Subject ID Reason for Exclusion
094 S 0498 ∗ transformation to MNI space failed
094 S 1188 transformation to MNI space failed
099 S 0551 reverted from MCI to HC
100 S 0743 ∗ cerebellum partially outside field of view
109 S 1343 ∗ scan time under 30 minutes
126 S 1221 timeframe information missing in header
127 S 0112 oscillates between HC and MCI
127 S 0754 cerebellum partially outside field of view
132 S 0987 ∗ scan time under 30 minutes
137 S 0443 reverted from MCI to HC
137 S 0669 oscillates between HC and MCI
137 S 0722 reverted from MCI to HC
141 S 1245 reverted from MCI to HC
941 S 1194 scan time under 30 minutes
941 S 1202 progressed from HC to MCI
Table B.1: Participants excluded from the work described in Chapter 4. These participants
were additionally excluded from the analyses described in Chapter 5, either for the same
reasons, or because they did not have longitudinal FDG-PET or MR imaging data available
(indicated with asterisks ∗).
